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ABSTRACT
The dissertation is about the design, synthesis and biological applications of polypeptoids
and boron dipyrromethenes (BODIPYs). The dissertation is divided into seven chapters reporting
various aspects of the background to my field of study and the results obtained during my PhD
program.
Chapter 1 is a concise overview of the fundamental concepts of polypeptoids and hydrogels, as
well as their recent developments on synthetic strategies, property investigations, and biological
applications in different fields.
Chapter 2 presents the design, synthesis and potential application as tissue engineering scaffold of
thermoreversible ABC polypeptoid hydrogels. A series of ABC copolypeptoids were synthesized
and their gelation behavior were investigated in water and biological media. The potential use of
the hydrogel as tissue engineering scaffold to induce chondrogenesis of human stem cells was also
investigated.
Chapter 3 describes the synthesis and characterization of a series of highly water soluble
PEGylated polypeptoids bearing oligomeric ethylene glycol side chains. Their potential use as
antifouling material was investigated.
Chapter 4 reports the solution self-assembly of coil-crystalline diblock copolypeptoids (PNMG-bPNDG). The relationship between polymer compositions and micelle morphologies was
investigated.
Chapter 5 is a brief introduction of BNCT and a concise overview of BODIPYs on their synthetic
methodologies, functionalization strategies, and potential applications.
Chapter 6 describes the design, synthesis and in vitro biological studies of a series of carboranecontaining BODIPYs. Their ability to cross the BBB was investigated.

xxii

Chapter 7 reports the design and synthesis of a series of push-pull BODIPYs. Their spectroscopic
and electrochemical properties were investigated by UV-Vis and fluorescence spectroscopy, cyclic
voltammetry and DFT calculation.
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: INTRODUCTION TO POLYPEPTOIDS AND HYDROGELS
1.1 Introduction to polypeptoids
Polypeptoids, composed of N-substituted polyglycine backbones, are structural mimics of
polypeptides (Figure 1.1). The polypeptoids are highly structural tunable by tailoring the side chain
groups, enabling manipulation over their hydrophilicity and lipophilicity balance (HLB),
conformation1-12, charge characteristics,13-14 thermal and crystallization properties.15 In contrast to
polypeptides, polypeptoids with the nitrogen being substituted, lack hydrogen bonding interactions
and chiral centers along the backbones. Thus, the conformation (e.g., random coils, helix1-4, 11-12
and -sheets5-10) of polypeptoids is strongly dependent on the backbone rigidity, steric, chirality,
and electrostatic characteristics of the side chains, in contrast to the polypeptides whose secondary
structure is stabilized by hydrogen bonding. The polypeptoids are thermally processable similar to
conventional thermoplastics due to the absence of hydrogen bonding on their backbones, whereas
polypeptides undergo thermal degradation before they can be melt-processed due to the extensive
hydrogen bonding interactions.15 In addition, studies of polypeptoids showed their enhanced
proteolytic stability relative to polypeptides16-17, good cytocompatibility18-19 and degradability
under oxidative conditions that mimics tissue inflammation20. These combined attributes render
polypeptoids an attractive material for biomedical and biotechnological applications. Recent
development in the organo-mediated controlled polymerization has enabled access to a variety of
well-defined polypeptoid homo and block copolymers. The synthetic methods, structural-property
relationship of polypeptoids as well as their potential applications in different fields such as in
biotechnological area are under investigation and some related reviews have been published.15, 2128
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Figure 1.1. Structure of polypeptoids and polypeptides.
1.2 Synthesis of R-NCAs and polypeptoids
1.2.1 Synthesis of N-substituted N-carboxyanhydride (R-NCA) monomers
A library of N-substituted N-carboxyanhydride (R-NCA) monomers bearing various side
chain structures (e.g., R= methyl, ethyl, allyl etc., Figure 1.2) have been synthesized using two
general routes from the N-substituted glycine precursors which are obtained from the reaction
between primary amine and glyoxylic acid or between ethyl bromoacetate and primary amine
(Scheme 1.1). 15, 29-32 The precursor (1) is treated with di-tert-butyl dicarbonate or chloroformate
to obtain the corresponding alkoxycarbonyl protected N-substituted glycine (2) followed by
cyclization to afford the R-NCAs using activating electrophiles (e.g., PCl3, PBr3, SOCl2 and
AcCl/Ac2O).

Figure 1.2. Representative chemical structures of N-substituted NCA (R-NCA) monomers.
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Scheme 1.1. Synthetic procedures of R-NCAs.

1.2.2 Ring-opening polymerizations of R-NCAs using primary amine initiators
Primary amines are good nucleophiles for the controlled ring-opening polymerization
(ROP) of R-NCAs to produce polypeptoids bearing amide end group and secondary amino living
chain ends by releasing CO2 during polymerizations (Scheme 1.2).15 The nucleophilic ROP
mechanism has been extensively studied for the primary amine-initiated ROPs of amino acidderived NCAs.33 The primary amine-initiated ROPs have been widely investigated on a variety of
R-NCAs. The N-methyl-N-carboxyanhyride (Me-NCA) was shown to polymerize in a controlled
manner without chain transfer or termination events after more than 10 iterative polymerization
steps (a.k.a., living polymerization) using benzyl amine as the initiator.34 The produced
polysarcosine (PNMG) analyzed by SEC chromatography, NMR and MALDI-TOF spectroscopy
exhibited narrow Poisson distribution (PDI<1.1-1.3) and controllable molecular weight by simply
changing the initial monomer to initiator feed ratios. The living chain end of PNMG was further
supported by the chain extension experiment with different monomers (e.g., Et-NCA, Pr-NCA,
Bu-NCA and Pe-NCA). The living polymerization character of other monomers (e.g., Et-NCA,
Pr-NCA, Bu-NCA) was also reported.29-30 The polymerization behavior of R-NCAs is highly
related to their side chain structures. It was shown that iPr-NCA could not (or very slowly) be
polymerized in benzylnitrile at room temperature under reduced pressure probably due to the steric
hindrance of the relatively bulky propagating species that decrease the statistical probability of the
nucleophilic attack at the C5 position of the monomer.30 Polymerization of monomer in neat above
3

its melting temperature was attempt, however, the low MW polymer (16 mer) exhibited broad
distribution (PDI=1.53). As to N-allyl NCA (Al-NCA)35 and N-2-phenylethyl NCA (2PE-NCA)12,
the chain lengths of the resulting polypeptoids were limited (DPn<100) probably due to the
formation of the corresponding 2,5-diketopiperazine from the intramolecular transamidation that
was kinetically competitive relative to the chain propagation.
Scheme 1.2. Mechanism of the primary amine-initiated ROP of R-NCA.

1.2.3 Ring-opening polymerizations of R-NCA using alcohol initiators and 1,1,3,3tetramethylguanidine

Recently, it was reported that N-butyl N-carboxyanhydride (Bu-NCA) can be polymerized
in low dielectric THF using benzyl alcohol initiator and catalytic amount of 1,1,3,3,tetramethylguanidine (TMG) promoter to produce poly (N-butyl glycine) (PNBG) with controlled
molecular weight and narrow molecular weight distribution (PDI=1.04-1.08) by adjusting the
initial monomer to initiator ratios.36 The alcohol alone, however, does not initiate the
polymerization of Bu-NCA under the same condition. The proposed mechanism was that the TMG
formed a hydrogen bonding complex with the alcohol, which enhanced the nucleophilicity of the
alcohols to facilitate the nucleophilic attack of the alcohol to the monomer (Scheme 1.3). The
polymerization activities and Mn control are strongly dependent on the steric and electronic
4

properties of the alcohols. Primary alcohols (e.g., methanol, ethanol, 2-methoxyethanol, propanol
and benzyl alcohol) with the presence of TMG promoter can polymerize the Bu-NCA with good
to moderate control over Mn and PDI. The resulting PNBG polymers were mainly end-capped with
the alcohol initiators, as evidenced by MALDI-TOF spectroscopic analysis. In contrast, the use of
more sterically hindered secondary alcohol (e.g., isopropyl alcohol) with the presence of TMG
produced PNBG polymers whose Mn were much higher than the theoretically predicated values.
Interestingly, no polymerization was observed at different monomer to initiator ratios when using
the even more sterically hindered tert-butyl alcohol. The polymerization using more electron
deficient alcohols with lower pKa s (e.g., 2,2,2-trifluoroethanol and phenol) were also investigated.
It turned out that using 2,2,2-trifluoroethanol in conjugation with TMG lead to PNBG polymers
of much higher Mns relative to the theoretical values, whereas using phenol with TMG yielded no
polymerization regardless of the initial monomer to alcohol ratios. The significant deviation of
Mns from the theoretical values suggested that the initiation was much slower relative to the
propagation due to significantly reduced nucleophilicity of the alcohol moiety in the hydrogen
bonding complexes. The control of polymerization over Mns was also strongly dependent on the
solvent used. In contrast to the polymerization in THF and toluene, polymerization in more polar
solvent (e.g., CH2Cl2 and DMF) was much less controllable showing comparable Mns regardless
of the initial monomer to alcohol ratios.
1.2.4 Synthesis of cyclic polypeptoids
Cyclic polypeptoids [i.e., poly(N-butyl glycine)] were synthesized using N-heterocyclic
carbenes (NHCs)-mediated zwitterionic ring-opening polymerization (ZROP) of Bu-NCA.31, 37 The
polymer MW and ring size can be easily tuned by controlling the initial monomer to NHC ratios in
low dielectric solvents such as THF and toluene. The polymerization was mediated by a zwitterionic
propagating intermediate with two proximate oppositely charged chain ends through electrostatic inte-
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Scheme 1.3. Mechanism of ROH-initiated ROP with TMG promoter.

raction (Figure 1.3). The polymerization in high dielectric solvents (e.g., DMF, DMSO) only produced
low MW mixtures of linear and cyclic polymers regardless of the initial monomer to initiator ratios,
due to the competitive intramolecular transamidation relative to chain propagation. The polymerization
in toluene showed a pseudo-first order kinetics and the polymerization rate was dependent on the steric
characteristic of the NHC used. A variety of cyclic polypeptoids with varied side chains were
synthesized by NHC-mediated ZROP of R-NCAs Me-NCA, Et-NCA, Pg-NCA, Bu-NCA, De-NCA,
2EH-NCA and 2PE-NCA.11-12 PEG-grafted cyclic random copolypeptoids (PNBG-r-PNPgG) was also
reported, which appear as toroid structures in AFM, supporting the cyclic architecture of the
polypepotid backbone.38 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU), a bicyclic amidine, was also
shown to mediated ZROP s of Bu-NCA in a controlled manner similar to NHCs (Figure 1.3).39 The
DBU exhibited enhanced moisture/air stability and availability compared to NHC.

1.3 Physicochemical properties of polypeptoids
1.3.1 Thermal properties of polypeptoids
The side chain structures of polypeptoids greatly affect their thermal properties.
Polypeptoids bearing 2 carbon aliphatic side chains were shown to be amorphous, whereas
polypeptoids bearing longer linear aliphatic side chains (C3-C14) are highly crystalline.40 The cyc-
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Figure 1.3. NHC- and DBU-mediated ZROPs of Bu-NCA to afford cyclic PNBGs.
lic and linear polypeptoids bearing linear aliphatic side chains (C4-C14) all exhibited two melting
points (Tm1 and Tm2) attributed to the side chain and main chain crystallization.41

The

crystallizations of main chain and side chain were strongly coupled: increasing side chain length
increased the side chain melting temperature while decreasing the main chain melting temperature
(Figure 1.4). The side chain and main chain crystallization of polypeptoid with branched aliphatic
side chain (2-ethylhexyl) was shown to be greatly suppressed. The cyclic polypeptoids exhibited
higher main chain melting points compared to the linear analog while the polymer architecture
does not appreciably affect the side chain melting points. The polymer crystallization was also
affected by the thermal history of the polymer.
1.3.2 Thermoresponsive properties of polypeptoids
The hydrophilicity and lipophilicity balance (HLB) of polypeptoids can be readily tailored
by controlling the structure of side chains. Amphiphilic polymer solutions, including polypeptoids,
often undergo dehydration and subsequent hydrophobic collapse at elevated temperature, the socalled reversible temperature-induced cloud point transition.42 It was found that poly (N-alkyl
glycine) with C3 carbon side chains (C3 = n-propyl, allyl, propargyl, and isopropyl) exhibited
thermoresponsive behavior in water and their cloud temperatures (Tcps) were dependent on the str7

Figure 1.4. DSC thermograms of cyclic (left) and linear poly (N-n-alkyl glycine)s (right) during
the second heating cycle (n in the plot designates the number of carbons on the n-alkyl side chains).
Reproduced from Ref.40 with permission from American Chemical Society.

uctural and electronic properties of the side chain, the backbone length, as well as the solution
concentration, whereas poly (N-propargyl glycine) was not soluble in water.30 The Tcps were found
to increase in the order C3 = n-propyl (15-25 oC) < allyl (27-54 oC) < isopropyl (47-58 oC). The
Tcps were also shown to be concentration-dependent: decrease with increasing solution
concentration. Long-term annealing of the aqueous solution of poly (N-(n-propyl) glycine) and
poly (N-allyl glycine) at above their cloud point temperatures lead to the formation of crystalline
microparticles and rose bud type morphology driven by the crystallization of the polymer
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coacervates. The crystallization mechanism and detailed information of the crystalline structure
has not been reported yet.
Another way to tune the cloud point transition temperature is to incorporate both
hydrophobic and hydrophilic segments through copolymerization strategy. NHC-mediated or
primary amine-initiated copolymerization of Et-NCA and Bu-NCA produced linear or cyclic
random copolymers, PNBG-r-PNEG, which were thermally responsive in water (Figure 1.5).43
The cloud point temperature (Tcp) in aqueous solution can be readily tailed in the range 20-60oC
by controlling the solution concentration, polymer composition, salt added, and polymer
architecture (cyclic vs linear). The Tcp was systematically shifted to higher temperature with the
increase of NEG content in the copolymer, indicating the critical role of hydrophobic effect in the
thermoresponsive behavior. The molecular weight of the copolymer with constant composition
was shown to have negligible effect on the Tcp. Interestingly, the cyclic copolyepeptoids exhibited
4-6 oC lower Tcps than the linear analogs with identical composition, which is tentatively attributed
to the less entropic loss of the cyclic copolymers during the solution phase transition associated
with its more compact conformation. The decreased Tcps with increasing concentration of the
copolymer solutions indicated that intermolecular aggregation rather than intramolecular coil-toglobule transition was mainly responsible for the reversible phase transition. The Tcp depression
caused by the addition of various salts is in agreement with the trend of Hofmeister series with
Na2SO4 decreasing the Td most, followed by NaCl and NaI.
Bottlebrush copolypeptoids prepared by grafting-through method via the ROMP of
norbornenyl-terminated PNEG-r-PNBG macromonomers underwent thermoresponsive phase
transition in aqueous solution similar to the linear macromonomers (Figure 1.6).44 In contrast to
the linear macromonomers, the bottlebrush copolypeptoids underwent cloud point transition that
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Figure 1.5. Plots of cloud point temperature (Tcp) versus the molar fraction of NEG segment in the
cyclic and linear P(NEG-r-NBG) random copolymers bearing different end groups and their
respective linearly fit curves [cyclic NHC-P(NEG-r-NBG) (●, —), linear Bu-P(NEG-r-NBG) (▲
,—) and linear Bn-P(NEG-r-NBG) ( ■ , —). Reproduced from Ref.43 with permission from
American Chemical Society.
is strongly dependent on the thermal history of the aqueous solutions. Freshly prepared aqueous
solutions of the bottlebrush copolypeptoids exhibited no notable phase transition, whereas the
solutions underwent sharp and reversible cloud point transition after thermally annealing at high
temperature. Interestingly, the aqueous solutions of the bottlebrush copolypeptoids showed normal
cloud point transition similar to the linear macromonomer which was independent of the thermal
history upon addition of inorganic salt. It was suggested that the conformational reorganization of
the bottlebrush copolypeptoids was facilitated upon thermal annealing and addition of salt to favor
the hydrophobic collapse and intermolecular aggregation, resulting in a thermoresponsive phase
transition.
1.3.3 Solution self-assembly of amphiphilic polypeptoid copolymers
Self-assembly of PNMG-b-poly (N-alkyl glycine). Self-assembly of block copolymers
have been a long-standing interests both in the fundamental investigation and application
perspective. Self-assembly based on many amphiphilic and double hydrophilic hetero-block and
graft copolymers, including PNMG-b-polypeptides, PNMG-b-poly (L-lactide) (AB, A2B, A3B ar-
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Figure 1.6. Polypeptoid bottlebrush copolymers comprised of linear P(NEG-r-NBG) side chains
exhibited cloud point transitions that are dependent on the thermal history. Reproduced from
Ref.44 with permission from Royal Society of Chemistry.
chitectural types), PEG-b-PNMG and PNMG-b-Cn=12-18, in solution have been studied.15, 26 The
recent report on aggregation behavior of block copolypeptoids, composed of hydrophilic PNMG
(DP ~ 50) and poly (N-alkyl glycine) with C2-C5 aliphatic side chains, studied the effect of
hydrophobicity and chain length of the solvophobic poly (N-alkyl glycine) on their critical micelle
concentration (CMC) and the size of aggregates formed in aqueous solution.45 Micellation was
observed for the copolypeptoids containing C3-C5 aliphatic side chains with CMC value ranging
from 0.6 × 10-6 to 0.1 × 10-3 M. The tendency to form micelles increased with increasing
hydrophobicity of the side chains in the solvophobic block (C5>C4>C3). It was also found that
increasing the chain length of hydrophobic block resulted in the formation of larger aggregates.
The aggregate size and distribution were also strongly dependent on the temperature and solvent
with smaller aggregate size in buffer (pH=7.4) than in water.
Redox-responsive polypeptoid micelles. Recently, a redox-sensitive micelle based on
poly (N-ethyl glycine)-b-poly [(N-propargyl glycine)-r-(N-decyl glycine)] (EPgD) synthesized by
sequential ROPs of the corresponding monomers using benzyl amine as the initiator, was reported
(Figure 1.7).19 The copolypeptoids underwent micellation in aqueous solution with CMC in the
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0.075-0.12 mg/mL range at room temperature. Similarly to previously reported studies, the CMC
value was gradually decreased with the increase of the hydrophobic segments. The selected
copolypeptoid (E204Pg13D15) formed well-defined spherical micelles in aqueous solution which
was further crosslinked in the micellar core with two different crosslinkers using copper-mediated
alkyne-azido cyclo-addition CuAAC chemistry. The core-crosslinked micelles (CCLMs) bearing
a disulfide linkage were cleavable in the presence of reducing agents (e.g., dithiothreitol, DTT),
whereas the other micelles permanently crosslinked with 1,4-diazidobutane were not. The CCLMs
showed a mono-modal size distribution and a decreased hydrodynamic diameter (d = 42.4 ± 0.8
nm) in comparison to the non-crosslinked micelles (NCLMs) (d = 60.1 ± 0.9 nm), as evidenced by
dynamic light scattering (DLS) analysis. As expected, the NCLMs disassembled in DMF, a nonselective solvent for all the blocks, with an increase of the hydrodynamic size, broadening of size
distribution (PDI = 0.41) and the appearance of unimers in the DLS analysis. In contrast, the
CCLMs maintained the micellar structure with narrow size distribution (d = 59.2 ± 1.6 nm, PDI =
0.19) in DMF due to the covalent crosslinking in the micellar core. Spherical micelles with some
short cylinders were observed from TEM analysis of dried CCLMs and NCLMs staining with
uranyl acetate with average diameter of the CCLMs (21.1 ± 2.3 nm) comparable to that of the
NCLMs (22.8 ± 2.9 nm), suggesting no appreciable change of the micellar morphology after
covalent core-crosslinking. Fluorescent dye (1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) or
hydrophobic anticancer drug doxorubicin (DOX) was further encapsulated into CCLMs and their
releasing behavior were monitored. For the CCLMs with DOX encapsulated, a maximal 23% drug
loading capacity and a 37% drug loading efficiency was achieved and the DOX was released in a
time-dependent manner associated with the disassembly of the CCLMs upon in contact with DTT.
In contrast, minimal releasing of DOX was observed even after 30 h without the presence of DTT,
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suggesting that the time-dependent DOX release was based on the cleavage of the disulfide
crosslinkers in the micellar core and the subsequent micelle disassembly. The redox-responsive
property make the CCLMs to be a potential smart drug delivery vehicle.

Figure 1.7. Synthesis of redox-responsive and core-cleavable micelles based on amphiphilic block
copolypeptoids PNEG-b-P(NPgG-r-NDG) and their potential use for DOX encapsulation. Reproduced
from Ref. 19 with permission from American Chemical Society.
Temperature-responsive polypeptoid micelles. Amphiphilic coil-crystalline cyclic diblock
copolyeptoids (c-PNMG-b-PNDG) and their linear analogue (l-PNMG-b-PNDG) were synthesized by
NHC-mediated and BnNH2-initiated ROP of the corresponding monomers, respectively, and their selfassembly in methanol at low concentration (1mg/mL) was investigated. 46 Both the cyclic and linear
PNMG-b-PNDG were shown to self-assemble into cylindrical micelles with PNDG as the core and
PNMG as the shell in uniform diameter in methanol at room temperature over the course of several
days after annealing at 70oC (above the first melting temperature of PNDG) (Figure 1.8). The kinetic
study of micellation for both cyclic and linear block copolypeptoids in methanol monitored by cryoTEM at different time intervals revealed the initial formation of amorphous spherical micelles followed
by subsequent reorganization into micrometer-long crystalline cylindrical micelles, suggesting that the
crystallization of the PNDG hydrophobic core was the driven force for the cylindrical micelle
formation. In addition, the spherical-to-cylindrical morphological transition occurred more rapidly for
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the linear copolypeptoid than for the cyclic analogue, which was probably due to the retarded
crystallization of PNDG core for the cyclic analogue associated with the conformational constraint.

Figure 1.8. Synthesis of c-PNMG105-b-PNDG10 block copolypeptoid and its Cryo-TEM images in
dilute methanol solutions after 1 h (spherical micelles) and 15 d (cylindrical micelles). Reproduced
from Ref. 46 with permission from American Chemical Society.
At higher concentrations in methanol (5-10 wt%), both cyclic and linear diblock copolyeptoids
(PNMG-b-PNDG) were shown to form free-standing gels consisting of entangled fibrils at room
temperature. The gelation is thermoreversible that reverse back to isotropic solution upon heating to
70oC, which results in the morphological change of crystalline cylindrical micelles to amporphous
spherical micelles or non-associated polymers induced by the melting of the PNDG crystalline
domains, as evidenced by both temperature-dependent 1H NMR and DLS analysis. The cyclic polymer
gels exhibited higher sol-to-gel transition temperatures and higher gel stiffness compared to the linear
analogs, suggesting enhanced crystallinity in the fibrilar network in the formers relative to the latters.

1.4 Biologically relevant properties
1.4.1 Cytotoxicity of polypeptoids
It is important to investigate the cytotoxicity of polypeptoids before being further used in
biomedical and biotechnological fields. The cytotoxicity assessment of polysarcosine and its
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copolymers as well as other water soluble polypeptoids in different cell lines have been reported.
Random copolypeptoid of cyclic P(NEG74-r-NBG15) exhibited minimal cytotoxicity (cell viability >
90 %) towards human embryonic lung fibroblasts (HEL229) up to 5.0 mg/mL concentration after
incubation in PBS buffer at 37oC for 24 h, as evidenced by CellTiter-Blue® assay.43
The cytotoxicity of the random copolymer of PNMG-r-PNEG with different compositions
synthesized from primary amine initiated copolymerization of the corresponding NTA monomers (MeNTA and Bu-NTA) was also evaluated in human heptoblastoma cells (HepG2) using the MTT cell
viability asssay.47 It was found that the relative cell viability was dependent on the polymer
composition and concentration. All the polymers investigated showed increased cytotoxicity towards
HepG2 cells with increasing polymer concentration from 0.05 to 3.0 mg/mL. P(Sar 48-r-NBG26) with
relative lower PNBG content displayed higher cell viability (>75%) at the whole concentration range
investigated (0.05-3 mg/mL) comparable to that of PNMG, whereas P(Sar47-r-NBG30) and P(Sar42-rNBG36) with relative higher PNBG content exhibited a significant increase of cytotoxicity at 3.0
mg/mL concentration, presumably due to the partial precipitation of these polymers at this
concentration associated with their onset cloud point being close to the incubation temperature.
The homopolymer PNMG (Mn =2.1 kDa, PDI=1.31), diblock and triblock copolypeptoids
(PNMG-b-PNprG, PNMG-b-PNpenG, PNMG-b-PNprG-b-PNMG) with MW in the range 3.6-9.6 kDa
all exhibited minimal cytotoxicity (cell viability > 90 %) toward HepG2 cells up to 10 mg/mL polymer
concentration, as evidenced by WST-1 assay.45

The above mentioned core-crosslinked micelles (CCLMs) composed of hydrophobic
[P(NPgG-r-NDG)] core and hydrophilic (PNEG) corona with redox-responsive disulfide crosslinkers
or non-redox responsive permanent crosslinkers all exhibited minimal cytotoxicity (cell viability > 95
%) towards HepG2 cells up to 1.0 mg/mL concentration upon incubation in MEMS medium for 48 h,
as evidenced by MTT assay. Both the redox-reponsive and non-redox responsive CCLMs loaded with
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the anticancer drug (DOX) displayed time and dosage dependent cytotoxicity towards HepG2 cells.
The DOX-loaded redox-responsive CCLMs showed higher cytotoxicity relative to the permanently
crosslinked CCLMs through the whole DOX dosage and time investigated, suggesting more efficient
release of DOX and more cell death associated with the cleavage of the disulfide crosslinkers of the
former under reductive environment in HepG2 cells. The DOX dosage- and time-dependent
cytotoxicity of the permanently crosslinked CCLMs, in a relatively lower level, was presumably due
to the degradation of polymers in the cellular environment.

1.4.2 Degradation of polypeptoids
Hydrolytic degradation. Polypeptoids, with a tertiary amide linkage on the backbone, are
potentially degradable through hydrolysis. polysarcosine-b-poly(L-proline) copolymer was shown to
degrade into the corresponding amino acids under highly acidic conditions (6 N HCl, 120 °C, 24 h).48
Since the hydrolysis of polypeptoids occurred under such a harsh condition, perhaps the hydrolytic
degradation of polypeptoids in the cellular environment is minimal and slow.

Enzymatic degradation. The incorporation of tertiary amide bonds is known to enhance
protease resistance in peptidomimetic therapeutics.26 Currently there is no systematic investigation
on the enzymatic degradation of high MW polypeptoids. Many studies on peptoid oligomers
showed their enhanced protease resistance compared to peptide analogs. In sharp contrast to the
peptide analogs that are readily protease degradable, the sequence-specific peptoid oligomers
exhibited no protease degradation with the presence of proteases including carboxypeptidase A,
papain, pepsin, trypsin, elastase, and chymotrypsin.16-17 A reasonable hypothesis was made that proline
imminopeptidase may also cleave the N-sarcosine terminus26, according to the reported observation
that the digestion of the copolymer comprised of

L-proline and sarcosine with proline

imminopeptidase produced 4.4 times higher free L-proline that of theroretically predicted49. Thus, the
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enzymatic degradation of (poly) peptoids should not be completely ruled out and more investigations
need to be carried out.
Oxidative degradation. It is important and necessary to study the degradation behavior under
oxidative conditions as increased local concentration of various reactive oxygenated species (ROS) are
generated by oxidative stress in various diseased states under cellular environment. 15 A comparative
investigation on the oxidative degradation of PNEG, PEG and poly (2-oxazoline) (Pox) was conducted
with the presence of ROS (e.g., HOO∙, HO∙) generated from the H2O2/Cu2+ source.20 It was found that
all polymers investigated were degradable at 50 mM H2O2 and Cu2+, with PEG being significantly
more stable than the PNEG and POx. Faster degradation rate was observed at higher H 2O2
concentration. It was also shown that high MW polymer exhibited faster degradation in terms of
percentage molecular weight reduction over time in comparison to the corresponding low MW
polymer, suggesting chain scission as a main mode of degradation.

1.5 Hydrogels in tissue engineering
Hydrogels are three-dimensional (3 D) hydrophilic polymeric networks that can absorb and
retain a considerable amount of water.50 Hydrogels have received continued interest for
encapsulating cells and most recently hydrogels have become especially attractive to be used as
tissue engineering scaffolds for repairing and regenerating a variety of tissues due to their highly
water-swelled 3 D environment that are similar to soft tissues and allow diffusion of nutrients,
metabolites and growth factors through the elastic networks.50-55
A major goal of hydrogels in tissue engineering technology is the development of injectable
hydrogels. In this case, the hydrogel precursors, bioactive agents and/or drugs are mixed in
aqueous solutions and immediately form hydrogels upon injection into targeted sites of body using
syringe administration. The injectable hydrogels allow an effective and homogeneous
encapsulation of drugs/cells for both in in vitro and in vivo studies. Moreover, the high moldability
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of injectable hydrogels can adapt to the defect shape of tissues. In addition, it provides a convenient
and minimally invasive method for in vivo surgical operation, causing smaller scar size, less pain
and faster recovery for patients.55-56 The immediate in situ gel formation is resulted from ether
physical crosslinking in response to environmental stimuli such as pH value, temperature, ionic
concentration, or chemical crosslinking through chemical reactions such as Michael addition,
Schiff base, disulfide bond formation, etc. In contrast to the chemically crosslinked hydrogels
which usually undergo significant volume changes during phase transition, the physically
crosslinked hydrogels usually exhibit sol-gel transitions without marked volume changes. Besides,
the crosslinking agents and/or photo irradiation used, as well as the heat released in chemically
crosslinked hydrogels may damage the encapsulated cells and surrounding tissues. Therefore,
injectable physical hydrogels have received considerable interests in the recent years for tissue
engineering applications.
Another important design criterion of injectable hydrogels is their biocompatibility and
biodegradability.55 The hydrogels should be made of biocompatible materials that are degraded
into biocompatible products in body. It is desirable that the degradation rate of hydrogels matches
the rate of tissue formation to give enough space for cell activity, oxygen and nutrients migration
as well as for the new tissue formed. Meanwhile, the hydrogels should still maintain a relatively
stable environment with sufficient strength that match the tissue.
The injectable hydrogels used in tissue engineering should display the following
characteristics: 1) nontoxic to the cells encapsulated and the surrounding tissue, 2) hydrolytically
and/or enzymatically degradable, 3) controlled degradation rate that matches with that of the tissue
formation, 4) controlled mechanical strength to create and maintain a space for tissue development,
5) provide biological cues (e.g., cell adhesion) to facilitate tissue regeneration.52-53 6), low viscosity
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before gelation for easy encapsulation of cells and drugs, 7) mild while rapid gelation to avoid
toxicity and tissue damage, A variety of hydrogels, both naturally occurring hydrogels and
synthetic hydrogels, have been developed and investigated as potential tissue engineering
scaffolds. No one material will satisfy all the design criteria, but a wide range of hydrogels will
provide possible uses in different tissue engineering applications.
1.6 Naturally occurring hydrogels
Naturally occurring hydrogels are made from natural polymer-based materials, such as
proteins (e.g., collagen, gelatin and fibrin), and polysaccharides (e.g., alginate, chitosan, agarose
and hyaluronic acid), which generally have biocompatibility, cell-controlled degradability, and
intrinsic cellular interaction. They may, however, exhibit batch-to-batch variations and have
limited tunability to their structure and mechanical properties.53
1.6.1 Proteins: collagen, gelatin and fibrin
Collagens are the main protein of extracellular matrices (ECM) of mammalian tissues
including skin, bone, cartilage, tendon, and ligament, and comprise 25 % of the total protein mass
of most mammals.53-54 Collagen is basically composed of three polypeptide chains, which wrap
around one another to form a three-stranded rope by hydrogen and covalent bonds.57 Collagen
strands can self-assemble into entangled collagen fibers to form fibrillar gels at physiological
temperature and pH.57-58 Collagen, composed of specific combinations of amino acid sequences,
can be recognized by cells and degraded by metalloproteases secreted from the cells (e.g.,
collagenase, serine proteases).54 Gelatin, a derivative of collagen, is formed by the natural triplehelix structure of collagen into single-stand molecules. Gelatin can form physical thermoreversible hydrogels by lowering the temperature of its aqueous solution for the chains to undergo
coil-to-helix transition.59 The collagen- and gelatin-based hydrogels, however, are short of
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physical strength and have potential immunogenic responses, as well as have variations between
produced batches.53 To increase mechanical strength of the hydrogel, different chemical
modification methods, including combining with other natural components60-61 and chemical
crosslinking using carbodiimide62, nitrocinnamate63, or glutaraldehyde64 have been investigated.
Collagen and gelatin hydrogels have been used for reconstruction of a variety of organs and tissues
including liver, skin and small intestine.53
Fibrin, a fibrous and non-globular protein, is an important component of the extracellular
matrix involving in wound healing.55 Fibrin is biocompatible and promotes adhesion and migration
of numerous cell types (e.g., fibroblasts). Fibrin is biodegradable through cell-associated
enzymatic activity and the degradation rate can be controlled by apronitin, a proteinase inhibitor.
Fibrin forms hydrogel by the enzymatic polymerization of fibrinogen in the presence of
thrombin.53, 55 One disadvantage of the fibrin hydrogels is their weak mechanical strength.53
1.6.2 Polysaccharides: alginate, chitosan and hyaluronic acid
Alginate, obtained from brown algae, is a linear unbranched polysaccharide (Figure 1.9)
which are biocompatible, non-toxic and relatively cheap.53 Alginate can simply form hydrogels
with divalent cations such as Ca2+, Mg2+, Ba2+, and Sr2+.65 The alginate hydrogels, however,
undergo an uncontrollable and unpredictable process involving loss of divalent ions to the
surrounding medium and subsequent dissolution.53 Covalent cross-linking with adipic
dihydrazide, methyl ester L-lysine, and PEG-diamines has been investigated to prevent the
dissolution process and improve mechanical strength.66 In addition, many alginates have high
molecular weight that are typically above the renal clearance threshold (40 KDa) of the kidney.67
Moreover, alginate has limited cellular interaction and is unable to specifically interact with
mammalian cells.68
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Hyaluronic acid (HA) , consisted of alternate disaccharide units (Figure 1.9), is the only
non-sulfated glycosaminoglycan which plays an important role in wound healing, cell motility,
angiogenesis as well as in construction of ECM.55 Hyaluronic acid is degradable by hyaluronidase,
which exists in cells and serum.69 High molecular hyaluronic acid at high concentrations in
solution (e.g., 5 MDa at >0.1 mg/mL) can form viscoelastic entangled molecular networks, but the
HA solutions do not have long-lasting mechanical integrity.70 Hyaluronic acid hydrogels can also
be formed by covalent cross-linking with different compounds such as hydrazine derivatives71 and
radical polymerization of glycidyl methacrylate72, or by physical cross-linking of the
thermoresponsive moieties (e.g., PNIPAM) attached73. The drawback of hyaluronic acid hydrogel
is its low mechanical properties, which limited their application in tissue engineering.53
Unlike alginate, agarose which is another type of marine algal polysaccharide, forms
thermoreversible hydrogels containing bundles of associated double helices.53 The physical
structure and mechanical strength can be simply tuned by changing the solution concentration of
agarose.
Chitosan (Figure 1.9), a copolymer of glusocamine and N-acetylglucosamine, is derived
from natural chitin.56 Chitosan is biocompatible and biodegradable with enzymes such as
chitosanase and lysozyme.53 Chitosan forms hydrogel through ionic or chemical cross-linking with
glutaradehyde. Chitosan is positively charged at low pH’s, while generally insoluble in neutral
solutions as well as in most organic solvents. Various modifications of chitosan have been reported
to increase its water solubility and processability.
1.7 Synthetic polymer-based hydrogels
In contrast to hydrogels based on naturally occurring biopolymers (e.g., collagen, fibrin,
alginate, chitosan and hyaluronic) which have potential immunologic responses, poor mechanical
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Figure 1.9. Chemical structures of alginate, hyaluronic acid, and chitosan.
strength and variation from batch to batch, synthetic polymer-based hydrogels offer the advantage
of adjustable mechanical strength, chemical composition and function, and gel morphologies, as
well as their lack of immune responses, making it possible to tune the material properties for
specific biomedical and biotechnological applications. Most of the synthetic polymer-based
hydrogels, nevertheless, are non-biocompatible and non-degradable in physiological environment,
and extensive purification steps may be required to remove any toxic residue that are left from
their synthesis or processing. In addition, in contrast to naturally occurring hydrogels, synthetic
hydrogels often do not exhibit any substantial biological activities (e.g., cell adhesion) to induce
differentiation and proliferation of cells and tissue regeneration. Therefore, the biodegradable and
bioactive synthetic polymer-based hydrogels have received special attention in the recent years
and various strategies have been applied to endow them bioactivity (e.g., cell adhesion and
migration) for various biological applications such as tissue engineering. Importing biological cues
such as components of specific tissues (e.g., chondroitin sulfate, hyaluronic acid), growth factors
(e.g., TGF-β1), extracellular matrix protein-derived cell-adhesive peptide (e.g., RGD) to the
synthetic hydrogels through covalent linkage is a common strategy to incorporate biological
activities to synthetic hydrogels.74-77 This strategy, though effective, has the drawbacks of
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enhanced synthetic complexity, potential emergence of cytotoxicity, and altered physicochemical
properties of the hydrogels. By contrast, synthetic hydrogels that are inherently biologically active
and can modulate cell function and differentiation de novo without additional biological cues or
factors will not only facilitate the preparation of tissue engineering scaffold but also provide an
improved platform to investigate the factors that give rise to the biological activities.74 For tissue
engineering applications, it is desirable that the hydrogel scaffold not only have tunable
mechanical stiffness and morphologies that can be made to match those of the native tissues but
also exhibit biological activities that can modulate the cell migration, proliferation, and
differentiation.52, 54
1.7.1 Hydrogels based on amphiphilic block copolymers: AB, ABA and BAB hydrogles
Hydrogels based on AB, ABA and BAB block copolymers, where A and B signify the
hydrophobic/thermoresponsive and hydrophilic blocks, respectively, have been widely
investigated in the past. The general gelation mechanisms for the amphiphilic block copolymers
was the association of formed micelles in aqueous solution with hydrophobic A block as the core
and hydrophilic B block as the shell. Among them, the polypeptide and polyester based
copolymers were of significant interest due to their biocompatibility and biodegradability.
Hydrogels based on polyesters. Aliphatic polyesters, including poly (glycolic acid)
(PGA), poly (L-lactic acid) (PLLA), and copolymers (PLGA), have received long-standing interest
in medical applications and are considered to be biocompatible and biodegradable by the FDA.53,
78-80

Over the last decades, various amphiphilic copolymers of biocompatible PEG and polyesters,

including diblock, triblock, multiblock architectures, have been developed as gelators. The block
copolymers, PEO-PLLA (BA) and PEO-PLLA-PEO (BAB), formed micelles driven by the
hydrophobic interactions of PLLA blocks in aqueous solutions and formed hydrogels at high
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concentration levels (> 12wt%) caused by the association of micelles.81-82 The copolymer solutions
exhibited sol-to-gel transition with decreasing temperature from higher temperature to the body
temperature (37oC). The sol-gel transition temperature and the onset gelation concentration can be
easily tuned by changing the block length of PLLA. For example, the sol state of PEO-PLLA-PEO
(MW, 5000-2040-5000) at 45oC formed gel upon injection into a rat, making it very promising for
drug delivery and/or tissue engineering. The aqueous solution of the ABA type copolymer (PLLAPEO-PLLA) bearing two hydrophobic blocks can form strong gels at body temperature with elastic
moduli greater than 10,000 kPa, which is an order of magnitude higher than previously reported
physically associated gels of similar chemistry.83 These ABA hydrogels showed tunable elastic
moduli in the range 100-18,300 Pa at ambient and physiological temperatures by changing the
solution concentration and block length of PLLA, render them potential for soft tissue engineering
where native tissues have moduli in the kPa range. An equimolar mixture of enantiomeric
copolymers, PLLA-PEG/PDLA-PEG or PLLA-PEG-PLLA/PDLA-PEG-PDLA, can form
thermoresponsive hydrogels (G'~1000 Pa) with sol-gel transition occurred around 37oC by the
stereo-complexation of the PLLA and PDLA segments.84-85 Their critical gelation concentrations
were considerably lower compared to polymer solutions containing only the single enantiomer.
The enantiometic PEG-(PLA)8 star block copolymers (10 wt%, 1.9 kPa) exhibited higher storage
moduli than those based on PEG-(PLA)2 (13 wt%, 0.9 kPa).86 One disadvantage of the
stereocomplex hydrogels is the relatively long gelation time.87 To manipulate the degradation rate
of copolymers of PEG and PLA, the ester bond linked the two blocks was changed to an amide
bond. It was shown that PEG-(NHCO)-(PLA)8 displayed slow degradation in vitro compared to
PEG-(OCO)-(PLA)8.88 Comonomer (glycolic acid) was incorporated to PLA to manipulate the
gelation concentration, gelation temperature and gel modulus etc.89 The sequence of lactic acid
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and glycolic acid in the copolymer influenced the hydrophobic/hydrophilic balance and thus alters
the macroscopic physical gelation in water.90 Mixing homopolymers or block copolymers to
gelator solutions was another simple method to tune the gelation properties. The addition of PEG
homopolymer to PLGA-PEG-PLGA aqueous solution lead to a gelation at a lower temperature,
probably due to the immiscibility between the PEG and the hydrophobic PLGA block.91 The recent
study showed the effect of molecular weight distribution (MWD) of middle block PEG on the
phase transition of the PLGA-PEG-PLGA aqueous solutions: a wider MWD of PEG block
enlarged the copolymer micelles and increased the solution viscosity, making it gel at low
temperatures.92
Poly (ε-caprolactone) (PCL) is another well-known biodegradable polyester and has been
extensively investigated in biomedical and biotechnological fields.93-94 The triblock copolymer
PCL-PEG-PCL (ABA) and PEG-PCL-PEG (BAB) (>15 wt%) underwent sol-gel-sol transition as
the temperature increases from 10-60oC.95-96 The mechanism of clear sol-to-turbid gel transition
seems to be micellar aggregation, whereas the turbid gel-to-turbid sol transition seems to be due
to the higher extent of aggregation driven by an increase in the molecular motion of PCL
accompanying the core-shell structure breakage. The gel modulus was increased as the pH
increased from 2 to 8 due to the decreased water solubility of the copolymer and hence hardening
of the gel modulus. Compared to PEG-PCL-PEG, PCL-PEG-PCL showed a lower sol-to-gel
transition temperature and larger gel window (15-32 wt%), which seems to be related to the
enhanced intermicellar bridges of PCL-PEG-PCL. The aqueous solutions of these triblock
copolymers, however, were not stable at room temperature due to the crystallization of PCL.97 It
was reported that PCTC-PEG-PCTC with incorporation of comonomer (trimethylene carbonate)
in PCL blocks98 or multiblock PEG/PCL copolymer97 increased the sol stability while keep the
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thermogelling property. The chondrocytes encapsulated in PCTC-PEG-PCTC hydrogel showed a
higher expression of collagen type II and aggrecan and suppression of collagen type I (fibroblastic
gene) compared to the control, as evidenced by RNA extraction and reverse transcription
polymerase chain reaction (RT-PCR), suggesting the excellent differentiation of chondrocytes in
the hydrogel.98
Hydrogels based on polypeptide block copolymers. Polypeptides have emerged as
attractive structural elements for hydrogel networks due to their potential biodegradability, a wide
range of chemical functionality, and adoption of ordered conformations that can drive structure
formation and also respond to stimuli.99-102 Various hydrogels based on amphiphilic polypeptide
copolymers have been reported. Their self-assembled secondary structures (e.g., -helixes, sheets, random coil) in aqueous solutions played a critical role in the sol-to-gel transition.103-105
The ionic hydrogels composed of poly-L-lysine-b-poly-L-leucine diblock and poly-Llysine-b-poly-L-leucine-b-poly-L-lysine

triblock

copolypeptides

formed

hydrogel

at

concentration as low as 0.25% induced by the rod-like helical secondary structure of
enantiomerically pure poly-L-leucine blocks.103 These hydrogels showed high stability in high
ionic strength media such as aqueous buffers and cell growth media,104 however, the copolymers
containing positive charges displayed cytotoxicity to in vitro cells106 and were not
thermoresponsive in aqueous solutions.
The copolymers of PEG and polyalanine are one of the mostly investigated amphiphilic
polypeptide copolymers in hydrogel formation and in both in vitro and in vivo biological studies.
The -sheet conformation of L-polyalanine plays a critical role in developing a fibrous assemblies
in aqueous solutions as well as the sol-to-gel transition of amphphilic PEG-polyananine.105, 107 It
was shown that only the L-isomer showed a sol-to-gel transition in physiological important
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temperature window (20-40 oC) at low concentration (6-12 wt%), while the DL-isomer remained
a random coil structure and exhibited much higher gelation concentration (> 16 wt%) and gelation
temperature (>70oC).105 The stereochemistry (L and D) also greatly affect the biological response
of polypeptide copolymer hydrogels. The histology study showed that only the hydrogel of Lisomer (PEG-L-PAF) was significantly degraded by cathepsin B and elastase both in vitro and in
vivo and caused milder acute inflammation compared to the D-isomer hydrogel.108 The PEG-LPA thermogels were reported to be used as cell scaffolds for cell proliferation, cell differentiation
and tissue formation. It was shown that PEG-L-PA hydrogel encapsulated with fibroblasts formed
in situ improved the formation of collagen types I/III and accelerated the wound closure on
incisions of rat skin compared to the controls.109 The PEG-L-PA hydrogels were also encapsulated
with tonsil-derived mesenchymal stem cells (TMSCs) and adipose-tissue-derived stem cells
(ADSCs), to facilitate the hepatogenic110 chondrogenic111 differentiation, respectively. Efforts
were made to control the differentiation pathway of stem cells encapsulated in hydrogels. The
recent study incorporated polystyrene microspheres with different functional groups in in situ
formed PEG-L-PA hydrogels to manipulate the differentiation pathway of TMSCs. The TMSCs
preferentially underwent adipogenesis in ammonium (-NH3+)- or thiol (-SH)-functionalized
polystyrene microsphere incorporated hydrogels; chondrogenesis in the thiol, phosphate (PO32-)-,
or carboxylate (-COO-)-functionalized polystyrene microsphere incorporated hydrogels; and
osteogenesis in phosphate-, carboxylate-functionalized or neat polystyrene microsphere
incorporated hydrogels.112 The PA113-114, PAF115 or PAL116 was end-capped to commercially
available PLX to enhance its gel duration for biomedical applications.
-esterified Polyglutamates is another common category of hydrophobic polypeptides as
hydrogel components. It was revealed that the subtle variation in the length of hydrophobic side
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group of polyglutamates greatly affected the gelation behavior of the PEG-Poly (L-glutamate)s
copolymers.117 The copolymers with polyglutamates bearing methyl and ethyl side chains
displayed significantly lower critical gelation temperatures (CGTs) compared to those bearing npropyl and butyl side groups due to the increased β-sheet conformation of the formers. In addition,
the block copolymers showed no detectable cytotoxicity against HeLa cells and accelerated
degradation in buffer containing proteinase K compared to controls. To confer bioactivities to the
hydrogels, poly poly (γ-propargyl-L-glutamate) (PPLG) was used to react with azide-modified
bioactive molecules, such as biotin and galactose via click chemistry.118 The hydrogel of PEGPPLG functionalized with hydrophilic galactose was found to improve cell adhesion, probably due
to its adhesion of fibronectin in cell ECM. In contrast, the biotin functionalized hydrogel lead to
suppressed effect on cell adhesion compared to galactose functionalized hydrogels, which may
due to the relatively hydrophobic character of biotin that tend to aggregate into the micelle core.
The galactose and biotin changed the phase transition temperature of the block copolymer as a
result of the variation of hydrophilic/hydrophobic balance. The sol-to-gel transitions of these PEGpolyglutamate based copolymers, however, were relatively broad with the transition temperature
window larger than 20oC.
The above mentioned hydrogel formation of polypeptide copolymers is driven by
dehydration of the PEG segments, as well as the transition of polypeptide segments to β-sheet rich
conformation at elevated temperature. The β-sheet structures stabilized hydrogels formation via
interchain hydrogen bonding, but also cause limited reversibility of the hydrogel transition.105, 107,
114-117,

119

The

poly(γ-[2-(2-methoxyethoxy)ethyl]-rac-glutamate)-block-poly(γ-[2-(2-

methoxyethoxy)ethyl]-L-glutamate-stat-L-leucine), (rac-EP2)-(EP2/L), was currently the only
reported thermoreversible hydrogels based solely on synthetic polypeptide components.120 EP2 is
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known to be -helical with a lower critical solution temperature (LCST) above 37oC in aqueous
solutions.121 The EP2 in the EP2/L block of the copolymer was hydrophilic at low T and became
hydrophobic with increased temperature which further associated to form 3D hydrogel networks
with hydrophilic rac-EP2 segments exposed. The sol-gel transition was fully reversible over
repeated heating and cooling cycles, presumably due to the stable -helix conformations of the
thermoresponsive domains. In addition, the sol-gel transition temperature and gel stiffness can be
well tuned by changing the solution temperature and copolymer compositions. These nonionic
thermoreversible polypeptide hydrogels supported the viability of mesenchymal stem cells in vitro,
in contrast to some reported polyelectrolyte hydrogels which were cytotoxic to cells.106
Hydrogels based on PNIPAM. Poly(N-isopropylacrylamide) (PNIPAM), showing a
LCST in water close to body temperature (∼32 °C), is the most commonly investigated
thermoresponsive polymer in the design of thermogels.122-125 The PNIPAM-based copolymers are
water-soluble at temperature below LCST and formed thermoreversible hydrogels in aqueous
solutions due to hydrophobic interactions between PNIPAM blocks at elevated temperature. The
sol-gel transition temperature and gel stiffness can be tuned by changing the solution
concentrations and compositions of copolymers. The ABA-typed copolymer (PNIPAM-PMPCPNIPAM) with the bio-inspired polyphosphorylcholine as the middle block, PNIPAM-PDMAPNIPAM, PNIPAM-PVP-PNIPAM formed free-standing physical gels (∼ 1000 Pa) at 37oC in
PBS at concentrations higher than 10 wt%.126-127 The hydrogels of PNIPAM-PMPC-PNIPAM
were sufficiently biocompatible as a culture medium for V97 cells.126
1.7.2 Hydrogels based on ABC block copolymers
The AB-, ABA- or BAB-typed hydrogels often exhibit broad or slow sol-gel transitions or
high critical concentration (cgc, where cgc ≥ 10 wt %). In the ABA- and BAB-type hydrogels,
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the inefficient sol-gel transition characteristic has been attributed to the formation of loops, flower
micells, and dangling ends in the formation of micellar network.127-129 Recently, ABC-type
hydrogels, where A, B, and C refer to thermoresponsive block with lower critical solution
temperature (LCST), hydrophilic and hydrophobic block, respectively, have received considerable
interest due to their much sharper so-gel transition and lower cgc. With the formation of separate
A and C domains, the intramolecular association of the end blocks to form loop configurations is
significantly suppressed, thereby giving rise to a rapid and sharp thermoreversible sol-gel
transition at low concentration (≤ 5 wt%) upon a temperature increase.128 Although ABC triblok
copolymer is an attractive structural motif for thermoreversible gelation, studies on the design,
characterization, and investigation of potential biomedical uses of ABC hydrogelators have been
limited. PNIPAM, showing a LCST in water close to body temperature (∼32 oC), is the most
commonly investigated thermoresponsive polymer in the design of ABC hydrogelators.128, 130-131
The earlier reported PNIPAM-PMPC-PPO triblock copolymer exhibit sol-gel transition around 37
C at high concentration (≥ 20 wt%) with low mechanical strength (G'∼25 Pa).130 Recently, a 5 wt

o

% aqueous solution of PEP-PEO-PNIPAM (PON) triblock copolymers was shown to undergo
thermoreversible sol−gel transition at 42 °C,128 which is higher than the physiological temperature.
The ABC copolymer (PON) was displayed much sharper sol-gel transition at a much lower
concentration, compared to the corresponding ABA copolymer (NON). A two-step gelation
mechanism was proposed, involving the initial formation of micelles with PEP cores at room
temperature and gelation due to PNIPAM block aggregation at elevated temperature. The
separation of micellation and gelation in the PON hydrogels greatly suppressed the looping
formation which happened in the NON hydrogels. The investigation of the aqueous solutions (1-5
wt%) of PON at different temperatures using cryo-SEM, cryo-TEM, and SANS further confirmed
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the two-compartment network structure consisting of distinct spherical PEP and PNIPAM cores
upon heating above the critical gelation temperature.132 Another recently reported cell protective
ABC copolymer (PNIPAM−PDMA−PPS) was shown to undergo rapid thermoreversible gelation
in PBS buffer at 2.5 wt % with a gelation temperature well below 37 °C.131 The reported hydrogel
was mechanically soft with storage modulus (G') lower than 1 kPa at 7.5 wt % polymer
concentration. The reported ABC synthetic polymers were all based on nondegradable
polymers.128, 130-131
Taking advantage of the synthetic development of polypeptoids, the attractive properties
of polypeptoids including the low cytotoxicity and potential biodegradability, and the effcient
gelation of ABC triblock copolymers, thermoresponsive ABC triblock copolypeptoids [i.e.,
poly(N-allyl glycine)-b-poly(N-methyl glycine)-b-poly(N-decyl glycine) (AMD)] with welldefined structure and varying composition have been synthesized by sequential primary amineinitiated ring-opening polymerization of the corresponding N-substituted N-carboxyanhydride
monomers (Al-NCA, Me-NCA, and De-NCA) were synthesized. The ABC block copolypeptoids
undergo sol-to-gel transitions with increasing temperature in water and biological media at low
concentrations (2.5−10 wt %). Detailed information was presented in Chapter 2. In Chapter 3, the
synthesis of highly water soluble polypeptoids bearing oligomeric ethylene glycol side chains and
their protein-resistant ability to protein lysozyme was presented. These PEGylated polypeptoids
are potentially to be a new benchmark of antifouling material. In Chapter 4, the solution selfassembly of coil-crystalline diblock copolypeptoids (PNMG-b-PNDG) was discussed.
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: THERMOREVERSIBLE AND INJECTABLE ABC
POLYPEPTOID HYDROGELS: CONTROLLING THE HYDROGEL
PROPERTIES THROUGH MOLECULAR DESIGN
2.1 Abstract
A series of ABC triblock copolypeptoids [i.e., poly (N-allylglycine)-b-poly (N-methyl
glycine)-b-poly (N-decyl glycine) (AMD)] with well-defined structure and varying composition
have been synthesized by sequential primary amine-initiated ring-opening polymerization of the
corresponding N-substituted N-carboxyanhydride monomers (Al-NCA, Me-NCA, and De-NCA).
The ABC block copolypeptoids undergo sol-to-gel transitions with increasing temperature in water
and biological media at low concentrations (2.5−10 wt %). The sol−gel transition is rapid and fully
reversible with a narrow transition window, evidenced by the rheological measurements. The
gelation temperature (Tgel) and mechanical stiffness of the hydrogels are highly tunable: Tgel in the
26.2−60.0 °C range, the storage modulus (G') and Young’s modulus (E) in the 0.2−780 Pa and
0.5−2346 Pa range, respectively, at the physiological temperature (37 °C) can be readily accessed
by controllingthe block copolypeptoid composition and the polymer solution concentration. The
hydrogel is injectable through a 24 gauge syringe needle and maintains their shape upon in contact
with surfaces or water baths that are kept above the sol−gel transition temperature. The hydrogels
exhibit minimal cytotoxicity toward human adipose derived stem cells (hASCs), evidenced from
both alamarBlue and PicoGreen assays. Furthermore, quantitative PCR analysis revealed
significant up-regulation of the Col2a1 gene and down-regulation of ANGPT1 gene, suggesting
that the hydrogel exhibited biological activity in inducing chondrogenesis of hASCs. It was also
* Chapter 2 previously appeared as Xuan, S.; Lee, C.-U.; Chen, C.; Doyle, A. B.; Zhang, Y.; Guo,
L.; John, V. T.; Hayes, D.; Zhang, D. Xuan, S.; Lee, C.-U.; Chen, C.; Doyle, A. B.; Zhang, Y.;
Guo, L.; John, V. T.; Hayes, D.; Zhang, D. Thermoreversible and Injectable ABC Polypeptoid
Hydrogels: Controlling the Hydrogel Properties through Molecular Design. Chem. Mater. 2016,
28 (3), 727-737. It is reprinted by permission of ACS Publisher (see page 260).
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demonstrated that the hydrogel can be used to quantitatively encapsulate water-soluble enzymes
(e.g., horseradish peroxidase) by manipulating the sol−gel transition. The enzymatic activity of
HRP remain unperturbed after encapsulation at 37 °C for up to 7 d, suggesting that the hydrogel
does not adversely affect the enzyme structure and thereby the enzymatic activity. These results
suggest that the polypeptoid hydrogel a promising synthetic platform for tissue engineering or
protein storage applications.
2.2 Experimental
2.2.1 General considerations
All chemicals used were purchased from Sigma-Aldrich and used as received unless
otherwise noted. THF, CH2Cl2, and acetonitrile used in polymerization reaction were purified by
passing through alumina columns under argon. 1H and 13C {1H} NMR were recorded on a Bruker
AV-400 Nanobay spectrometer, and the chemical shifts in parts per million (ppm) were referenced
to protio impurities of CDCl3 and CD2Cl2. SEC analyses were performed using an Agilent 1200
system (Agilent 1200 series degasser, isocratic pump, auto sampler and column heater) equipped
with three Phenomenex 5 μm, 300 × 7.8 mm columns, a Wyatt OptilabrEX differential refractive
index (DRI) detector with a 690 nm light source, and a Wyatt DAWN EOS multiangle light
scattering (MALS) detector (GaAs 30mW laser at λ = 690 nm). DMF with 0.1M LiBr was used as
the eluent at a flow rate of 0.5 mL min-1. The column and detector temperature was room
temperature. The standard used was twenty three pauci-disperse polystyrene standards (590 g·mol1

-1472 kg·mol-1 MW, Polymer Laboratories, Inc.). All data analysis was performed using Wyatt

Astra V 5.3 software.
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2.2.2 Monomer synthesis
All the monomers used were synthesized by adapting reported procedures.1 N-alkyl Ncarboxyanhydrides

(R-NCAs)

with

allyl,

butyl,

octyl,

decyl,

and

methoxyethyl,

methoxyethoxyethyl side chains were synthesized via synthetic routes (I), whereas Me-NCA was
synthesized via route II (Scheme 2.1).
Scheme 2.1.Synthesisof N-alkyl N-carboxyanhydrides (R-NCAs).

Figure 2.1.1H NMR spectrum of allyl-NCA in CDCl3.
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Figure 2.2. 13C {1H} NMR spectrum of allyl-NCA in CDCl3.

Figure 2.3. 1H NMR spectrum of Methyl-NCA in CDCl3.
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Figure 2.4. 13C {1H} NMR spectrum of Methyl-NCA in CDCl3.

Figure 2.5. 1H NMR spectrum of Decyl-NCA in CDCl3.
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Figure 2.6. 13C {1H} NMR spectrum of Decyl-NCA in CDCl3.
2.2.3 Polymer synthesis
All the ABC triblock copolypeptoids were synthesized by primary amine-initiated ringopening polymerization of the corresponding N-substituted N-carboxyany-drides (R-NCAs) in a
sequential manner. A representative procedure for the synthesis of A98M98D18 was presented. In
the glovebox, Al-NCA (136.3 mg, 0.97 mmol, [M1]0=0.4 M) was dissolved in anhydrous
acetonitrile. Stock solution of benzyl amine (104 µL, 92.7 mM, [M1]: [BnNH2]0=100:1) was
added. The reaction mixture was heated at 50 oC for 24 h to reach a complete conversion of
polymerization. Acetonitrile solution of Me-NCA (2.4 mL, 0.4 M, 0.97 mmol, [M1]0:[M2]0:
[BnNH2]0=100:100:1) was added to the above mixture and allowed to stir at room temperature for
another 24 h to reach a full conversion. Acetonitrile solution of De-NCA (475 µL, 0.4 M, 0.19
mmol, [M1]0:[M2]0:[M3]0:[BnNH2]0=100:100:20:1) was added and stirred at room temperature for
an additional 24 h. The polymer was precipitated out by the addition of excess THF. The polymer
was collected by filtration and washed with ample THF and hexane followed by drying under
vacuum (178 mg, 89%). The composition of the polymer was determined by 1H NMR
spectroscopy using end-group analysis. The number average degree of polymerization (DP n) of
48

each block was calculated based on the integration ratios of characteristic proton peaks due to
individual block. DPn (A) = (5 × integration of –CH=)/(1 × integration of C6H5); DPn (M) = (5 ×
integration of aCH3)/(3 × integration of C6H5); DPn (D) = (5 × integration of bCH3)/(3 × integration
of C6H5) (a. methyl protons of M block, b. methyl protons of D block).

Figure 2.7. 1H NMR spectrum of the A98M98D18 triblock copolypeptoid in CD2Cl2.

Figure 2.8. 1H NMR spectrum of the A45M47O10 triblock copolypeptoid in CD2Cl2
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Figure 2.9. 1H NMR spectrum of the A41M47B11 triblock copolypeptoid in CD2Cl2.

Figure 2.10. 1H NMR spectrum of the A50m55D11 triblock copolypeptoid in CD2Cl2.
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Figure 2.11. 1H NMR spectrum of the A46d42D9 triblock copolypeptoid in CD2Cl2.
2.2.4 Hydrogel preparation
The 5 wt% aqueous solution of triblock copolypeptoids used for the rheological
measurement was prepared by “thin-film hydration”, as reported by Zhou et al.2 Briefly, a known
amount of dry polymer was dissolved in CH2Cl2, followed by evaporation of the solvent under a
stream of N2 overnight to form a thin film on the wall of the vial. The thin film was further dried
under vacuum for 1 d. Nanopure water was added, and the solution was stirred at room temperature
for 3 d before further characterization. 1 wt% and 2.5 wt% aqueous solutions were prepared by
direct dilution of the concentrated solution (5 wt%).
2.2.5 Characterization of hydrogel and dilute solution of polymer
Rheological measurements. Rheological study was conducted using a TA AR 2000ex
rheometer. A parallel-plate geometry of 40 mm diameter was used. In each experiment,
approximately 0.3 mL of the hydrogel sample was loaded between the plates with a gap of 200
μm. The metallic plate covers were then put on the plates that were sealed with highly viscous oil.
Dynamic storage modulus (G') and loss modulus (G'') were measured by oscillatory shear
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experiments. Dynamic strain sweep experiments were conducted at a frequency of 10 rad/s at 25
o

C and 45 oC to determine the linear viscoelastic regime. Dynamic frequency sweep measurements

were conducted within the linear viscoelastic regime with angular frequency from 0.1 to 100 rad/s.
Temperature sweep measurements were conducted from 15 oC to 60 oC at a heating rate of 1
o

C/min. Below the critical gelation temperature, the solution was measured at a strain of 50 %, and

above the gelation temperature at a strain of 0.75 %. The storage moduli (G') show some
fluctuation after the sol-gel transition. This could be due to the structural reorganization within the
gels.
Dynamic light scattering measurement of dilute solution. An aqueous solution of
polymers (0.5 wt% in nanopure water) that was filtered through a 0.22 µm filter. All the DLS
measurements were conducted using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser
operating at 633 nm was utilized, and scattered light intensity was detected at an external angle of
173 oC using non-invasive backscatter (NIBS) technology. Data from three measurements with 12
scans for each measurement was recorded. At each temperature, the sample was equilibrated for 3
min.
Temperature dependent 1H NMR experiments of polymer solution. The temperature
dependent 1H NMR experiments of polymer solution was conducted on a Bruker AV-400 Nanobay
spectrometer. The A92M94D12 triblock copolypeptoid was dissolved in CD2Cl2 and D2O at 5 wt%
respectively. In CD2Cl2, the 1H NMR spectrum was obtained at 25 oC, whereas the spectra were
collected at 25, 37 and 60 oC with increasing temperature in D2O.
TEM/CryoTEM sample preparation and analysis. FEI Vitrobot was used for the sample
preparation of cryo-TEM experiment. 5 µL aqueous solution of ABC copolymer (1 wt%) was
applied to a 300 mesh lacey carbon coated TEM grid. Double side blotting to the grid for 2 seconds
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leaves a thin film on the grid. The grid then was quickly plunged into liquid ethane chilled by
liquid nitrogen. The vitrified sample grid was loaded in a single tilt liquid nitrogen cryo transfer
holder, and was then inserted to FEI G2 F30 Tecnal TEM operated at 120keV, with a FEI digital
camera and analyzed using FEI Digital Micrograph software. The grids for the regular TEM was
prepared by adding 5 µL polymer aqueous solution (0.2 wt%) onto the 300 mesh carbon grid
followed by blotting with a filter paper and drying at room temperature. The grids then were
stained with uranyl acetate for 1 min.
Cryo-SEM sample preparation and analysis. Aqueous Polymer solution of 5 wt%
A92M94D12 (~40 µL) was pipetted on top of a metal rivet and was heated up by a hot plate for gel
formation, indicated by the color change of the liquid drop from clear to white. The gel sample
was then plunged into liquid nitrogen, followed by fracturing at -130 oC using a flat-edge cold
knife. The solvent was sublimated at -95 oC for 5 min and the sample was sputtered with a
platinum-palladium composite at 10 mA for 88 seconds before imaging. The vitrified sample was
imaged on a Hitachi S-4800 field emission scanning electron microscope using cryo-mode
operated at a voltage of 3 kV.
Cloud point measurement of ABC triblock copolypeptoid solutions. Cloud point
measurements of aqueous solutions of both poly(N-allyl glycine) homopolymer (A) and
A98M98D18 triblock copolymers (1 wt%) were conducted using Varian Cary 50 Bio-UV-vis
spectrophotometer equipped with a Thermo/Neslab RTE-7 refrigerated bath circulator for
temperature control. The experimental temperature range is 15-60 oC and all UV-vis absorptions
were referenced against distilled water. The temperature at 50 % UV-vis transmittance (λ = 450
nm) is defined as the cloud point.
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2.2.6. Protein encapsulation study of hydrogel
10 µL of 0.14 mg/mL HRP in PBS buffer was added to 100 µL of aqueous polymer solution
(5 wt%) and well mixed. The mixture was incubated at 37 oC in an oil bath for different time (1 h,
4 h, 7 h, 24 h, and 7 d). After each time period, the mixture was cooled down to room temperature
and diluted with PBS buffer using 1.0 ml volumetric flask, which was further used for the kinetic
study. To a disposable cuvette, 3 ml of PBS buffer, 20 µL of 0.1 M Guaiacol in PBS buffer and 40
µL of the above diluted solution was added. 20 µL of 0.1 M H2O2 in PBS buffer was quickly
injected to the above mixture and well mixed. The cuvette was immediately monitored at room
temperature every 40 seconds by a Varian Cary 50 Bio-UV-Vis spectrophotometer at a wavelength
range of 200-600 nm. All UV-Vis absorptions were referenced against PBS buffer. For
comparison, the enzymatic activity of two sets of controls was measured using the same method
described above. One control involves incubation of HRP in PBS buffer at 37 oC for different
duration (1, 4, 7, 24 h and 7 d). The other control is the as-received HRP whose enzymatic activity
was directly measured in PBS at 25 oC.
2.2.7. Biological studies of hydrogels and polymer solutions
Adult stem cells isolation and culture. Liposuction aspirates from subcutaneous adipose
tissue were obtained from three healthy adult subjects (male = 1 and females = 2) undergoing
elective procedures. All tissues were obtained with informed consent under a clinical protocol
reviewed and approved by the Institutional Review Board at the LSU Pennington Biomedical
Research Center and used under an exempted protocol at LSU A&M College. Isolation of hASC
was performed as published.3 Passage 2 of each individual was used for in vitro hASC evaluation
on tissue culture treated plastic or on scaffold of hydrogel. In both cases, hASC were cultured in
stromal (control - DMEM, 10 % FBS, and 1 % triple antibiotic solution) media with media
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maintenance performed three times a week. For the live control, stem cells were cultured in plain
media. For the dead control, stem cells were cultured in media and then introduced to 70 % ethanol.
Extract cytotoxicity Assessment. The extract cytotoxicity study was modified based on
FDA protocol.4 The hydrogel samples (0.1 g) were incubated on an orbital shaker with 5 mL
stromal media at 37 C and 200 rpm/min for 7 days. The extractives were filtered (0.22 μm pore
size) and pipetted (100 μL/well) into a 96-well plate previously sub-cultured with hASC (2,500
cells/well) and incubated in a CO2 incubator at 37 C containing 5 % CO2 for 24 hours. 10 μL
alamarBlue® reagent to each well and re-incubated at 37 C in 5 % CO2 for 2 h. The fluorescence
was measured at an excitation wavelength of 530 nm and an emission wavelength of 595 nm using
a fluorescence plate reader. The tissue culture treated plastic 96-well plate served as a control
substrate.
hASC loading on ABC hydrogel and culture. The ABC hydrogel was filtered through a
0.22 µm filter at 20 C and 100 µL aliquots was mixed with 1 × 104 cells/µL for total volume of
10 µL. The cells and hydrogel mixture was transferred to a 96 well plate afterwards. 100 µL
stromal medium was added to each well after the cells/hydrogel mixture was solidified at 37 C.
In vitro hASCs viability on scaffolds with alamarBlue® stain. The viability of cells
within ABC hydrogel in stromal media was determined after 3 days using an alamarBlue®
metabolic activity assay. The cells/hydrogel mixture were removed from culture, washed three
times in PBS, and incubated with 10 % alamarBlue® in Hank’s balanced salt solution (HBSS)
without phenol red (pH 7) for 90 min. Aliquots (100 μL) of alamarBlue®/HBSS were placed in a
96-well plate in triplicate, and the fluorescence was measured at an excitation wavelength of 530
nm and an emission wavelength of 595 nm using a fluorescence plate reader.
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In vitro quantification of DNA on scaffolds. Total DNA content was used to determine
the number of cells on each scaffold as previously described.5 After the scaffolds were minced by
a scalpel and the DNA was digested with 0.5 mL 0.5 mg/mL proteinase K (Sigma-Aldrich) at 56
C

overnight, aliquots (50 µL) were mixed with equal volumes of 0.1 g/mL PicoGreen dye solution

(Invitrogen) in 96-well plates. Samples were then excited at 480 nm with a plate reader (Wallac
1420 multilabel hts counter). Scaffolds without cells were used as negative controls.
In vitro hASCs Viability on polymer solution with alamarBlue® Stain. The copolymer
was dissolved in stem cell media (40 % v/v). The solution was used as a stock solution to dilute
and receive concentration values of 20 %, 10 %, 5 %, 2 %, and 1 % copolymer in media. Stem
cells were seeded in a 96-well plate at a density of 40,000 cells per well and incubated for 24 h at

penicillin, streptomycin, and amphotericin) was subsequently replaced with serum-free media.
Polypeptoids were then added at 40, 20, 10, 5, 2, and 1 % (v/v) per well. Cells were incubated for
4 h before the medium was replaced with serum-containing media. Cell viability was assessed
using the standard alamarBlue® cell viability assay 24 h later. Following 4 h of alamarBlue uptake,
fluorescence data was collected at an excitation wavelength of 530 nm and an emission wavelength
of 595 nm using fluorescence plate reader.
Quantitative real-time polymerase chain reaction (QPCR). Quantitative real-time
polymerase chain reaction (QPCR) was utilized to examine the effects of the hydrogel on human
adult stem cell (hASC) differentiation. hASC were cultured in 100 µL of hydrogel (5 wt% of
A92M94D12 in medium) and stromal media (Dulbecco's minimal essential medium (DMEM), 10 %
fetal bovine serum (FBS), and 1 % antibiotic solution (penicillin, streptomycin, fungizone)) at 37
C

and 5 % CO2 in a humidified atmosphere. Following incubation, RNA was extracted with TRI
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Reagent® (Sigma) according to the manufacturer’s instructions. The isolated RNA was then used
to perform QPCR with iScript™ One-Step RT-PCR Kit with SYBR®Green (Bio-Rad) using a
MiniOpticon™ Real-Time PCR Detection System (Bio-Rad). Expression of the genes Col2a1 and
ANGPT1 was used to quantify the hydrogel’s ability to induce chondrogenic and angiogenic
differentiation, respectively. QPCR samples were normalized against the house keeping gene 18s
rRNA and relative to separate hASC cultures maintained in chondrogenic growth medium
(StemPro® Chondrogenesis Differentiation Kit; Life Technologies) and endothelial growth
medium (EGM™-2 BulletKit™; Lonza) with SingleQuots™ (Lonza) containing vascular
endothelial growth factor (VEGF), human basic fibroblast growth factor (hFGF-b), epidermal
growth factor, insulin-like growth factor-1, heparin, ascorbic acid, and 5 % FBS.
Statistical analysis. The results of alamarBlue, PicoGreen and QPCR analysis were
reported as mean ± standard deviation. Data was evaluated with one or two way analysis of
variance (ANOVA), and analyzed by Tukey’s minimum significant difference (MSD) post hoc
test for pairwise comparisons of main effects. A P-value < 0.05 was considered significant for all
comparisons.6
2.3. Results and discussion
2.3.1. Synthesis and characterization of ABC triblock copolypeptoids
A series of ABC triblock copolypeptoids have been synthesized by benzyl amine-initiated
ring-opening polymerization of the corresponding N-substituted N-carboxyanhydrides (R-NCAs)
in a sequential manner (Scheme 2.2). Representative 1H and

13

C {1H} NMR spectra of the

monomers were shown in Figure 2.1-2.6 in section 2.2. The hydrophobic C segment consists of
poly (N-alkyl glycine) where the alkyl groups is varied from butyl (B), octyl (O) to decyl (D) with
increasing hydrophobicity. The hydrophilic B segment consists of either poly (N-methyl glycine)
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(M) or poly(N-methoxyethyl glycine) (m) or poly(N-methoxyethoxyethyl glycine)(d)

with

increasing hydrophilicity. The M, m and d homopolymers are highly water soluble with solubility
in the 20-200 mg/mL range. The thermoresponsive A segment is based on poly (N-allyl glycine)
(A) for all samples. Poly(N-allyl glycine) has previously been demonstrated to be
thermoresponsive with cloud point in the 27-54 C range, which is dependent on the chain length
and concentration.7
Scheme 2.2. Synthesis of ABC copolypeptoids.

All polymerization reactions were conducted in 50 °C anhydrous acetonitrile and were
allowed to reach complete conversion prior to the addition of another monomer. The resulting
triblock copolymers were purified by precipitation in hexane and dried under vacuum prior to
further analysis. The ABC triblock copolypeptoid compositions were determined by 1H NMR
spectroscopy (Figure 2.7−2.11). For example, the number-averaged degree of polymerization
(DPn) of the AMD polymers (Entry 1−6, Table 2.1) was determined by the integrations at 0.91,
3.0, and 5.8 ppm due to the methyl protons in D and M blocks as well as the terminal alkenyl
protons in the A block relative to the integration of signals at 7.3 ppm due to the benzyl end-group.
The triblock copolypeptoids composition can be systematically adjusted by controlling the initial
monomer to initiator feed ratio (Table 2.1). The weight fraction of individual block is varied in the
0.31−0.50, 0.34−0.54, and 0.13−0.21 range for the A, B, and C segments, respectively (Table 2.1).
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Table 2.1. Molecular Parameters of ABC Triblock Copolypeptoids and the Corresponding
Hydrogel Properties.
Sample
compositi
on a

[M1]0:[M
2]0
:[M3]0:[I]
0

1

A98M98D

b

Mn(th
eor.)
(kDa)

Mn(N
MR)
(kDa) d

c

Mn(S
EC)
(kDa)

P
DI

f1 f

f2 f

f3 f
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(C)

e

g

G''
(Pa) h

G'
(Pa) h

E (Pa) i

e

100:100:
20

20.8

20.0

36.7

1.
04

0.
47

0.
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0.
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762±6
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D16
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0.
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8

573±2
2

4
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-j

-j

-j

9
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0

5
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3
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14

42.6±
1.1
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5

7
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1
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1

1
0
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a.

The numbers in subscripts correspond to the DPn of individual block determined by end-group
analysis using 1H NMR spectroscopy in CD2Cl2; b. initial monomer to initiator ratio; c. theoretical
molecular weights were calculated from the initial monomer to initiator ratio; d. determined by 1H
NMR analysis; e. determined by the SEC-DRI method using polystyrene standards (0.1 M
LiBr/DMF, room temperature); f.f1, f2, and f3 refer to the weight fraction of the thermoresponsive
A end block, the hydrophilic middle block and the hydrophobic end block respectively; g.Tgel is
the crossover point of G' and G'' in the plot of G' and G'' versus temperature: average of two
measurements; h. G' and G'' in the gel state at physiological temperature (37 oC): average of two
measurements; i.Young’s modulus is calculated using E = 2G (1+), G = (G'2+G''2)1/2,  = 0.5,  is
he Poisson’s ratio;8 j. The polymer solution did not form a gel at 37 oC.

Size exclusion chromatographic (SEC) analysis of the polymer products obtained after the growth
of each block revealed monomodal peaks that are consistently shifted toward lower elution time,
in agreement with the block copolymer formation (Figure 2.12). The polymer molecular weight
distribution remains narrow with low polydispersity indices (PDI) in the 1.03−1.15 range (Figure
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2.13), consistent with the formation of well-defined block copolypeptoid polymers. The molecular
parameters of the triblock copolypeptoid samples are summarized in Table 2.1.

Figure 2.12. Representative SEC chromatograms showing the successful enchainment for the
synthesis of the ABC triblock copolypeptoid (A98M98D18, Entry 1, Table 2.1).
2.3.2. Preparation of the ABC hydrogels
All aqueous solutions of ABC triblock copolymers were prepared by the “thin film
hydration” method, as reported by Zhou et al.2 All samples underwent thermoreversible gelation
in DI water, as evidenced by rheological measurements (vide infra). The 5 wt % solutions of
selected polymers (Entry 1, 2, 3, 5, 7, and 9, Table 2.1) form free-standing opaque gels at closeto-body temperature, and return to a free-flowing liquid when cooled down to room temperature
(Figure 2.14−2.15). The ABC triblock copolymers also underwent sol-to-gel transition in
biological media (stromal media) at the same concentrations.The sol-to-gel transition is rapid with
the formation of free-standing gels in less than 30 s. Repeated heating and cooling experiments
indicate that the sol-to- gel transition is fully reversible. The hydrogels appear opaque, suggesting
the occurrence of phase separation to some extent during gelation. The hydrogels are injectable th60

Figure 2.13. Representative SEC chromatograms of all ABC triblock copolypeptoids (Entry 1-10,
Table 2.1).
rough a 24 gauge syringe needle and maintain the shape upon contact with 37 °C surfaces or DI
water bath.

Figure 2.14. Optical images showing the thermoreversible gelation of A98M98 D18 at different
concentration in DI water.
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Figure 2.15. Optical images showing the thermoreversible gelation of ABC triblock copolymers
at 5 wt% in DI water.
2.3.3. Rheological characterization of the sol−gel transition
Rheological measurements of the ABC polypeptoid hydrogels were conducted to quantify
the gelation temperature and assess the relative mechanical stiffness of the hydrogels. Two
measurements were conducted for each sample (see representative data in Figures 2.16-2.18).
Temperature-dependent dynamic shear moduli (storage moduli G' and loss moduli G'') of the
polypeptoid aqueous solution were recorded at a frequency of 10 rad/s and heating rate of 1 °C/min
over a 15−60 °C temperature range. A representative evolution of G' and G'' with increasing
temperature is shown in Figure 2.18 for a 5 wt % aqueous solution of A98M98D18 (Entry 1, Table
2.1). The storage (G′) and loss modulus (G″) are both low with G″ larger than G′ at low temperature
range, which indicates the viscous liquid-like behavior of the solution. As the temperature
increases to the transition point, the G′ and G″ of the sample increase sharply to reach a crossover
point at which the G′ starts to exceed the G″, indicating an elastic solid-like behavior of the solution
beyond the critical temperature point. Here, we define the crossover point of the G′ and G″ as the
gelation temperature (Tgel). With further increase of the temperature, the G′ and G″ values continue
to increase and eventually plateau, suggesting the formation of stable hydrogels with a certain
62

mechanical stiffness. To investigate the reversibility of the gelation, a second temperature sweep
of the G′ and G″ was conducted after the sample was cooled down to the starting temperature
(Figure 2.19). The two measurements are nearly overlapped, indicating that the sol−gel transition
is reversible.

Figure 2.16. Plots of storage (G', filled symbols) and loss moduli (G'', open symbols) versus
temperature for the A92M94D12 (5 wt%): 1st trial (G', ■ ; G'', □) and 2nd trial (G', ■ ; G'', □).

Figure 2.17. Plots of storage (G', filled symbols) and loss moduli (G'', open symbols) versus
temperature for the A45M45D10 (5 wt%): 1st trial (G', ■ ; G'', □) and 2nd trial (G', ■ ; G'', □).
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Figure 2.18. Plots of storage (G′, filled symbols) and loss moduli (G″, open symbols) versus
temperature for the A98M98D18 (5 wt %): first heating (G′, ■ ; G″, □) and second heating (G′, ■ ;
G″, □).

Figure 2.19. Plots of storage (G′, filled symbols) and loss moduli (G″, open symbols) versus
temperature for the A98M98D18 (Entry 1, Table 2.1) polymer solutions at 1 wt % (G′, ▲; G″ Δ),
2.5 wt % (G′, ■; G″,□), and 5 wt % (G′, ● ; G″, ○). Inset shows the plot of Tgel versus polymer
concentration.
To further characterize the rheological properties of the sol and the gel based on the
A98M98D18 triblock copolypeptoid (Entry 1, Table 2.1), measurement of dynamic shear moduli as
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a function of angular shearing frequency was conducted (Figure 2.20). At 22 oC, the loss modulus
(G″) is larger than the storage modulus (G′) and both moduli are close to zero at low frequency
and adapt a terminal rheological behavior indicative of a viscous liquid. At 25 oC, the G′ started to
superimpose on the G″ and approaches the critical gelation temperature when G′ and G″ follow a
power law with an exponential of approximately 1/2 (G′ ≈ G″ ∼ ω0.5) (Figure 2.20).2 At 37 °C, G′
is large than G″ through the whole frequency range and is nearly frequency independent, indicating
the formation of a stable elastic solid-like hydrogel.

Figure 2.20. Plots of storage modulus (G′, filled symbols) and loss modulus (G″, open symbols)
versus angular frequency (ω) for the 5wt % aqueous solution of A98M98D18 (Entry 1, Table 2.1) at
different temperatures: 37 °C (G′, ■; G″, □), 25 °C (G′, ●; G″, ○), and 22 °C (G′, ▲; G″ Δ).
2.3.4. Microscopic characterization of the hydrogel
To investigate the microscopic structure of the hydrogel, cryo-SEM was conducted on the
A92M94D12 hydrogel (5 wt %, 2.5wt% and 1 wt%) freshly formed at 37 °C. The cryo-SEM
microgram revealed a highly porous structure with large mesh size in the micron regime (>3 μm)
(Figure 2.21), consistent with a gel structure formed by phase separation. The pore size of the
hydrogel can be easily tailored by controlling the concentration of the polymer solution. As
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expected, the pore size of the hydrogel gradually increased with decreasing polymer solution
concentration, consistent with the decreased hydrogel stiffness with increasing concentration
measured by rheological analysis. The average pore size measured long the longest and shortest
axis of at least 50 pores for 5wt% hydrogel (Figure 2.21 A and B) was 3.23 ± 0.68 µm and 7.26 ±
1.46 µm, respectively. As the concentration decreased to 2.5 wt%, the pore size of the hydrogel
(Figure 2.21 C) along the longest and shortest axis increased to 3.48 ± 0.82 µm and 10.38 ± 5.06
µm, respectively. As the concentration further decreased to 1wt%, the hydrogel exhibited a
lamellar morphology. The average spacing between the lamella was 4.13 ± 0.71 µm, whereas the
lamellar morphology spans more than 50 μm continuously.

Figure 2.21. Cryo-SEM images of the 5 wt % (A,B), 2.5 wt% (C) and 1wt% (D).A92M94D12
hydrogel The scale bar in (A) and (B) is 50.0 and 10.0 μm, respectively. The scale bar in (C) and
(D) is 20.0 μm.
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2.3.5. Characterization of micellation of ABC triblock copolypeptoids in dilute solution
We hypothesize that the ABC triblock copolypeptoids undergo a thermoreversible sol−gel
transition through the formation of micellar networks (Figure 2.22) similar to early studies on other
ABC block copolymer systems.2, 9-10As the three blocks are mutually immiscible, the C block is
hydrophobic and the B and A blocks are water-soluble below the sol−gel transition temperature,
the triblock copolymers are expected to form core−shell−corona micelles below Tgel. Upon
temperature increases, the corona blocks (A) undergo cloud point transition and become
dehydrated to form hydrophobic domains. This results in the formation of a three-dimensional
micellar network.

Figure 2.22. Schematic showing the proposed gelation mechanism of aqueous solutions of the
ABC triblock copolypeptoids.
The cloud point of the AMD triblock copolypeptoids, as determined from the turbidity
measurement, was shown to be higher than of the poly (N-allyl glycine) homopolymer (A) itself
by 8 °C (Figure 2.23). It is attributed to the attachment of hydrophilic M block at the A terminal,
resulting in an increased cloud point of the A segment.
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Figure 2.23. (A) Plots of transmittance at  = 450 nm versus temperature for the aqueous solutions
of homopolymer A105 and (B) the A98M98D18 triblock copolypeptoid (both samples: 1 wt% in DI
water).
To verify the micelle formation, TEM analysis of the diluted triblock copolypeptoids
solutions were conducted. Spherical micelles with a uniform diameter (13.4 ± 1.1 nm) were
observed for the A92M94D12 sample (Entry 2, Table 2.1) (Figure 2.24A); for the A98M98D18 sample
with slightly increased D segmental length (Entry 1, Table 2.1), rod-shape micelles with
moderately uniform diameter (16.6 ± 1.7 nm) become notably present (Figure 2.24C). Consistent
with the TEM analysis on the dried and uranyl acetate stained micellar samples, Cryo-TEM
analysis of a dilute aqueous solution (1 wt %) of the same A92M94D12 and A98M98D18 sample also
confirm the formation of spherical and rod-shape micelles, respectively (Figure 2.24B and D). In
addition, DLS analysis of the dilute solution of A98M98D18 (0.5 wt %) at 25 °C revealed the
presence of particles of a much larger hydrodynamic size than that of A92M94D12 (0.5 wt %, Figure
2.25), in accordance with their different micellar morphologies observed by TEM. These results
together with the cryo-SEM analysis of the polypeptoid hydrogel (Figure 2.21) suggest that the
hydrogel structure is highly hierarchical with spatial features ranging from micron down to
nanometer in dimension.
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Figure 2.24. (A, C) TEM images of the micelles based on A92M94D12 and A98M98D18 polymers
respectively (stained with uranyl acetate) and (B, D) cryo-TEM image of 1 wt% aqueous solution
of the same A92M94D12 and A98M98D18 polymers respectively.

Figure 2.25. (A) Hydrodynamic size distribution of the A92M94D12 and A98M98D18 micelles (0.5
wt% in nanopure water) at room temperature (below the Tgel) and (B) the corresponding
correlograms.
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The micelle formation is further supported by 1H NMR spectroscopic study of a dilute
solution of AMD. (Figure 2.26). In CD2Cl2, which is a good and nonselective solvent for all three
blocks in the triblock copolypeptoids, proton signals from the three different blocks (A, M, D) are
notably present. In D2O, which is a poor solvent for the D segment and a good solvent for the A
and M segments, the proton signals due to the D segment have completely disappeared. This is
consistent with micellation where the insoluble D block becomes buried in the core of the micelles.
As the temperature is increased to 37 °C, which is above the cloud point of the block
copolypeptoids, the proton signals due to the A block was significantly decreased. This indicates
the increased dehydration of the A block above the cloud point. The broadening of the proton
signals of the M block at elevated temperature was attributed to structural heterogeneity within the
gel due to the phase separation during gelation.

Figure 2.26. 1H NMR spectra of A92M94D12 in solvent CD2Cl2 and D2O at different temperature
(from below to above the Tgel).
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To further support the proposed mechanism, a temperature-sweep dynamic light scattering
(DLS) measurement within 20−60 °C range was performed on the dilute aqueous solution of
A92M94D12 (0.5 wt %) (Figure 2.27 and 2.28). At 20 °C, DLS revealed a relatively narrow
distribution of micellar sizes with an average 40.6 ± 0.4 nm diameter. As the temperature increases,
the average size of the particles also increases (Figure 2.27). Plot of the derived count rate of the
micelle solution versus temperature revealed a sharp increase at 27 °C, indicating the onset of
micellar aggregation (Figure 2.28A). The temperature- dependent DLS measurement suggests the
association of micelles at elevated temperature, in agreement with the proposed gelation
mechanism (Figure 2.22).

Figure 2.27. Diameter distribution of the A92M94D12 micellar solution (0.5 wt%) at different
temperature obtained by DLS measurements.

2.3.6. Tuning the Hydrogel Properties
The gelation temperature and mechanical stiffness of the ABC block copolypeptoid
hydrogels can be adjusted by controlling the polymer solution concentration and the polymer
composition. For example, the aqueous solutions of A98M98D18 (Entry 1, Table 2.1) in the 1−5 wt
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% range all underwent thermoreversible sol−gel transitions (Figure 2.18). The sol−gel transition
temperature can be systematically increased from 26.2 to 33.6 °C as the polymer concentration is

Figure 2.28. (A) Plots of derived count rate and (B) Z-averaged diameter versus temperature for
the A92M94D12 micellar solution (0.5 wt% in water) together with (C) the corresponding
correlograms.
decreased from 5 to 1 wt %. The sol−gel transition window also becomes narrower as the polymer
concentration increases. The mechanical stiffness of the hydrogel at 37 oC, as indicated by storage
modulus (G'), increases from approximately 2 to 251 Pa as the polypeptoid concentration increases
from 1 to 5 wt %. It corresponds to an increase of Young’s modulus from 6 to 762 Pa. This is
attributed to the increased cross-linking density at higher concentrations, resulting in micellar
networks with increased stiffness.2 The concentration dependence of the sol−gel transition
temperature is consistent with the concentration dependence of the cloud point of block
copolymers: the higher the concentration, the lower the cloud point transition.7, 11
To investigate the impact of polymer composition on the gelation characteristics, we
conducted rheological measurements on the aqueous solutions of triblock copolypeptoids where
the chain length of a selective block in the AMD triblock copolypeptoids is systematically varied
while the chain length of the remaining two blocks are kept constant. It has been found that the
chain length of each block impacts the gelation temperature and gel modulus to different extents.
For example, Tgel does not change appreciably when the length of the hydrophobic D end block is
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increased by 50% from DPn =12 to 18 (Figure 2.29C), whereas the G' at 37 oC decreases from 780
to 251 Pa. By comparison, when the length of the M middle block is increased by 60% from DP n
= 98 to 158 while the chain length of the other two blocks are kept constant, Tgel is increased from
26.2 to 30.7 oC and the G' value at 37 oC was reduced from 251 to 189 Pa (Figure 2.29B). This is
consistent with the general observation that increasing the molar fraction of the terminal
hydrophilic moiety in thermoresponsive block copolymers enhances the cloud point.11 By contrast,
a dramatic increase of gelation temperature from 26.6 to 40.9 °C occurred (Figure 2.29A) when
the length of A block is decreased by 53% from DPn = 92 to 43. The latter sample did not form a
gel at physiological temperature (37 °C). The change in the Tgel is in agreement with the previous
report where the cloud point of the A homopolymer exhibits chain length dependence: the shorter
chain length of A gives rise to a higher cloud point.7 The gelation temperature (40.9 °C) is much
higher than the reported cloud point of the A homopolymer with similar DPn (30 °C). This is
expected as the A segment in the triblock copolypeptoids is directly attached to a long hydrophilic
M segment, thereby resulting in an increase in cloud point.11 Compared to the ABC hydrogelators,
the corresponding ABA triblock copolymer exhibit a very different gelation behavior: no gelation
occurs up to 60.0 °C (Figure 2.29D). It is probably due to the long-range structural arrangement
during the simultaneous micellation and gelation process. In addition, the same end block may
cause loops or flower-like conformation that suppresses the formation of bridging structure.2, 12-13
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Figure 2.29. Plots of storage (G′, filled symbol) and loss moduli (G″, open symbol) versus
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids having varying
compositions: A98M98D18 (G′, ●; G″, ○), A92M94D12 (G′, ■; G″, □), A94M158D16 (G′, ●; G″, ○),
A43M92D9 (G′, ●; G″, ○), A45M93A45 (G′, ●; G″, ○).
To elucidate the influence of the total chain length on the gelation characteristics,
rheological measurements were also conducted on aqueous solutions of AMD triblock
copolypeptoids where the total polymer chain length is varied while the weight fraction of each
block is kept constant (Figure 2.30 and entries 1, 5, and 6 in Table 2.1). The sol−gel transition
temperature was shown to systematically increase from 26.2 to 31.0 to >60.0 °C as the total chain
length (DPn) decreases from 214 to 100 to 53. In fact, the shortest chain sample remains a solution
at the highest temperature (60.0 °C) that was tested. G' and G'' appear to crossover at this
temperature limit (Figure 2.30). The chain length dependence of Tgel is consistent with the chain
length dependence of the cloud point for A homopolymer: shorter chains exhibit higher cloud
points.7 This indicates that tuning the A chain length is the most effective strategy to control the
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sol−gel transition temperature in the triblock copolypeptoid system. In addition, the hydrogel
stiffness at 37 oC, as indicated by the G' value, is reduced from 251 to 125 Pa with the decrease of
total chain length (DPn) from 214 to 53 (Figure 2.30).

Figure 2.30. Plots of storage (G', filled symbol) and loss moduli (G'', open symbol) versus
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids with varying block chain
length and same block molar ratio: A98M98D18 (G', ●; G'', ○), A45M45D10 (G', ■; G'', □), A23M25D5
(G', ▲; G'', Δ).
To elucidate how the hydrophobicity of the core block (i.e., C segment) affect the gelation
temperature and mechanical stiffness of the hydrogel, rheological measurements were conducted
on the aqueous solutions of triblock copolypeptoids where the hydrophobic D end block was
replaced with less hydrophobic O and B (Scheme 2.2), whereas the length of each block was kept
nearly the same. As the hydrophobicity of the core block decreases (D > O > B), the T gel was
slightly increased from around 31.0 to 31.4 to 32.7 °C. The hydrogel at 37 °C shows decreased
storage modulus from 125 to 0.2 Pa asthe hydrophobic core block is changed from D to B (Figure
2.31). Thus, the hydrophobicity of the C segment plays an important role in the gelation that
increased hydrophobicity lowers the Tgel and raises the hydrogel stiffness.
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Figure 2.31. Plots of storage modulus (G', filled symbol) and loss modulus (G'', open symbol)
versus temperature for aqueous solutions (5 wt %) of triblock copolypeptoids having varying
hydrophobic end block: A45M45D10 (G', ■; G'', □), A45M47O10 (G', ●; G'', ○), A41M47B11 (G', ▲;
G'', Δ).
To further investigate how the hydrophobicity of the B middle block affects the gelation
characteristics, rheological measurements were conducted on the aqueous solutions of triblock
copolypeptoids where the hydrophilicity of the middle block was altered. As the hydrophilicity of
the middle block increases in the following order: M < m < d (Scheme 2.1), the Tgel was increased
from 31.0 to 42.6 °C. The storage modulus at 37 °C is decreased from 125 to 60 Pa with the
increase of the middle block hydrophilicity from M to m (Figure 2.32). In contrast, as the middle
block hydrophilicity further increased to d, the polymer solution remains in the sol state at 37 °C.
These results strongly indicate that the gelation temperature and stiffness of the gels are highly
dependent on the hydrophilicity and hydrophobicity of the constituent block. We are able to adjust
the Tgel and G' by tuning the polymer composition (i.e., chemistry and molar fraction) for targeted
applications.
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Figure 2.32. Plots of storage (G', filled symbol) and loss moduli (G'', open symbol) versus
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids with varying middle block:
A45M45D10 (G', ■; G'', □), A50m55O11 (G', ●; G'', ○), A46d42D9 (G', ▲; G'', Δ).
2.3.7. Protein Encapsulation Study
Thermoreversible hydrogels are useful for encapsulation and delivery of water-soluble
therapeutics such as proteins/peptides or cells.14-15 For encapsulation of proteins, it is important
that the hydrogels do not adversely affect the protein structure and function. Because the
polypeptoids are structurally similar to polypeptides, it is of concern that the hydrogel materials
may interact with the proteins and alter the protein functions, even though the polypeptoids only
present in low weight fraction in the hydrogel. To assess the suitability of the polypeptoid hydrogel
for protein encapsulation, a model water-soluble enzyme (horseradish peroxidases, HRP) was
encapsulated in the hydrogel and examined for any functional change over an extended period of
time.
HRP is known to catalyze the reaction of guaiacol and H2O2, giving rise to colored product
(Scheme 2.3).16 This allows the enzymatic activity of HRP to be readily quantified by measuring
the initial reaction rate using an UV−vis spectrometer (Figure 2.33). HRP was encapsulated in the
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A92M94D12 hydrogel (sample 2, Table 2.1) at 37 °C for up to 7 d, over which period the enzymatic
activity was examined and quantified.16 The HRP encapsulated in hydrogels do not exhibit any
appreciable changes in the specific enzymatic activity in the first 24 h of encapsulation (Table 2.2,
Figure 2.34). The activities are comparable to thecontrol sets (no gel, Figure 2.34), where the HRP
was kept in PBS buffer at 37 °C for the same duration. The encapsulated HRP also shows
comparable enzymatic activity to the as-received HRP in PBS buffer at 25 °C without any
prolonged incubation (control, Figure 2.34). Increasing the encapsulation to 7 days resulted in a
slight decrease of the enzyme activity by 9.4%. This is ascribed to the prolonged heating as the
control sample where the enzyme is incubated in buffer at 37 °C without hydrogel shows the
similar percentage reduction of activity. The results indicate that the polypeptoid hydrogel does
not adversely affect the HRP enzymatic function.
Scheme 2.3. Catalytic Reaction of Guaiacol with HRP and H2O2.

2.3.8. Cytotoxicity Assessment of the Polypeptoid Solution and Hydrogel
AlamarBlue assay was used to assess the cytotoxicity of ABC triblock copolypeptoids
diluted solution to human adipose-derived stem cells (hASCs). The diluted polymer solution
(A92M94D12) was shown to be minimally cytotoxic to hASC with concentration up to 20 mg/mL
(Figure 2.35).
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Figure 2.33. (A) Representative UV-Vis spectra of the enzymatic reaction involving Guaiacol,
HRP and H2O2 showing the absorbance increase over time after incubation of HRP in the
A92M94D12 hydrogel for 24 h; (B) plot of absorbance at  = 470 nm versus time.

Figure 2.34. Specific enzyme activity with different incubation time at 37 °C: incubation in the
A92M94D12 hydrogel (sample 2, Table 2.1) (filled symbol: ■) and incubation without the hydrogel
(open symbol: □). Control (circular symbol: ○): the enzymatic activity of as-received HRP was
measured in PBS buffer at 25 °C without any treatment.
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Table 2.2. Systematic study of HRP enzyme activity upon incubation in hydrogel for different
time.

Enzyme

1h-in

gela

1h-no gelb

4h-in gela

4h-no gelb

7h-in gela

7h-no gelb

24h-in
gela
24h-no
gelb
7d-in gela

7d-no gelb

controlc

Entry

dA/dt
(s-1) d

Enzyme
Activity
(umol/min) e

1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

0.0054
0.0053
0.0053
0.0054
0.0054
0.0052
0.0055
0.0053
0.0053
0.0053
0.0053
0.0052
0.0055
0.0054
0.0054
0.0054
0.0053
0.0052
0.0054
0.0055
0.0052
0.0054
0.0053
0.0055
0.0047
0.0050
0.0048
0.0048
0.0049
0.0048
0.0053
0.0054
0.0053

0.187
0.183
0.183
0.187
0.187
0.180
0.190
0.183
0.183
0.183
0.183
0.180
0.190
0.187
0.187
0.187
0.1837
0.180
0.187
0.190
0.180
0.187
0.183
0.190
0.166
0.173
0.163
0.166
0.170
0.166
0.183
0.187
0.183
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Average
Enzyme
Activity
(umol/min) f

Specific Enzyme
Activity
(umol/min/mg) g

0.185±0.002

329.71±3.6

0.185±0.004

329.71±7.1

0.186±0.004

331.7±7.1

0.182±0.002

325.5±3.6

0.188±0.002

335.9±3.6

0.183±0.003

327.6±6.2

0.186±0.005

331.7±9.4

0.187±0.003

333.8±6.2

0.167±0.002

298.8±3.6

0.167±0.005

298.8±9.4

0.185±0.002

329.7±3.6

Figure 2.35. Relative metabolic activity of hASC cultured in dilute solutions of A92M94D12 triblock
copolypeptoids (Entry 2, Table 2.1). The results are normalized to live control.
AlamarBlue assay was further used to investigate the effect of ABC hydrogel on hASCs
metabolic activity. After 24 h of culturing in the ABC hydrogel extractives or 3 d of culturing
within the hydrogel matrix in direct contacting, hASCs showed a significant decrease (P-value
<0.05) of relative metabolic activity compared to the live control (Figure 2.36A). The
corresponding total DNA content was quantified using Quanti-T PicoGreen assay to analyze the
hASC proliferation on ABC hydrogel (Figure 2.36B). No significant inhibition of hASC
proliferation compared to the live control was observed when hASCs exposed to the ABC hydrogel
extractives for 24 h or cultured within the hydrogel matrix in direct contact for 3 d. The results
indicated that the slight decrease of cells proliferation rate does not correlate with a decrease in
metabolic activity and may be indicative of stem cells leaving the proliferative cell cycle to
differentiate. The differentiation pathway of hASCs happening within the hydrogel matrix was
further indicated by the QPCR analysis (Figure 2.38). Moreover, hASC maintained a healthy
spindle shape both when exposed to hydrogel extractives and cultured within hydrogel matrix
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(Figure 2.37). Overall, the results demonstrated that ABC hydrogel is a cytocompatible material
that can be potentially used as a tissue engineering scaffold.

Figure 2.36. (A) Relative metabolic activity of hASC cultured in A92M94D12 hydrogel (Entry 2,
Table 2.1) (5 wt % in PBS). The results are normalized to positive control. (B) Corresponding
number of hASC obtained using Quanti-T PicoGreen assay. Star symbol (*) indicates statistical
significant difference between two groups.
2.3.9. QPCR Quantification of Chondrogenesis Markers
To further investigate the effect of hydrogel on stem cell differentiation, quantitative realtime polymerase chain reaction (QPCR) analysis were conducted to quantify the expression of two
marker genes, Col2a1 and ANGPT1, for chondrogenesis and endotheliogenesis, respectively.17-19
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Figure 2.37. Optical microscopic images of hASC with different treatments.
Chondrogenesis is a multistep process characterized cell commitment, expression of
chondrogenic markers, condensation, and cellular morphological changes.17 The product of the
Col2a1 gene is an early and abundant marker of chondrocytes differentiation pathway.18 The
expression of Col2a1 and ANGPT1, a marker of angiogenesis, was assessed by QPCR at the 7 and
21 day time point. The A92M94D12 hydrogel was shown to up-regulate the Col2a1 and downregulated the ANGPT1 gene expression of hASCs at 7 and 21 d of the chondrogenesis study (Figure
2.38). Others studies have also shown up-regulation of Col2a1 and down-regulation of ANGPT1
gene expression when hASCs committed to chondrogenesis pathway.17, 19 These results indicate
that the polypeptoid hydrogel may have potential use as scaffold or graft materials for stem cell
based tissue repair.
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Figure 2.38. QPCR analysis of gene expression within A92M94D12 hydrogel matrix (Entry 2, Table
2.1).
Several synthetic hydrogels have previously been reported to influence the differentiation
of specific cell lines. For example, polypeptide-based hydrogels (PA-PLX-PA20and PEG-L-PA21)
have led to chondrogenesis of chondrocytes and adipose tissue derived cells. Although many
factors [e.g., cell morphologies, proliferation rate, cell density, size of cell aggregation, swelling
ratio, gel modulus, gel morphology, functional group (e.g., −COO−, −SH, −NH3), and charge state
in the hydrogel as well as degradation rate]20-29 have been suggested to contribute to this unique
phenomenon, the exact role of each factor and their complex interplays are not well understood.
Our future efforts will be directed toward understanding how the structural characteristics of the
polypeptoid hydrogels affect the stem cell differentiation by systematically tuning the hydrogel
composition and structure.
2.4. Conclusions
Well-defined amphiphilic ABC triblock copolypeptoids with varying composition and
chain length can be synthesized by primary amine-initiated ring-opening polymerization. The
polymer aqueous solutions undergo rapid thermoreversible sol−gel transitions. The gelation is
attributed to the temperature-induced formation of micellar networks. The hydrogel exhibit shearthinning behavior and can be injected through 24 gauge syringe needles. The gelation temperature
84

of the hydrogel can be readily adjusted between 26.2 and 60.0 °C, and the mechanical stiffness
(G') at physiological temperature (37 °C) can be tuned from between 0.2 and 780 Pa, corresponding
to the Young’s modulus in the 0.5−2346 Pa range. Encapsulation of model proteins (HRP) in the
polypeptoid hydrogel for up to 7 d does not adversely affect the enzymatic activity. Furthermore,
the ABC hydrogel and hydrogel extractives show minimal cytotoxicity to hASCs as indicated by
standard metabolic and proliferation assays. The study of chondrogenic marker expression
indicated that the hydrogel may have de novo bioactivity and is capable of modulating the
expression of chondrogenic differentiation markers in hASCs. The combination of low
cytotoxicity and bioactivity renders the polypeptoid hydrogel a highly promising tissue
engineering material. The ABC hydrogel motif is highly versatile and structurally tunable. We
envision the further functionalization of the hydrogel by photoinitiated thiol-ene addition
chemistry to incorporate various biologically active ligands (e.g., peptides) and further
enhancement of the mechanical stiffness of the hydrogels by chemical cross-linking. These studies
are currently in progress and will be reported in due course.
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: SYNTHESIS OF PEGYLATED POLYPEPTOIDS AS
ANTIFOULING POLYMERS
3.1 Introduction
Nonspecific protein adsorption to the surface of biomaterials and medical devices
accompanied by slow protein denaturation can induce cascades of biological responses when they
get into contact with human blood, including thrombosis, chronic inflammation and fast
immunological recognition.1-4 Those biological responses may hinder the function and
effectiveness of biomedical devices and drug delivery vehicles.1-4 The resistance of nonspecific
protein adsorption, therefore, is critical in improving the biocompatibility of biomaterials for
various biomedical and biotechnological applications (e.g., tissue engineering, therapeutic
delivery)
The mechanisms responsible for non-specific protein adsorption to surfaces are not fully
understood and more investigation is needed.3 The interaction between a protein and a surface is
considered to be the result of a balance between van der Waals, electrostatic, hydrophobic, and
hydration forces.3 It is believed that the water layer bound to hydrophilic polymer chains is mainly
responsible for resisting protein adsorption.4-5 Based on the reported studies, a protein-resistant
material usually obey four molecular-scale criteria, the so-called “Whitesides rules”: 1)
hydrophilicity, 2) the presence of hydrogen bond acceptor groups, 3) the absence of hydrogen bond
donor groups, and 4) the absence of net charge.

4, 6-7

The “Whitesides rules” have been widely

applied for the rational design of protein-resistant materials. Many types of protein-resistant
materials have been developed including poly(ethylene glycol) (PEG),3, 8 oligo/polypeptides,9-10
polycarbonates,11 polyoxazolines,12-14 polyacrylamides15-16 and zwitterionic polymers3, 17. PEG is
considered as the gold standard of protein-resistant stealth polymers in polymer-based therapeutic
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delivery. The drug-PEG conjugates enhance the water solubility of drugs and decrease their
interaction with blood components, leading to increased circulation half-life and decreased toxicity
of drugs. However, PEG has obvious drawbacks including non-biodegradability, potential
immunological recognition and hypersensitivity provocation, as well as accumulation in tissue
when the molecular weight of PEG exceeds 40 KDa.3-4, 8 Zwitterionic polymers (e.g., zwitterionic
polycarbonate17 and polybetanes3) which form a very stable hydration shell through strong iondipole bonding with water and absence of net charge are very promising protein-resistant
materials.3-4 They are, nevertheless, minimally soluble in most commonly used organic solvents
and thereby enhance their subsequent process complexity especially when conjugation to a
hydrophobic drug is desired.11 Polyoxazolines (e.g., poly(2-methyl-2-oxazoline), with similar
stealth behavior as PEG, is not backbone degradable and the potential formation of poly (ethylene
imine) from enzymatic degradation of the amide bonds on the side chain may confer
cytotoxicity.14, 18-19 Polyacrylamides are another category of protein-resistant material that is not
backbone degradable. Moreover, the thermoresponsive behavior of, in particular, poly (Nisopropylacrylamide) makes it absorb proteins at body temperature due to the enhanced
hydrophobicity.15-16,

20

Some oliogomeric21-24 and polymeric peptides9,

25-26

were shown to be

enzyme degradable, while the problem with the common water-soluble polypeptides (e.g., polyL-lysine and poly-L-aspartate) is their pH dependency and limited circulation lifetime caused by
the aggregation with oppositely charged moieties.27-28 Besides, the enzymatic proteolysis of
peptides may results in short in vivo half-lives and therefore limit their use in long-term biological
application (e.g., long-term drug delivery). Polycarbonates have attracted considerable attention
in the recent years due to their low toxicity, potential biocompatibility and biodegradability; 29
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however, studies showed that polycarbonates are prone to fast degradation (within several days or
weeks) both hydrolytically30-31 and enzymatically32 and thus limit their long-term biological use.
Poly (N-substituted glycine) (a.k.a, polypeptoids), with an N-substituted polyglycine
backbone, are structural mimics of polypeptides. In contrast to polypeptides, which adopt
secondary structures (e.g., helix or sheet) stabilized by hydrogen bonding, polypeptoids lack
extensive hydrogen bonding and chirality on the backbone and render them excellent thermal
processability, good solubility in commonly used solvents, as well as enhanced enzymatic and
hydrolytic stability relative to polypeptides.21-23,

33-34

In addition, some studies showed that

polypeptoids exhibit minimal cytotoxicity,35-38 and are degradable under oxidative conditions that
mimics tissue inflammation.38 These excellent properties make polypeptoids an attractive material
for biomedical and biotechnological applications.33, 39-43 In recent years, oligo polypeptoids (DPn
≤ 20) (e.g., polysarcocine,44 polymethoxyethylyglycine,45-46 polyhydroxyethylglycine46) grafted
onto TiO2 surface through a DOPA-Lys surface anchor were shown excellent antifouling
characteristic to resist protein (e.g., human fibrinogen) adsorption and cell (e.g., mammalian cell)
attachment. These polypeptoids prepared by solid-phase method appeared to have length limitation
to around 50 mer.41 Surface initiated ring-opening polymerization (SI-ROP) of N-substituted
glycine N-carboxyanhyrides (NNCA) was also reported to tether longer polypeptoid chains
(polysarcosine) to the targeted surface for antifouling purpose.47 Studies of polypeptoids regarding
their protein resistance, to our best knowledge, all focused on surface attached polymer chains and
there is no study on their protein resistance in bulk solution.
Here, for the first time, we designed and synthesized a series of polypeptoids bearing
oligometic ethylene glycol side chains with well-defined structure by primary amine-initiated ringopening polymerization of the corresponding N-substituted N-carboxyanhydrides (Scheme 3.2).
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These PEGylated polypeptoids are highly water soluble, charge neutral and have hydrogen bond
acceptor both on the backbone and side chains, which fulfill all the criteria of the abovementioned
“whitesides rule” for protein-resistant materials. The small angle neutron scattering (SANS) and
dynamic light scattering (DLS) study indicated there is no obvious adsorption of lysozyme to
PNMeOEtG. All the results suggested that the PEGylated polypeptoids are becoming a new
benchmark of protein-resistant materials for biological applications.
3.2 Experimental
3.2.1 General considerations
All chemicals were purchased from Sigma Aldrich and used as received unless otherwise
noted. All the solvents used in monomer preparation and polymerization were purified by passing
through alumina columns under argon. Toluene-d8 was purified by vacuum transfer after stirring
over CaH2 overnight. 1H and

13

C {1H} NMR spectra were obtained using a Bruker AV-400

Nanobay spectrometer (400 MHz for 1H NMR and 100 MHz for 13C {1H} NMR) and a Bruker
AV-500 spectrometer (500 MHz for 1H NMR and 125 MHz for

13

C {1H} NMR) at 298 K.

Chemical shifts (δ) given in parts per million (ppm) were referenced to protio impurities or the 13C
{1H} isotopes of deuterated solvents (CDCl3 and D2O).
3.2.2 Synthesis of MeOEt-NCA and PNMeOEtG
Synthesis of ethyl 2-((2-methoxyethyl)amino)acetate (1). 2-methoxyethylamine (10g,
0.13mol) and triethylamine (18.6 mL, 0.13mol) was dissolved in 100 mL ethyl acetate. Ethyl
bromoacetate (14.7 mL, 0.13 mol) dissolved in 50 mL ethyl acetate was added dropwise to the
above mixture at room temperature and stirred at room temperature for 4h. The white precipitation
was removed by filtration and the filtrate was condensed to obtain the crude product as pale yellow
liquid (21.2 g, 99.1%). The crude product was purified by column chromatography performed on
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silica gel (230-400 mesh, 60 Å, Sorbent Technologies) using ethyl acetate/methanol as the eluent
to afford the desired product as colorless liquid (17.2 g, 82.3 % yield). 1H NMR (δ in CDCl3, 400
MHz, ppm): 1.23-1.26 ppm (t, J = 7.16 Hz, 3H, -COOCH2CH3); 1.87 ppm (s, 1H, -NH-); 2.762.79 ppm (t, J = 5.12 Hz, 2H, -CH2NHCH2CH2-); 3.33 ppm (s, 3H, -OCH3); 3.40 ppm (s, 2H, NHCH2COO-); 3.45-3.48 ppm (t, J = 5.08, 2H, CH3OCH2CH2-); 4.14-4.19 ppm (q, J = 7.12 Hz,
2H, -COOCH2CH3). 13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 14.2 ppm (-COOCH2CH3);
48.8 ppm (-CH2NHCH2CH2-); 51.0 ppm (-OCH3); 58.7 ppm (-NHCH2COO-); 60.7 ppm
(CH3OCH2CH2-); 72.1 ppm (-COOCH2CH3); 172.3 ppm (-CH2COOH).
Synthesis of ethyl 2-((2-methoxyethyl)amino)acetic acid hydrochloride (2). Compound
1 (16.5 g, 0.10 mol) was added aqueous HCl (104 mL, 4 M) and heated at 80 oC for 24 h. The
water was removed by rotary evaporation to obtain a colorless oil (12.8 g, 94.1 %yield). 1H NMR
(δ in D2O, 400 MHz, ppm): 3.25-3.27 ppm (t, J = 4.00 Hz, 2H, -CH2NHCH2CH2-); 3.30 ppm (s,
3H, -OCH3); 3.64-3.66 ppm (t, J = 4.00 Hz, 2H, CH3OCH2CH2-); 3.91 ppm (s, 2H, -NHCH2COO). 13C {1H} NMR (δ in D2O, 125 MHz, ppm): 46.7 ppm (-CH2NHCH2CH2-); 47.2 ppm (-OCH3);
58.3 ppm (CH3OCH2CH2-); 66.7 ppm (-NHCH2COO-); 168.8 ppm (-CH2COOH).
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-methoxyethyl)amino)acetic acid (3).
Compound 2 (16.0 g, 0.09 mol), triethylamine (62.7 mL, 0.45 mol) and di-tert-butyl dicarbonate
(49 g, 0.23 mol) were mixed in distilled water (200 mL) and stirred at 25 oC for 24 h. The reaction
mixture was extracted with hexane (2 x 200 mL) to remove extra di-tert-butyl dicarbonate. The
aqueous phase was acidified with aqueous HCl (4 M) at 0oC and extracted with ethyl acetate (3 x
100 mL). The organic phase was washed with brine (1 x 200 mL) followed by drying over
anhydrous MgSO4. After filtration, the solvent was removed to obtain the desired product as white
solid (18.5 g, 88.2 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 1.45-1.49 ppm (d, 9H, -C(CH3)3);
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3.35-3.38 ppm (d, 3H, -OCH3); 3.47-3.53 (m, 2H, CH3OCH2CH2-); 3.59-3.61 ppm (m, 2H,
CH3OCH2CH2-); 4.01-4.09 (d, 2H, HOOCCH2-). 13C {1H} NMR (δ in CDCl3, 125 MHz, ppm):
28.2-28.3 ppm (-C(CH3)3); 48.5-48.7 ppm (CH3OCH2CH2-); 50.3-51.6 ppm (CH3OCH2CH2-);
58.7-57.4 ppm (CH3OCH2CH2-); 71.5-71.6 ppm (HOOCCH2-); 80.9-81.0 ppm (-C(CH3)3); 155.0155.8 ppm (-COOC(CH3)3); 174.2-174.5 ppm (-CH2COOH).
Synthesis of MeOEt-NCA (M1). Compound 3 (10.5 g, 0.045 mol) was dissolved in dry
dichloromethane (150 mL) under a nitrogen atmosphere. PCl3 (3.1 mL, 0.036 mol) was added
dropwise to the solution at 0oC and the mixture was stirred at 25oC for 2 h. The solvent was
removed under vacuum to obtain yellowish viscous residue. In the glovebox, the residue was
extracted with dry dichoromethane (3 x 20 mL) and filtered and the filtrate was stirred with small
amount of sodium hydride. After filtration, the filtrate was condensed to afford a pale yellow liquid
(5.7 g, 80.5 %). The crude monomer was washed by soxhlet extraction with hexane and further
purified by sublimation (50oC, 20-50 militorr) to afford a colorless liquid (4.5 g, 85.1 %). 1H NMR
(δ in CDCl3, 400 MHz, ppm): 3.38 ppm (s, 3H, CH3O-); 3.60 ppm (s, 2H, CH3OCH2CH2-); 4.28
ppm (s, 2H, -OOCCH2-). 13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 43.6 ppm (CH3OCH2CH2); 50.8 ppm (CH3OCH2CH2-); 59.0 ppm (CH3OCH2CH2-); 70.9 ppm (-OOCCH2-); 152.2 ppm (CH2OCOOC-); 163.8 ppm (-CH2OCOOC-).
Representative synthetic procedure for PNMeOEtG. In the glovebox, M1 (56.9 mg,
0.36 mmol, [M]0 = 1 M) was dissolved in dry THF (201 µL). A volume of BnNH2/THF stock
solution (157 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid.
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Freeze drying yielded a white fluffy solid (34.1 mg, 82.3 %). 1H NMR (δ in D2O, 400 MHz, ppm):
7.25-7.33 ppm and 2.77-2.82 ppm (benzyl end group); 4.01-4.53 ppm (m, -COCH2-); 3.49-3.83
ppm (m, -CH2CH2OCH3); 3.02-3.31(d, -CH2CH2OCH3).
3.2.3 Synthesis of Me(OEt)2-NCA and PNMe(OEt)2G
Synthesis of 2-(2-methoxyethoxy)ethanamine (4). 4 was synthesized by using a reported
procedure. overall yield: 61.3%. 1H NMR (δ in CDCl3, 400 MHz, ppm): 3.61-3.64 ppm (m, 2H, CH2CH2NH2); 3.51-3.58 ppm (m, 4H, CH3OCH2CH2-); 3.40 ppm (s, 3H, CH3O-); 2.87-2.90 ppm
(t, J=5.28 Hz, 2H, -CH2NH2); 1.58 ppm (bs, 2H, -NH2).
Synthesis of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate (5). 5 was synthesized
with the same protocol as 1. Yield: (70.5 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.18-4.24
ppm (q, J= 7.12Hz, 2H, -COOCH2CH3); 3.56-3.65 ppm (m, 6H, CH3OCH2CH2OCH2-); 3.45 ppm
(s, 2H, -NHCH2COO-); 3.41 ppm (s, 3H, CH3O-); 2.83-2.86 ppm (t, J=10.6 Hz, 2H, -CH2NHCH2); 1.83 ppm (s, -NH-); 1.28-1.31 ppm (t, J=14.3 Hz, 3H, -CH2CH3). 13C {1H} NMR (δ in CDCl3,
125 MHz, ppm): 172.3 ppm (-COOCH2CH3); 70.3-71.9 ppm (CH3OCH2CH2OCH2-); 59.0-60.7
ppm (-CH2COOCH2-); 48.8-51.0 ppm (CH3OCH2CH2OCH2CH2NH-); 14.2 ppm (-COOCH2CH3).
Synthesis of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate hydrochloride (6). 6
was synthesized with the same protocol as 2 in 95.1%-96.8% yield. 1H NMR (δ in CDCl3, 400
MHz, ppm): 3.91 ppm (s, 2H, -NHCH2COOH); 3.55-3.74 ppm (m, 6H, CH3OCH2CH2OCH2-);
3.31 ppm (s, 3H, CH3O-); 3.27-3.29 ppm (t, J=9.96 Hz, -CH2CH-). 13C {1H} NMR (δ in CDCl3,
125 MHz, ppm): 169.0 ppm (-COOH); 65.3-71.0 ppm (CH3OCH2CH2OCH2CH2NHCH2-); 58.0
ppm (-CH2CH2NH-); 46.9-47.3 ppm (CH3OCH2CH2OCH2CH2-).
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-(2-methoxyethoxyethyl)amino)acetic acid
(7). 7 was synthesized with the same protocol as 3. Yield: (82.9 %). 1H NMR (δ in CDCl3, 400
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MHz,

ppm):

4.03-4.11

ppm

(d,

2H,

HOOCCH2-);

3.48-3.69

ppm

(m,

8H,

-

CH2CH2OCH2CH2OCH3); 3.39 ppm (s, 3H, -OCH3); 1.45-1.48 ppm (d, 9H, (CH3)3-). 13C {1H}
NMR (δ in CDCl3, 125 MHz, ppm): 28.2-28.4 ppm (-C(CH3)3); 48.4-50.1 ppm
(CH3OCH2CH2OCH2CH2-);

58.7-58.8

ppm

(CH3OCH2CH2OCH2CH2-);

69.9-70.5

ppm

(CH3OCH2CH2-); 71.9-72.0 ppm (HOOCCH2-); 80.5-80.6 ppm (-C(CH3)3); 155.3-155.7 ppm (COOC(CH3)3); 172.6-172.7 ppm (-CH2COOH).
Synthesis of Me(OEt)2-NCA (M2). M2 was synthesized with the same protocol as M1.
Yield: 70.8 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.34 ppm (s, 2H, -OOCCH2-); 3.51-3.72
ppm (m, 8H, -CH2CH2OCH2CH2O-); 3.38 ppm (-OCH3). 13C {1H} NMR (δ in CDCl3, 125 MHz,
ppm): 166.1 ppm (-COOCO-); 152.3 ppm (-COOCO-); 69.4-71.7 ppm (-OOCCH2-, CH2CH2OCH2CH2O-); 59.1 ppm (-CH2CH2OCH2CH2O-); 50.9 ppm (-CH2CH2OCH2CH2O-);
43.5 ppm (-OCH3).
Representative synthetic procedure for PNMe(OEt)2G. In the glovebox, M2 (66.4 mg,
0.33 mmol, [M]0 = 1 M) was dissolved in dry THF (184 µL). A volume of BnNH2/THF stock
solution (143 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid.
Freeze drying yielded a white fluffy solid (46.1 mg, 87.8 %). 1H NMR (δ in D2O, 400 MHz, ppm):
7.22-7.32 ppm and 2.93-2.94 ppm (benzyl end group); 4.09-4.63 ppm (m, 2H, -COCH2-); 3.513.60 ppm (m, 8H, -CH2CH2OCH2CH2OCH3); 3.26-3.28(m, -OCH3).
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3.2.4 Synthesis of Me(OEt)3-NCA and PNMe(OEt)3G
Synthesis of 2-(2-(2-Methoxyethoxy)ethoxy)ethylamine (8). 8 was synthesized by using
a reported procedure. Yield: 67.2 %. 1H NMR (δ in CDCl3, 400 MHz, ppm): 3.40-3.55 ppm (m,
10H, -CH2OCH2CH2OCH2CH2OCH3); 3.28 ppm (s, 3H, -OCH3); 2.77 ppm (s, 2H, -CH2NH2);
1.77 ppm (s, 2H, NH2).
Synthesis of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate (9). 9 was synthesized
with the same protocol as 1 and 5. Yield: 71.6 %. 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.164.21

ppm

(q,

J=7.12

Hz,

2H,

CH3CH2COO-);

3.54-3.66

ppm

(m,

10H,

-

CH2OCH2CH2OCH2CH2OCH3); 3.44 ppm (s, 2H, -NHCH2COO-); 3.38 ppm (s, 3H, -OCH3);
2.80-2.83 ppm (t, 2H, -CH2NHCH2COO-); 2.09 ppm (bs, 1H, -NH-); 1.26-.1.29 ppm (t, 3H, COOCH2CH3). 13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 172.2 ppm (-COO-); 70.3-71.9 ppm
(-CH2CH2OCH2CH2OCH2CH2NHCH2COOCH2-); 59.0-60.7 ppm (-CH2CH2NHCH2-); 48.8-50.9
ppm (CH3OCH2CH2OCH2CH2OCH2CH2-); 14.2 ppm (-COOCH2CH3).
Synthesis of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate hydrochloride (10).
10 was synthesized with the same protocol as 2 and 6 in 95.8 %-97.7% yield. 1H NMR (δ in CDCl3,
400 MHz, ppm): 3.28-3.29 ppm (m, 5H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.53-3.55 ppm (m,
2H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.61-3.65 ppm (m, 6H, CH3OCH2CH2OCH2CH2-);
3.74-3.75 ppm (m, 2H, CH3OCH2-); 3.92 ppm (s, 2H, HOOCCH2-). 13C {1H} NMR (δ in CDCl3,
125

MHz,

ppm):

46.9-47.2

ppm

(CH3OCH2CH2OCH2CH2OCH2CH2-);

58.0

ppm

(CH3OCH2CH2OCH2CH2OCH2CH2-); 65.2 ppm (CH3OCH2CH2OCH2CH2-); 69.4-69.5 ppm
(CH3OCH2CH2OCH2CH2-); 70.9 ppm (HOOCCH2-); 168.9 ppm (HOOCCH2-).
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-(2-(2-(2-ethoxyethoxy)ethyl)amino) acetic
acid (11). 11 was synthesized with the same protocol as 3 and 7. Yield: 80.1%. 1H NMR (δ in
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CDCl3, 400 MHz, ppm): 4.00-4.08 ppm (d, 2H, HOOCCH2-); 3.47-3.64 ppm (m, 12H, CH2CH2OCH2CH2OCH2CH2-); 3.39-3.41 ppm (m, 3H, -OCH3); 1.44-1.47 ppm (d, 9H, (CH3)3-).
C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 28.2-28.3 ppm (-C(CH3)3); 48.5-51.3 ppm

13

(CH3OCH2CH2OCH2CH2OCH2CH2-); 58.9-59.0 ppm (CH3OCH2CH2OCH2CH2-); 70.1-70.4 ppm
(CH3OCH2CH2OCH2CH2-); 71.6-71.8 ppm (HOOCCH2-); 80.7-80.8 ppm (-C(CH3)3); 155.1155.8 ppm (-COOC(CH3)3); 173.9 ppm (-CH2COOH).
Synthesis of Me(OEt)2-NCA (M3). M3 was synthesized with the same protocol as M1 and
M2. Yield: 69.9 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.38 ppm (s, 2H, -OOCCH2-); 3.713.73 ppm (m, 2H, CH3OCH2-); 3.59-3.66 ppm (m, 8H, CH3OCH2CH2OCH2CH2OCH2-); 3.533.56 ppm (m, 2H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.39 ppm (CH3O-).

13

C {1H} NMR (δ in

CDCl3, 125 MHz, ppm): 166.1 ppm (-COOCO-); 152.4 ppm (-COOCO-); 69.4-70.5 ppm
(CH3OCH2CH2OCH2-); 71.9 ppm (-OOCCH2-); 59.0 ppm (CH3OCH2CH2OCH2CH2-); 50.9 ppm
(CH3OCH2CH2OCH2CH2OCH2CH2-); 43.5 ppm (CH3OCH2CH2OCH2CH2OCH2CH2-).
Representative synthetic procedure for PNMe(OEt)3G. In the glovebox, M3 (70.7 mg,
0.29 mmol, [M]0 = 1 M) was dissolved in dry THF (160 µL). A volume of BnNH2/THF stock
solution (126 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid.
Freeze drying yielded a white fluffy solid (51.2 mg, 86.9 %). 1H NMR (δ in D2O, 400 MHz, ppm):
7.24-7.32 ppm (benzyl end group); 4.10-4.55 ppm (m, 2H, -COCH2-); 3.53-3.59 ppm (m, 12H, CH2CH2OCH2CH2OCH2CH2OCH3); 3.29 (m, -OCH3).
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3.2.5 Characterization of PNMe(OEt)nG (n=1-3)
Size exclusion chromatography (SEC) analysis. SEC analysis of the polypeptoids were
performed using an Agilent 1200 system (Agilent 1200 series degasser, isocratic pump, auto
sampler and column heater) equipped with three Phenomenex 5 μm, 300 × 7.8 mm columns [100
Å, 1000 Å and Linear (2)], a Wyatt OptilabrEX differential refractive index (DRI) detector with a
690 nm light source, and a Wyatt DAWN EOS multiangle light scattering (MALS) detector (GaAs
30mW laser at λ = 690 nm). DMF with 0.1M LiBr was used as the eluent at a flow rate of 0.5
mL·min-1. The column and detector temperature was set at room temperature (20oC). All data
analysis was performed using Wyatt Astra V 5.3 software. Polymer molecular weight (MW) and
molecular weight distribution (PDI) were obtained by the Zimm model fit of the MALS-DRI data.
The absolute polymer molecular weight (Mn) was determined using the measured refractive index
increment dn/dc values. The refractive index increment (dn/dc) of the polymer was determined
using Wyatt’s rEX DRI detector and Astra software dn/dc template. The polymer was dissolved
in DMF with 0.1 M LiBr to prepare six dilute solutions with known concentrations (0.05-3.00
mg/mL) using volumetric flasks. The solutions were injected to the DRI detector and the
corresponding dn/dc value was determined from the linear fit to a plot of refractive index versus
polymer concentration. The dn/dc values measured for PNMeOEtG106, PNMe(OEt)2G102 and
PNMe(OEt)3G106 are 0.0633(4), 0.0686(8) and 0.0563(6) mL/g, respectively.
Thermogravimetric analysis. TGA analysis of the polypeptoids was conducted on a TA
TGA 2950 under nitrogen at the heating rate of 10 oC·min-1. The decomposition temperature (Td)
of the polypeptoids was determined from the onsets of weight loss.
Differential scanning calorimetry (DSC) analysis. DSC analysis of the polypeptoids
were conducted on a TA DSC 2920 calorimeter under nitrogen. The polymer (~5 mg) was sealed
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into the hermetic aluminum pan and an empty hermetic aluminum pan was used as the reference.
The sample containing pans were first heated from -50 oC to 200 oC at 10 oC /min, cooled to -50
o

C at 10 oC /min and remained at -50oC for 5min, and reheated to 200 oC at 10 oC/min. The glass

transition temperature (Tg) was determined by the inflection on the slope of heat flow shifting.
Kinetic Studies of BnNH2-initiated ring-opening polymerization of Me (OEt)n-NCA
(n=1-3). A predetermined amount of BnNH2 stock solutions in toluene-d8 were added to a toluened8 solution of Me(OEt)n-NCA (n=1-3) ([M]0 = 0.2 M, [M]0:[BnNH2]0 = 25:1) at room temperature
followed by transferring into a resealable J-Yong NMR tube. 1H NMR spectra were collected every
3 min 44 s at 50oC to determine the conversion of monomers for more than four half-lives. Kinetic
experiments were repeated twice for each monomer.
Study of Mn vs polymerization conversion. The polymerization of Me(OEt)n-NCA (n=13) was conducted in THF at 50oC ([M]0:[I]0=50:1, [M]0=1 M) and aliquots were taken at different
time intervals and analyzed with 1H NMR spectroscopy to determine the conversion. The aliquots
taken at different time intervals were further analyzed with MALDI-TOF spectroscopy to obtain
the polymer molecular weight (Mn) and molecular weight distribution (PDI). The obtained Mns
were plotted against the corresponding polymerization conversion.
3.2.6 Study of protein-resistant behavior of polypeptoids
Dynamic light scattering analysis. PNMeOEtG (DPn =106), PEG8000 or lysozyme was
dissolved in PBS at 1wt% and filtered through 0.22 µm filters before measurement. All the samples
were conducted using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser operating at 633
nm was utilized, and scattered light intensity was detected at an external angle of 173oC using noninvasive backscatter (NIBS) technology. Data from three measurement with 12 scans for each
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measurement was recorded. The hydrodynamic diameters and PDI of the samples were obtained
from cumulant analysis.
Small-angle neutron scattering (SANS). The small angle neutron scattering (SANS)
studies were performed at the NIST Center for Neutron Research (NCNR) in Gaithersburg, MD,
on the NG7 30 m SANS instrument, using neutrons with wavelength  = 6 Å and wavelength
spread, / = 11%. The temperature was maintained to 200.1C using a circulating bath. A
typical SANS data reduction protocol, which consisted of subtracting scattering contributions from
the empty cell (2 mm demountable titanium cells), background scattering, and sorting data
collected from two different detector distances was used to yield normalized scattering intensities,
I(Q) (cm-1) a.k.a. the macroscopic scattering cross-section ( 𝑑Σ⁄𝑑Ω ) as a function of the
scattering vector, Q (Å-1). Data reduction was conducted employing the NCNR Igor-pro platform.
The SANS scattering intensity for our macromolecular solution 48 is modelled as
𝑑Σ
= 𝜙∆𝜌2 𝑉𝑃(𝑄)𝑆(𝑄)
𝑑Ω

(1)

Here, 𝜙 is the volume fraction of the molecules, ∆𝜌 and V, are their average scattering
contrast and volume, respectively. The single molecular form factor, 𝑃(𝑄), averaged particle
scattering over the ensemble of sizes and orientations, is related to the particle structure. The
effective structure factor, 𝑆(𝑄), provides information about the intermolecular interaction. For
dilute solutions of non-interacting molecules, 𝑆(𝑄) ≈ 1.
In the current work we have modelled the form factor and the structure for lysozyme
molecule using a hard sphere approximation49-50. The form factor for the polymer is modelled
using the random Gaussian coil51.
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3.2.7 Cytotoxicity study of polypeptoids
The cytotoxicity study was conducted by adapting a reported procedure.52 The HEp2 cells
were plated at 8600 cells per well in a Costar 96-well plate (BD biosciences) and allowed to grow
for 48 h. The polypeptoids were dissolved in Eagle's Minimum Essential Medium (EMEM) and
diluted to final working concentrations (0, 0.0625, 0.125, 0.25, 0.5, and 1mg/mL). The cells were
exposed to the working solutions of polypeptoids up to 1 mg/mL and incubated for 24 h (37oC,
95% humidity, 5% CO2). The working solution was removed, and the cells were washed with 1X
PBS. The medium containing 20% CellTiter Blue (Promega) was added and incubated for 4 h. The
viability of cells is measured by reading the fluorescence of the medium at 570/615 nm using a
BMG FLUOstar Optima micro-plate reader. In this assay, the indicator dye resazurin is reduced
to fluorescent resorufin in viable cells, while non-viable cells are not able to reduce resazurin nor
to generate a fluorescent signal. The fluorescence signal of viable (untreated) cells was normalized
to 100 %.
3.3 Results and discussion
3.3.1 Synthesis and characterization of Me(OEt)n-NCA and PNMe(OEt)nG
It was the first time to report the synthesis of PEGylated N-carboxyanhyride monomers,
MeOEt-NCA, Me(OEt)2-NCA and Me(OEt)3-NCA. Me(OEt)n-NCA (n=1-3) were synthesized in
moderate overall yields (40.9 -49.7 %) by adapting a reported procedure53-54 as outlined in Scheme
3.1.

The

primary

amine

(2-(2-methoxyethoxy)ethanamine

and

2-(2-(2-

Methoxyethoxy)ethoxy)ethylamine) used were synthesized in good yields (61.3-67.2%, Scheme
3.2, Figure 3.1 and 3.2) by adapting a reported procedue.55 The monomer precursors (3, 7 and 11)
showed rotamers at 25oC in CDCl3 due to restricted rotating of the amide bond, which was
supported by the broadening and merged peaks shown in 1H NMR spectra collected at elevated
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temperature (50oC) (Figure 3.7, 3.16 and 3.25). The structures of the desired monomers were
confirmed by 1H and 13C {1H} NMR spectroscopic analysis (Figure 3.9-3.10, 3.18-3.19 and 3.273.28). The polypeptoids bearing oligomeric ethylene oxide side chains (PNMe(OEt)nG, n=1-3)
were synthesized by ring-opening polymerizations of their corresponding monomers using benzyl
amine as the initiator (Scheme 3.3). All polymerization reactions were conducted in anhydrous
THF at 50oC for 24-48 h to reach 100 % conversion at different initial monomer to initiator ratios
([M]0:[I]0). The polymers were purified by precipitation in hexane and collected by filtration
followed by drying under vacuum to yield ether crispy white solids (PNMeOEtG) or viscous
liquids (PNMe(OEt)nG, n=2-3) in good yields (82.3-87.8%). The number-averaged molecular
weight (Mn) and degree of polymerization (DPn) of the polymer was determined by both the 1H
NMR spectroscopy using end-group analysis and by SEC analysis using dn/dc values of the
polymers. For example, the DPn and Mn of PNMeOEtG was determined by the integrations at
4.01-4.52 ppm due to the methylene group in the backbone relative to the integration of signals at
7.3 ppm due to the benzyl end-group (Figure 3.11). The molecular weight of the polymers (Mn)
increased as the initial monomer to initiator ratio ([M]0:[I]0) was systematically increased (Table
3.1), as evidenced by 1H NMR and SEC analysis. The polymer molecular weights (Mn) agreed
with the theoretically predicated values at low molecular weight range ([M]0:[I]0 < 200:1).
However, at high [M]0:[I]0 ratios (200:1 and 400:1), the molecular weight of the polymers (Mn)
determined from SEC analysis deviated from the theoretical values probably due to presence of
impurities and the impurities were probably also behaved as initiators to react with the monomers.
The polymer molecular weight distributions were narrow with low polydispersity indices (PDI) in
the 1.03-1.10 range (Table 3.1, Figure 3.30, 3.32 and 3.34) as determined by SEC analysis in 0.1
M LiBr/DMF at room temperature (oC). The structure of low molecular weight PNMe(OEt)nG
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(n=1-3) was further confirmed by MALDI-TOF spectroscopic analysis. The spectra showed a
symmetric monomodal set of mass ions where m/z equals to integral numbers of the desired
repeating unit mass (115.2, 159.7 and 203.3 g/mol) for (PNMe(OEt)nG, n=1-3) plus 22 or 39 for
sodium or potassium ion. This is consistent with the targeted polypeptoid structures bearing one
benzyl amide and one secondary amine chain end (Scheme 2), in support of controlled
polymerization initiated by benzyl amine initiator. (Figure 3.31, 3.33 and 3.35).

Scheme 3.1.Synthetic procedures of Me(OEt)n-NCA (n=1-3).

Scheme 3.2. Synthetic procedures
Methoxyethoxy)ethoxy)ethylamine.

of

2-(2-methoxyethoxy)ethanamine
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and

2-(2-(2-

Figure 3.1.1H NMR spectrum of 2-(2-methoxyethoxy)ethanamine in CDCl3.

Figure 3.2. 1H NMR spectrum of 2-(2-(2-Methoxyethoxy)ethoxy)ethylamine.
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Figure 3.3. 1H NMR spectrum of ethyl 2-((2-methoxyethyl)amino)acetate in CDCl3.

Figure 3.4. 13C {H} NMR spectrum of ethyl 2-((2-methoxyethyl)amino)acetate in CDCl3.
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Figure 3.5. 1H NMR spectrum of ethyl 2-((2-methoxyethyl)amino)acetic acid hydrochloride in
D2O.

Figure 3.6. 13C {H} NMR spectrum of ethyl 2-((2-methoxyethyl)amino)acetic acid hydrochloride
in D2O.
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Figure 3.7. 1H NMR spectrum of 2-(N, N-tert-butoxycarbonyl-2-methoxyamino)acetic acid in
CDCl3: (A) at 25 C and (B) at 50 C.

Figure 3.8. 13C {H} NMR spectrum of 2-(N, N-tert-butoxycarbonyl-2-methoxyamino)acetic acid
in CDCl3 at 25 C.
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Figure 3.9. 1H NMR spectrum of MeOEt-NCA in CDCl3.

Figure 3.10. 13C {1H} NMR spectrum of MeOEt-NCA in CDCl3.

Scheme 3.3. Benzyl amine-initiated ROP of Me(OEt)n-NCA (n=1-3).

109

Figure 3.11.1H NMR spectrum of PNMeOEtG26 in D2O.

Figure 3.12. 1H NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate in CDCl3.
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Figure 3.13.
CDCl3.

13

C {H} NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate in

Figure 3.14. 1H NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetic acid
hydrochloride in D2O.
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Figure 3.15. 13C {1H} NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetic acid
hydrochloride in D2O.

1
Figure
3.16.
H
NMR
spectrum
of
2-(N,N-tert-butoxycarbonyl-2-(2methoxyethoxyethyl)amino)acetic acid in CDCl3: (A) at 25 C and (B) at 50 C.
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13
Figure
3.17.
C
{1H}
NMR
spectrum
of
methoxyethoxyethyl)amino)acetic acid in CDCl3 at 25oC.

Figure 3.18. 1H NMR spectrum of Me(OEt)2-NCA.
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2-(N,N-tert-butoxycarbonyl-2-(2-

Figure 3.19. 13C {1H} NMR spectrum of Me(OEt)2-NCA.

Figure 3.20. 1H NMR spectrum of PNMe(OEt)2G in D2O.
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Figure 3.21. 1H NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate in CDCl3.

Figure 3.22.
CDCl3.

13

C {1H} NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate in
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Figure 3.23. 1H NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino) acetic acid
hydrochloride in D2O.

Figure 3.24. 13C {1H} NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino) acetic acid
hydrochloride in D2O.
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1
Figure
3.25.
H
NMR
spectrum
of
2-(N,N-tert-2-(2-(2-methoxyethoxy)
ethoxyethoxycarbonylmethyl)amino) acetic acid in CDCl3: (A) at 25 C and (B) at 50 C.

Figure 3.26. 13C {1H} NMR spectrum of 2-(N,N-tert-2-(2-(2-methoxyethoxy)
ethoxyethoxycarbonylmethylamino) acetic acid in CDCl3 at 25oC.
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Figure 3.27. 1H NMR spectrum of Me(OEt)3-NCA.

Figure 3.28. 13C {1H} NMR spectrum of Me(OEt)3-NCA.
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Figure 3.29. 1H NMR spectrum of PNMe(OEt)3G in D2O.

Figure 3.30. SEC chromatograms of PNMeOEtGs prepared from benzyl amine initiated
polymerization of MeOEt-NCA (M1) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1
(—), 400:1 (—)). The DPs listed in the figure were determined from the SEC-MALDI-DRI using
the dn/dc= 0.0633(4) mL/g (0.1 LiBr/DMF, 20°C) of the polymer.
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Figure 3.31. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMeOEtG
(Mn=2.7 kg/mol, PDI=1.03, matrix: CHCA).

Figure 3.32. SEC chromatograms of PNMe(OEt)2Gs prepared from benzyl amine initiated
polymerization of Me(OEt)2-NCA (M2) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1
(—), 400:1 (—), Table). The DPs listed in the figure were determined from SEC-MALDI-DRI
using the dn/dc= 0.0686(8) mL/g (0.1 LiBr/DMF, 20°C) of the polymer.

120

Figure 3.33. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMe(OEt)2G
(matrix: CHCA).

Figure 3.34. SEC chromatograms of PNMe(OEt)3Gs prepared from benzyl amine initiated
polymerization of Me(OEt)3-NCA (M3) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1
(—), 400:1 (—), Table). The DPs listed in the figure were determined from SEC-MALDI-DRI
using the dn/dc= 0.0563(6) mL/g (0.1 LiBr/DMF, 20°C) of the polymer.
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Figure 3.35. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMe(OEt)3G
(matrix: CHCA).
Polymerization kinetics were investigated at a constant initial monomer to initiator ratio
([M]0:[BnNH2]0 = 25:1, [M]0 = 0.2 M) in Tolene-d8 at 50oC in J-Yong NMR tube and the
polymerization conversion was determined from the integration of the monomer and
corresponding polymer peaks. The polymerizations of the three monomers all exhibited a pseudofirst order dependence on the monomer concentration (i.e., d[M]/dt = kobs [M]), consistent with a
living polymerization. As the number of ethylene oxide moiety on the monomer side chain
increased from one (MeOEt-NCA) to three (Me(OEt)3-NCA), the observed rate constant (kobs) of
the polymerization decreased from 0.01285(±6) to 0.00291(±7) min-1 (Figure 3.36C). It was
probably due to the higher steric hindrance and more electron-withdrawing effect associated with
the increased number of ethylene oxide moiety on the side chain that weakened the nucleophilicity
of the secondary amino chain end and thus decreased the propagation rate. In addition, the plot of
Mn of the corresponding polymer exhibited a linear relationship as a function of conversion (Figure
3.36-3.37), revealing a constant concentration of propagation species, in agreement with a living
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polymerization. The molecular weight distribution (PDI=1.01-1.18) remained relatively narrow
during the polymerization.
DSC and TGA analysis of (PNMe(OEt)nG, n=1-3). The PEGylated polypeptoids were
characterized by TGA and DSC. The TGA thermograms of PNMe(OEt)nG50 (n=1-3) shown in
Figure 3.38 and 3.39 revealed a three-stage decomposition profiles with a slow and gradual mass
loss at low temperatures (25 oC-100 oC) which was attributed to the loss of small amount of water
contained in the polymers due to their hydroscopic property, followed by a drastic mass loss
occurring at 250-400 oC for all three PEGylated polypeptoids and then a gradual decrease of mass
loss from 400-500 oC. The decomposition temperature (Td) of the three polymers was higher than
250oC and thus temperature window (-50oC-200oC) was selected for DSC analysis. The respective
DSC thermograms of the second heating cycle were showed in Figure 3.38 and 3.39. The absence
of melting peak and crystallization exotherm peak revealed that all the three PEGylated
polypeptoids (Mn = 3.26-16.9 kg/mol) are amorphous, in agreement with the previously reported
oligomeric PEO-mimetic peptoids.55 The glass transition temperature (Tg) as determined by the
inflection on the slope of heat flow shifting are shown in Table 3.2. The Tg values of the PEGylated
polypeptoids decreased with increasing the length of ethylene oxide side chains (PNMeOEtG (Tg
= 24.5 – 46.4 oC) > PNMe(OEt)2G (Tg = -6.0 – -16.9 oC) > PNMe(OEt)3G (Tg = -34.9 – -41.1 oC)),
which is consistent with the previously reported observations for oligomers.55
The Tg values observed for all the peglated polypeptoids were significantly lower than the
amorphous PNMG (127-143oC) and PNEG (93-114 oC) with comparable MW.56. The Tg values
of the polymer increased with the increase of MW, in consistence with other reported
observations,57 which is attributed to the reduction of free volume due to diminished chain end
contents at increasing molecular weight.58 The Tg of PNMeOEtG20 (Tg = 24.5 oC, PDI = 1.09)
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synthesized by ROP was about 14oC lower than the corresponding 20 mer (Tg = 38.6 oC, PDI <
1.0003) synthesized by solid phase “submonomer” method,55 probably due to the larger PDI of the
former polymer that increased the flexibility of the polymer chains. The discrepancy is presumably
resulted from the difference in end-group structures and polydispersity of the samples. As the
chains are relative short, end-group structural different will contribute significantly to a difference
in free volume and thus Tg. The polymeric sample contains a mixture of chains that are shorter or
longer than 20 mer in varying amounts, which will have different T gs due to free volume
difference.
Table 3.1. BnNH2-initiated ROP of MeOEt-NCA (M1), Me(OEt)2-NCA(M2) and Me(OEt)2NCA(M3).a

Entry [M]0/[I]0 Calcd
PNMeOEtG

PNMe(OEt)2G

PNMe(OEt)3G

1
2
3
4
5
1
2
3
4
5
1
2
3
4
5

25:1
50:1
100:1
200:1
400:1
25:1
50:1
100:1
200:1
400:1
25:1
50:1
100:1
200:1
400:1

2.98
5.86
11.6
23.1
46.1
4.08
8.06
16.0
31.9
63.7
5.18
10.3
20.4
40.7
81.3

Mn (Kg/mol)
SECb
3.26
6.26
11.1
17.0
24.8
4.03
8.57
13.5
18.9
26.8
5.29
9.34
16.9
28.2
28.6

a

NMRc
3.09
6.32
12.4
24.6
4.24
8.69
16.3
33.9
5.18
11.7
21.6
41.3
-

PDIb
1.10
1.08
1.05
1.04
1.04
1.06
1.09
1.03
1.04
1.05
1.07
1.05
1.07
1.06
1.08

Reaction
Conv.(%)
time (h)
24
100
24
100
24
100
48
100
48
100
24
100
24
100
24
100
48
100
48
100
24
100
24
100
24
100
48
100
48
100
24
100

All the polymerizations were conducted in THF at 50oC with [M]0=1M. SEC analysis were
conducted by directly injecting the polymerization solutions into SEC column after reaching 100%
conversion. bDetermined from a tandem SEC-MALS-DRI system using dn/dc 0.0633(4) mL/g for
PNMeOEtG, 0.0686(8) mL/g for PNMe(OEt)2G and 0.0563(6) mL/g for PNMe(OEt)3G in 0.1 M
LiBr/DMF at room temperature. cDetermined by 1H NMR end-group analysis. Entry 4: the BnNH2
content is too low to be accurately integrated and therefore the Mn cannot be reliably determined
from the end-group analysis.
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Figure 3.36. (A) MALDI-TOF MS of PNMeOEtG (PDI = 1.07-1.11) at different polymerization
conversion. (B) Plots of Mn and PDI verses conversion for BnNH2 initiated polymerization of
MeOEt-NCA in THF ([M]0:[I]0=50:1, [M]0 =1 M). (C) Plots of ln ([M]/[M]0) versus the reaction
time for BnNH2 initiated polymerization of Me(OEt)n-NCA (n=1-3) ([M]0:[BnNH2]=25:1,
[M]0=0.2 M) in toluene-d8 at 50oC.
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Figure 3.37. (A,B) MALDI-TOF MS of PNMe(OEt)nG (n=2-3) at different polymerization
conversion in THF ([M]0:[I]0=50:1, [M]0 =1 M).: (A) PNMe(OEt)2G and (B) PNMe(OEt)3G .
(C,D) Plots of Mn and PDI verses conversion for BnNH2 initiated polymerization of Me(OEt)nNCA (n=2-3): (C) Me(OEt)2-NCA and (D) Me(OEt)3-NCA.
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Figure 3.38. (A) Thermogravimetric analysis of PNMeOEtG58. (B) DSC thermograms of
PNMe(OEt)nG (n=1-3). (C) DSC thermograms of PNMeOEtG at different MW during the second
heating cycle. (D) Plot of Tg verses Mn of PNMe(OEt)nG (n=1-3). The DPns listed in the figures
were determined from NMR end-group analysis.
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Figure 3.39. Thermogravimetric analysis of PNMe(OEt)2G (A) and PNMe(OEt)3G (B); DSC
thermograms of PNMe(OEt)2G (C) and PNMe(OEt)3G (D) at different MW during the second
heating cycle.
Table 3.2. Tg of PNMe(OEt)nG (n=1-3) at different MW.

Sample
PNMeOEtG

PNMe(OEt)2G

PNMe(OEt)3G

Mn (kg/mol)
3.26
6.26
11.1
4.03
8.57
13.5
5.29
9.34
16.9

Tg (oC)
24.5
37.6
46.4
-16.9
-8.6
-6.0
-41.1
-36.9
-34.9

3.3.2 Protein adsorption investigation on PNMeOEtG by DLS analysis
As the PEGylated polypeptoids are highly water soluble, charge neutral and have hydrogen
bond acceptor both on the backbone and side chains, which fulfill all the criteria of the abovementi128

Figure 3.40. DLS analysis of 1wt% PNMeOEtG106 in PBS (A, C) Hydrodynamic size
distribution, (B) correlograms and (D) derived count rates up to 24 h.
oned “whitesides rule” for protein-resistant materials, we hypothesized that the PEGylated
polypeptoids may display antifouling property. PNMeOEtG was selected as the model polymer to
study the protein resistant characteristics of the PEGylated polypeptoids. DLS was used to monitor
the size change of PNMeOEtG, protein (lysozyme) and their mixture in PBS. Lysozyme was
selected here as the protein due to their comparable size with PNMeOEtG. Increased
hydrodynamic size would be expected for the mixture of lysozyme and PNMeOEtG in PBS if
appreciable amount of lysozyme was absorbed to the polymer chains. Both the PNMeOEtG and
lysozyme at 1wt% in PBS showed no apparent aggregation up to 24 h investigated based on their
hydrodynamic size distribution, correlograms and derived count rates (Figure 3.40-3.41). The
mixture of 1wt% lysozyme and 1wt% PNMeOEtG in PBS revealed no obvious hydrodynamic size
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Figure 3.41. DLS analysis of 1wt% lysozyme in PBS (A, C) Hydrodynamic size distribution, (B)
correlograms and (D) derived count rates up to 24 h.
increase up to 24 h investigated (Figure 3.42). Furthermore, the hydrodynamic size (dh =5.56 ±
0.16 nm), derived count rates and correlograms of the mixture lies in between that of 1wt%
PNMeOEtG (6.39 ± 0.09 nm) and 1wt% lysozyme (4.69 ± 0.25 nm) in PBS, indicating there is no
apparent adsorption of lysozyme onto polymer chains (Figure 3.43). For comparison purposes,
PEG, a well-known antifouling material, was selected as a positive control to be investigated by
DLS analysis. Similarly, the hydrodynamic size (dh = 5.48 ± 0.10 nm), derived count rates and
correlograms of the mixture also lies in between that of 1wt% PEG8000 (5.84 ± 0.40 nm) and
1wt% lysozyme (4.69 ± 0.25 nm) in PBS (Figure 3.44), which further supported our hypothesis
that no appreciable adsorption of lysozyme was absorbed onto polymer chains.
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Figure 3.42. DLS analysis of mixture of 1wt% lysozyme and PNMeOEtG106 in PBS:
hydrodynamic size distribution (A, C), correlograms (B) and derived count rates (D) up to 24 h.

Figure 3.43. DLS analysis of mixture of 1wt% PNMeOEtG106, 1wt% lysozyme, 1wt% lysozyme
and 1wt% PNMeOEtG106 in PBS: hydrodynamic size distribution (A) and derived count rates (B)
up to 24 h; hydrodynamic size distribution (C) and correlograms (D) at 5h.
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Figure 3.44. DLS analysis of mixture of 1wt% PEG8000, 1wt% lysozyme, 1wt% lysozyme and
1wt% PEG8000 in PBS: hydrodynamic size distribution (A) and derived count rates (B) up to 24
h; hydrodynamic size distribution (C) and correlograms (D) at 5h.
3.3.3 Protein adsorption investigation on PNMeOEtG by SANS analysis
To further support our hypothesis, the interaction between PNMeOEtG and lysozyme was
investigated by small angle neutron scattering (SANS) studies in D2O. The data presented in Figure
3.45 is after background subtraction of the buffer solvent in D2O.
Figure 3.45(a) represents the SANS diffraction data for the Lysozyme at pH 7.0 and 7.4.
The structure factor at low Q, 𝑆(𝑄 = 0), is proportional to the osmotic compressibility and it
decreases with increase in concentration (𝜙). In addition, 𝑆(𝑄) shows a peak at small angles that
is related to the average distance between the neighbouring molecules.
Interestingly we saw the evolution of the structure factor with lowering of the pH value.
Following equation (1) at pH 7.4 the data was modelled using a hard sphere form factor (𝑆(𝑄) =
1)59, whereas the data at pH 7.0 was modelled using a hard sphere (HS) form factor and a structure
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Figure 3.45. SANS diffraction pattern: (a) lysozyme in buffer for different pH values (b)
comparison of the scattering pattern among lysozyme, polymer (PNMeOEtG) and 1:1 lysozyme –
polymer mixture. The solid lines are the fits using equation (1) as explained in the text.
factor (Percuss Yevick approximation)49-50. The solid blue line is the calculated form factor from
the atomic coordinates of the lysozyme60-61. It should be noted that the modelled form factor is in
good agreement with that calculated from the atomic coordinates of the lysozyme. The small
discrepancy is attributed to the concentration effect. The HS form factor for the lysozyme yields a
radius of, RL = 1.750.01 nm which is in agreement with that obtained from the literature
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However we do not find difference in size while modelling with an ellipsoidal form factor 60. The
contrast in water is calculated, ∆𝜌 ~ 2.6 1010 cm-2, for the density of 1.32 g/cm3 63. In Figure 3.45
(a) the highlighted box shows an increase in scattering, that illustrates the formation of clusters or
aggregates. It results from the attractive interaction between the lysozyme molecules. However,
the HS S(Q) interaction radius yields, RC = 4.850.02 nm, which is ~ 2.8 times larger than R L.
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This point towards the fact that the formation of equilibrium clusters as a result of lowering of the
pH value (from 7.4 to 7.0) is responsible for the structure factor peak in Figure 3.45 (a). Formation
of dynamic clusters was also reported by Shukla et al. 60 where the S(Q) peak position was found
to be independent of concentration for lysozyme molecules. The strong repulsive interaction
𝑑Σ

between the clusters causes a sharp decrease in the overall forward scattering, 𝑑Ω (𝑄 → 0), that is
manifested as a structure factor (interaction) peak. The interaction peak reveals the distance
between the clusters (~ 2RC) but not the individual lysozyme molecules. Our studies also point to
the fact that formation of such clusters might be related to the change in the pH or the surface
charge density of the lysozyme molecules.
In Figure 3.45 (b) a comparison of the SANS diffraction pattern for a mixture of lysozyme
and PNMeOEtG polymer is presented. For the pure polymer the form factor was modelled using
a Debye function that resembles a random Gaussian coil 51 in equation (1) for, 𝑆(𝑄) = 1. It yields
a radius of gyration, Rg = 2.620.02 nm. The corresponding open square data, represents 1:1
mixture of the polymer and the lysozyme in a pH 7.4 buffer solution. We can model the data simply
by calculating 1:1 ratio of the scattering pattern obtained from the Debye function for the polymer
and the HS form factor for the lysozyme. This univocally point out the fact that there is no
interaction between the polymer and the lysozyme. The resulting scattering curve is a mere sum
of the individual scattering pattern. The small discrepancy of the modelled line for the mixture at
high Q (> 0.26 Å-1) is due to the absence of correct resolution data for the lysozyme solution. It
should be noted that these are in contrast to the previous study on hemoglobin protein interaction
with polyethylene oxide (PEO), where a marked increase in interaction was observed64.
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3.3.4 Cytotoxicity
The cytotoxicity study was investigated in HEp2 cells, and the result was shown in Figure
3.46. PEG (8000 Da), a gold standard for antifouling material, is used as a positive control. The
PNMeOEtG of different molecular weight (3.26-11.1 kg/mol) showed minimal toxicity (cell
viability > 90 %) towards HEp2 cells up to concentration of 1mg/mL investigated, which is critical
for them to be used as biomaterials in biomedical and biotechnological fields.

Figure 3.46. Cell viability study of PNMeOEtG polypeptoids compared to PEG (8000 Da).
3.4 Conclusions
N substituted N-carboxyanhydride monomers bearing oligomeric ethylene glycol side
chains (Me(OEt)n-NCA, for the first time, were successfully synthesized with moderate yields.
PEGylated polypeptoids (PNMe(OEt)3G, n=1-3) were successfully synthesized by BnNH2initiated ring-opening polymerization of the corresponding monomers with controlled molecular
weight ([M]0:[I]0 < 200:1) and narrow molecular distribution (PDI=1.03-1.10). Kinetic studies
revealed a pseudo-first order dependence on the monomer concentration (i.e., d[M]/dt = kobs [M]),
consistent with a living polymerization. The resulting PEGylated polypeptoids are hydrophilic
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both on the polymer backbone and side chain with good water solubility (>200 mg/ml). Similarly
to the previously reported PEO-mimetic oligomers (20 mer), the PEGylated polypeptoids are
amorphous and the glass transition temperature (Tg) is increased with decreasing side chain length:
PNMe(OEt)3G (Tg = -34.9 – -41.1 oC) < PNMe(OEt)2G (Tg = -6.0 – -16.9 oC) <PNMeOEtG (Tg =
24.5 – 46.4oC). The glass transition temperature (Tg) of the PEGylated polypeptoids is also
increased with increasing of molecular weight investigated. The preliminary DLS results showed
that the PNMeOEtG remained fully hydrated without apparent aggregation in PBS buffer for more
than one month and no obvious hydrodynamic size increase was observed for the mixture of
lysozyme and PNMeOEtG up to 24 h based on dynamic light scattering (DLS) analysis. The
preliminary small angle neutron scattering (SANS) analysis of lysozyme, PNMeOEtG, and
mixture of lysozyme and PNMeOEtG in D2O revealed no appreciable interaction between
lysozyme and PNMeOEtG, indicating minimum adsorption of lysozyme to PNMeOEtG. The
SANS structure factor analysis has pointed out a sharp increase in repulsive interaction with the
change in pH content of the buffer that results in equilibrium cluster formation. In addition, the
polypeptoids at different MW showed minimum cytotoxicity towards HEp2 cells. All of these
results suggest the PEGylated polypeptoids a potential antifouling material for the biomedical and
biotechnological application.
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: SOLUTION SELF-ASSEMBLY OF COIL-CRYSTALLINE
DIBLOCK COPOLYPEPTOIDS (PNMG-b-PNDG)
4.1 Introduction
The solution self-assembly of amphiphilic coil-crystalline AB diblock copolymers has
attracted growing interest recently; however, the theoretical and experimental studies on their
solution equilibrium morphologies are limited so far. Studies have shown that a variety of
unconventional micellar morphologies (e.g., cylindrical1-2, discal3, tape-like4, platelet micelles5-6)
can be obtained by the solution self-assembly of amphiphilic coil-crystalline AB diblock
copolymers. Recently, we have shown that both linear and cyclic diblock copolypeptoids (c/lPNMG-b-PNDG) self-assembled into spherical micelles that reorganized into long cylindrical
micelles with uniform diameter in methanol, which was driven by the crystallization of the
crystalline PNDG domain (section 1.3.3).7 At higher concentrations in methanol (5-10 wt%), both
cyclic and linear diblock copolyeptoids (c/l-PNMG-b-PNDG) were shown to form free-standing gels
consisting of entangled fibrils at room temperature.8

Following our previous studies, we have synthesized a series of linear amphiphilic
crystalline-coil diblock copolypeptoids (i.e., l-PNMG-b-PNDG and l-PNMG-b-PNBG) having
well-controlled degree of polymerization but different compositions by sequential benzyl amineinitiated ROPs of the corresponding N-substituted N-carboxyanhydrides (Me-NCA, De-NCA and
Bu-NCA).The preliminary study of the copolypeptoid composition effect on their solution
morphologies was conducted.
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4.2 Experimental
4.2.1 Synthesis and characterization of diblock copolymers
All the crystalline-coil AB diblock copolypeptoids were synthesized by primary amineinitiated ring-opening polymerization of the corresponding N-substituted N-carboxyanhydrides
(R-NCAs) in a sequential manner. A representative procedure for the synthesis of l-PNMG-bPNDG was presented. In the glovebox, Me-NCA ([M1]) (87.2 mg, 0.76 mmol, [M1]0=0.4 M) was
dissolved in anhydrous acetonitrile. Stock solution of benzyl amine in acetonitle (82 µL, 92.7 mM,
[M1]: [BnNH2]0=100:1) was added. The reaction mixture was stirred at room temperature for 16 h
to reach a complete conversion of polymerization. Acetonitrile solution of De-NCA ([M2]) (189
µL, 0.4 M, 0.076 mmol, [M1]0:[M2]0: [BnNH2]0=100:10:1) was added to the above mixture and
allowed to stir at 50oC for another 24 h to reach a full conversion. The polymer solution was dried
under vaccume and re-dissolved in DCM followed by addition of excess hexane to precipitate out
the polymer. The polymer was collected by filtration and washed with ample hexane followed by
drying under vacuum to afford white solid (55.8 mg) in 81.2% yield. The molecular weights (Mns)
were determined by end-group analysis using 1H NMR spectroscopy.
4.2.2 Self-assembly of diblock copolypeptoids
The diluted solutions of diblock copolypeptoids (l-PNMG130-b-PNDG70, l-PNMG114-bPNDG89, l-PNMG125-b-PNDG117, PNMG105-b-PNBG115) were prepared by dialysis method due to
their limited solubility in MeOH: the diblock polymers were dissolved in DCM at 1.0 mg/mL
concentration followed by dialysis against MeOH for 7days. The resulting solutions were heated
at 70-80oC, above the side chain melting point of PNDG, for 1h and slowly cooled down to room
temperature. All the dilute solutions of other diblock copoypeptoids were prepared by directly
dissolving in MeOH at 1.0 mg/ml and heated at 70oC for 1h followed by slowly cooling down to
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room temperature. The prepared dilute solutions of diblock copolypeptoids were characterized by
DLS and TEM analysis at different time intervals.
4.2.3 DLS measurement of dilute polymer solutions
Polymer solution in MeOH (1.0 mg/mL) was filtered through a 0.22 µm filter and heated
at 70-80 oC for 1 h followed by slowly cooling down to room temperature. The polymer solution
was characterized by DLS at different time intervals. All the DLS measurements were conducted
using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser operating at 633 nm was utilized,
and scattered light intensity was detected at an external angle of 173 oC using non-invasive
backscatter (NIBS) technology. Data from three measurements with 12 scans for each
measurement was recorded. At each temperature, the sample was equilibrated for 3 min.
4.2.4 TEM/cryo-TEM analysis of dilute polymer solutions
Polymer solution in MeOH (1.0 mg/mL) was filtered through a 0.22 µm filter and heated
at 70-80 oC for 1 h followed by slowly cooling down to room temperature. The polymer solution
was stored at room temperature for 3 d. FEI Vitrobot was used for the sample preparation of cryoTEM experiment. 5 µL of the above polymer solution in MeOH (1 mg/mL) was applied to a 300
mesh lacey carbon coated TEM grid. Double side blotting to the grid for 2 seconds leaves a thin
film on the grid. The grid then was quickly plunged into liquid ethane chilled by liquid nitrogen.
The vitrified sample grid was loaded in a single tilt liquid nitrogen cryo transfer holder, and was
then inserted to FEI G2 F30 Tecnal TEM operated at 120keV, with a FEI digital camera and
analyzed using FEI Digital Micrograph software. The grids for the regular TEM was prepared by
adding 5 µL of the above polymer solution in MeOH (1mg/mL) onto the 300 mesh carbon grid
followed by blotting with a filter paper and drying at room temperature. The grids then were
stained with uranyl acetate for 1 min.
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4.3 Results and discussion
4.3.1 Synthesis and characterization of AB diblock copolypeptoids
A series of linear AB diblock copolypeptoids (l-PNMG-b-PNDG and l-PNMG-b-PNBG)
have been synthesized by benzyl amine-initiated ROP of the corresponding R-NCAs in a
sequential manner (Scheme 4.1). The compositions of the AB diblock copolypeptoids were
determined by 1H NMR spectroscopy (Table 4.1, Figure 4.1 and 4.2). For example, the numberaveraged degree of polymerization (DPn) of l-PNMG-b-PNDG (l-AB) was determined by the
integrations at 2.89-3.04 ppm and 0.91 ppm due to the methyl protons in the PNMG block and the
methyl protons in the PNDG block relative to the integration of the benzyl end-group signals at
7.31 ppm. The compositions of the AB diblock copolypeptoids can be well tuned by controlling
the initial monomer to initiator ratio ([M]0:[BnNH2]0). The volume fraction of the PNDG block
was systematically varied in the 0.27-0.79 range. The l-PNMG-b-PNDG diblock copolymers were
not suitable for size exclusion chromatographic (SEC) analysis using LiBr/DMF and THF due to
their limited solubility in these solvents. The molecular weights (Mns) determined by 1H NMR
spectroscopy were comparable to the theoretically predicted values, as shown in table 4.1.
Scheme 4.1. Synthesis of diblock copolypeptoids (l-PNMG-b-PNDG and l-PNMG-b-PNBG).
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Figure 4.1.1H NMR spectrum of l-PNMG99-b-PNDG9 in CD2Cl2.

Figure 4.2. 1H NMR spectrum of l-PNMG96-b-PNBG12 in CD2Cl2.
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Table 4.1. Molecular parameters of AB diblock copolytoids.
Entry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

a

Sample

l-PNMG99b-PNDG9
l-PNMG90b-PNDG17
l-PNMG92b-PNDG37
l-PNMG168b-PNDG35
l-PNMG145b-PNDG52
l-PNMG130b-PNDG70
l-PNMG114b-PNDG89
l-PNMG125b-PNDG117
l-PNMG96b-PNBG12
PNMG105-bPNBG45
PNMG184-bPNBG16
PNMG205-bPNBG60
PNMG163-bPNBG65
PNMG138-bPNBG84
PNMG105-bPNBG115

b

[M]1:[M]2:[I]0

Φ PNDG
c
d
Calcd
NMR

e

Micelle
Sturcture

f

Diameter
(nm)

100:10:1

0.29

0.27

Cylindrical

12.6±0.8

100:20:1

0.45

0.44

Cylindrical

10.9±1.2

100:40:1

0.62

0.62

Cylindrical

13.4 ± 1.8

180:40:1

0.48

0.46

Cylindrical

12.9±1.2

160:60:1

0.61

0.60

Cylindrical

29.0±4.5

140:80:1

0.70

0.69

Cylindrical

21.1±5.8

120:100:1

0.77

0.76

Cylindrical

30.6±6.0

100:120:1

0.83

0.79

100:10:1

-

-

100:40:40

-

-

200:20:1

-

-

180:40:1

-

-

160:60:1

-

-

140:80:1

-

-

100:120:1

-

-

a

Precipitate
out
g
Not
Cylindrical
Not
Cylindrical
Not
Cylindrical
Not
Cylindrical
Not
Cylindrical
Not
Cylindrical
Not
Cylindrical

-

The actual DPn was determined by 1H NMR. bTheoretical monomer to initiator ratio cTheoretical
volume fraction of PNDG using the known density of PNMG (1.405 g/cm3) and PNDG (0.95
g/cm3). dActual volume fraction of PNDG determined by 1H NMR. eEntry 6,7,8 and 15 were
prepared by dialysis method and other entries were prepared by direct dissolving method at
1mg/ml in MeOH. fAverage diameter of more than 30 individual micelles from TEM. The error
bar is the standard deviation of the measured diameters. gThere is no large aggregation formed
from DLS results.
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4.3.2 Solution self-assembly of AB diblock copolypeptoids
Self-assembly of l-PNMG-b-PNDG in MeOH. To investigate the effect of polymer
compositions on the self-assembled morphology of l-PNMG-b-PNDG in MeOH, the selfassembly of l-PNMG-b-PNDG bearing constant chain length of PNMG block (targeted DPn = 100)
while different chain length of PNDG block (Φ PNDG = 0.27-0.62) were investigated by
transmission electron microscopy (TEM) using uranyl acetate as the staining reagent, as shown in
Figure 4.3 (A-F). At 3 d, cylindrical micelles were observed for all the three samples, l-PNMG99b-PNDG9, l-PNMG90-b-PNDG17 and l-PNMG92-b-PNDG37. The cylinder like structures of sample
l-PNMG92-b-PNDG37 were also confirmed by cryo-TEM, as shown in Figure 4.3 (G,H). For
sample PNMG90-b-PNDG17 with longer PNDG block length, cylindrical micelles with larger
diameters were observed, probably due to the aggregation of individual cylindrical micelles during
the TEM preparation process, as evidenced by the cryo-TEM images of the micelles showing no
aggregation of individual micelles (Figure 4.4). The diameters of the individual micelles in Figure
4.3 (A-F) (average of at least 50 micelles) were measured for these three samples: d (PNMG99-bPNDG9) = 12.6 ± 0.8 nm, d (PNMG90-b-PNDG17) = 13.0 ± 0.9 nm and d (PNMG92-b-PNDG37) =
13.4 ± 1.8 nm. It is interesting that the diameter of the cylindrical micelles formed by PNMG99-bPNDG9 well matched the diameter of a zig-zag conformation of a fully stretched PNDG segment,
whereas the diameters of the cylindrical micelles formed by PNMG90-b-PNDG17 and PNMG92-bPNDG37 were much smaller than the theoretically predicated diameter assuming the PNDG was
fully stretched, indicating that the PNDG micellar core adopted a chain folded structure.
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Figure 4.3. TEM images of dilute solutions of l-PNMG99-b-PNDG9 (A, B), l-PNMG90-b-PNDG17
(C, D), and l-PNMG92-b-PNDG37 (E, F) in MeOH after 3 d. The samples were prepared by direct
dissolution method and stained with uranyl acetate. Cryo-TEM images of dilute solutions of lPNMG92-b-PNDG37 (1mg/mL) in MeOH after 3 d (G,H).

Figure 4.4. Cryo-TEM images of dilute l-PNMG90-b-PNDG17 solution in MeOH at 3 d.
To investigate the effect of different sample preparation method on micelle morphology,
solution of l-PNMG92-b-PNDG37 in MeOH (1mg/mL) prepared by dialysis method was also
analyzed by TEM. As shown in Figure 4.5, longer cylindrical micelles (d = 12.6 ± 1.0 nm) were
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formed by dialysis method compared to that formed by direct dissolution method (Figure 4.3 G,H),
probably due to the slow diffusion of MeOH in the dialysis method that allow the micelles to
crystallize slowly.

Figure 4.5. TEM images of dilute solutions of l-PNMG92-b-PNDG37 in MeOH prepared by dialysis
method. The sample was stained with uranyl acetate prior to TEM imaging.
The self-assembly of the diblock copolypeptoids (l-PNMG-b-PNDG) with constant total
chain length (targeted DPn = 220) while different volume fraction ratio of PNMG and PNDG (Φ
PNDG = 0.46-0.79), were also investigated in MeOH. Miceller solutions of l-PNMG168-b-PNDG35
and l-PNMG145-b-PNDG52 were prepared by direct dissolution in MeOH, whereas miceller
solutions of l-PNMG130-b-PNDG70, l-PNMG114-b-PNDG89 and l-PNMG125-b-PNDG117 were
prepared by dialysis method due to their higher hydrophobicity and limited solubility in methanol.
All the samples formed cylinder-like structures in MeOH at 3 d (Figure 4.5). The core of the
cylindrical micelles were more likely to adopt a chain folded structure, as evidenced by the average
diameters of the individual cylindrical micelles (d = 12.9 ± 1.0 – 29.0 ± 4.5 nm) which were much
smaller than the theoretically predicated value assuming the PNDG core adopted a fully stretched
conformation. Sample l-PNMG125-b-PNDG117 was too hydrophobic that precipitation occured
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after dialysis against MeOH and sheet-like structure was observed of the suspension under TEM
(Figure 4.6).

Figure 4.6. TEM images of dilute solutions of l-PNMG168-b-PNDG35 (A), PNMG145-b-PNDG52
(B), PNMG130-b-PNDG70 (C) and PNMG114-b-PNDG89 (D). (A) and (B) were stained with uranyl
acetate, whereas (C) and (D) were not.

Figure 4.7. TEM images of l-PNMG125-b-PNDG117 in MeOH stained with uranyl acetate.
The self-assembly of the polymers was also monitored by DLS for l-PNMG168-b-PNDG35
and l-PNMG145-b-PNDG52.in dilute methanol solution (1.0 mg/mL) at room temperature. For
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sample l-PNMG168-b-PNDG35 (Figure 4.7 A), two size distribution peaks were observed after
immediately dissolution in MeOH, which was tentatively attributed to the spherical micelles and
short cylinders formed at the beginning. The peaks shifted to larger size with increasing time,
indicating the formation of longer cylinders, consistent with the TEM results (Figure 4.5). For
sample l-PNMG145-b-PNDG52 of higher PNDG volume fraction (Φ PNDG = 0.60), monomodel
size distribution was observed at all time investigated (from t=0 to t=10d) (Figure 4.7B), probably
due to the “freezed morphology” of short cylinders as shown in TEM (Figure 4.5).

Figure 4.8. DLS-determined hydrodynamic size distribution of 1.0 mg/mL PNMG168-b-PNDG35
and 1.0 mg/mL PNMG145-b-PNDG52 in methanol at room temperature.
Self-assembly of l-PNMG-b-PNBG in MeOH. Cylindrical micelles were observed in
MeOH under TEM in a wide composition window (Table 4.1 and Figure 4.8). The crystallization
of the solvophobic PNDG block including both main chain and side chain crystallization, was
expected to drive the formation of cylindrical micelles. To support our hypothesis, l-PNMG-bPNBG polymers where the PNBG blocks only undergo main chain crystallization were
synthesized and their solution self-assembly in MeOH was compared with that of l-PNMG-bPNDG. As expected, no evidence of cylindrical micelle formation for l-PNMG-b-PNBG polymers
at the entire compositions range, as indicated by the lack of large particle formation over time from
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DLS analysis. Representative DLS measurement (Figure 4.9A and B) indicated that diameters of
micelles formed by PNMG205-b-PNBG60 and PNMG163-b-PNBG65 remained almost constant (< 10
nm) over time, indicating no large aggregates formed. No cylindrical micelles were observed under
TEM for sample PNMG105-b-PNBG115 with the highest volume fraction of PNBG block in room
temperature MeOH at 1.0 mg/mL (Figure 4.9C). The results were consistent with the observation
that no gel was formed for PNMG105-b-PNBG45 at 20 wt% in MeOH at room temperature over a
period of two months.

Figure 4.9. Composition-solution morphology diagrams for (A) l-PNDG-b-PNMG and (B) lPNBG-b-PNMG in 1.0 mg/mL MeOH solution at room temperature. NA: DPn of PNMG; NB: DPn
of PNDG or PNBG. The non-cylindrical region in (B) is determined by DLS analysis.

Figure 4.10. DLS-determined hydrodynamic size distribution of (A) PNMG205-b-PNBG60 and (B)
PNMG163-b-PNBG65 in MeOH at room temperature. (C) TEM images of dilute solution of
PNMG105-b-PNBG115 in MeOH stained with uranyl acetate.
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4.4 Conclusion and future work
A series of amiphiphilic coil-crystalline l-PNMG-b-PNDG and l-PNMG-b-PNBG diblock
copolypeptoids were synthesized by ROP of the corresponding monomers. l-PNMG-b-PNDG
formed cylindrical micelles in MeOH in a wide composition window (Φ PNDG = 0.27-0.79). By
contrast, l-PNMG-b-PNBG bearing shorter alkyl side chains in the solvophobic segment than that
in l-PNMG-b-PNDG showed no evidence of cylindrical micelle formation based on DLS and TEM
analysis. TEM analysis revealed that the cylindrical micelles formed by l-PNMG99-b-PNDG9 with
short PNDG block (Φ PNDG = 0.27) appears to adopt a core of fully stretched PNDG chains,
while the micellar core of all other l-PNMG-b-PNDG polymers were likely to adopt a chain folded
conformation. To further investigate the driving force of the cylindrical micelle formation of the
coil-crystalline diblock copolypeptoids (l-PNMG-b-PNDG) in methanol, l-PNMG-b-PNEHG
with the hydrophobic block PNEHG having no side chain crystallization will be synthesized and
its solution self-assembly in methanol will be investigated. A systematic study on how the polymer
composition, architecture and crystalline packing affect the morphology of crystalline-coil block
copolymers in dilute solution is currently in progress. The solution morphologies will be fully
characterized by, TEM/crto-TEM, S/WAXS, and SANS methods to determine the micellar
structure and the crystalline packing in the micellar core.
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: INTRODUCTION TO DIPYRROMETHENES (BODIPYS)
AND BORON NEUTRON CAPTURE THERAPHY (BNCT)
5.1 Introduction to BODIPYs
5.1.1 Synthetic methodologies of BODIPYS
Boron dipyrromethene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene), abbreviated as BODIPY
(Figure 5.1), has been considered as a versatile fluorophore dye in the last three decades.1 BODIPY is
formed by boron complexation of a dipyrromethene with boron trifluoride diethyl etherate (BF3O
(CH2CH3)2), leading to a rigid tricyclic system usually associated with narrow absorption and emission
spectra and high fluorescence quantum yields.2

Figure 5.1. Structure of BODIPY fluorophore and its IUPAC numbering system.
Since the first BODIPY reported by Treibs and Kreuzer in 19683, numerous BODIPYs have
been synthesized using several following strategies. The first synthetic approach (Scheme 5.1), which
usually is used to build symmetrical BODIPYs, involves the acid-catalyzed condensation between α-

free pyrroles (1) and various aldehydes (2)4. The resulting dipyrromethanes (5) were further oxidized
to corresponding dipyrromethenes (6) using dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) followed
by complexation with boron trifluoride diethyl etherate (BF3·OEt2) under basic conditions to afford
the desired BODIPYs (7). Additionally, the condensation can also be achieved between α-free
pyrroles (1) and acyl chloride (3)5, or anhydride (4)6 to directly yield the dipyrromethene (6) followed
by deprotonation with base (e.g., triethylamine) and boron complexation to afford the symmetrical
BODIPYs (7). As shown in Scheme 5.2, the second method7, which generally is used to approach both
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symmetrical and unsymmetrical BODIPYs, involves the acid catalyzed condensation of 2-acetyl
pyrroles (8) and an α-free pyrroles (9) followed by oxidation with DDQ to provide the corresponding
dipyrromethenes (11). Subsequent complexation of 11 with BF3·OEt2 provides symmetrical or
unsymmetrical BODIPYs (12). The third method (Scheme 5.3)8 is usually used to synthesize mesounsubstituted symmetrical BODIPYs. It involves the condensation between two identical α-

formylpyrroles (13) catalyzed by POCl3 to produce the corresponding dipyrromethenes (14),
followed by boron complexation to afford desired BODIPYs (15). One advantage of this method is
that it can afford higher yields in comparison with the first method.
A new synthetic method (Method 4, Scheme 5.4), using dipyrro (thio) ketone, to synthesize
symmetrical or unsymmetrical BODIPYs, has been developed and investigated in recent years.9-15 The
dipyrrothioketone precursors can be obtained from the condensation between α-free pyrroles (16) and
thiophosgene (CSCl2), further treated with CH3I, organic base, and BF3·OEt2 to obtain meso-thioester
BODIPYs (18), or treated with KOH/H2O2 to yield dipyrroketones (19).9 Alternatively, dipyrroketones
(19) can also be synthesized using Pb(OAc)4/PbO2 oxidation of dipyrromethanes, which can be
prepared by condensation of readily available 2-methyl pyrroles (21) in the presence of bromine,
followed by DDQ oxidation.11 Another alternative way to synthesize both symmetrical (19) or
unsymmetrical dipyrroketones (25) is via a reaction between α-(N,N-dimethyl-amido) pyrroles (24)

in the presence of POCl3, followed by hydrolysis with aqueous sodium acetate.13-15 Oxidative
halogenation using POX3 (X = Cl or Br) or phosgene (COCl2) of the dipyrroketones (19 and 25),
followed by deprotonation with base and complexation with BF3·OEt2 yields the corresponding
symmetrical (20, 23) or unsymmetrical (26) meso-halo-BODIPYs.
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Scheme 5.1. The first synthetic method of symmetric BODIPYs.

Scheme 5.2. The second synthetic method of symmetrical or unsymmetrical BODIPYs.

Scheme 5.3. The third synthetic method of symmetrical BODIPYs with meso position unsubstituted.
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Scheme 5.4. The fourth synthetic method of symmetrical and unsymmetrical BODIPYs.

5.1.2 Functionalization of BODIPYs
To synthesize versatile BODIPYs for different applications, different methodologies have
been developed to introduce various functional substituents to the BODIPY skeleton. The
convention method, the so-called pre-functionalization, is to develop various pyrrole precursors
for the synthesis of BODIPYs as shown in Scheme 5.1-5.4. For example, five- or six-member ring
cyclic anhydride can be used as the carbonyl source in Method 1 to introduce carboxylic acids at
the meso position of BODIPYs.6 The carboxylic acid group can be activated with Nhydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide (DCC) for further conjugation
with peptides or proteins.
Scheme 5.5. Resonance structures of BODIPY.
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As outlined in Scheme 5.5, the BODIPY skeleton have different resonance structures with
carbons 1, 3, 5, 7 and 8 bearing more positive charge character, therefore is more electrophilic than
carbons 2 and 6. Post-functionalization of BODIPYs can be realized by taking advantage of the
different electrophilicity at different carbon positions to introduce different functional groups to
BODIPYs.14
Halogenated BODIPYs have emerged as a versatile platform for the post-functionalization
of BODIPYs to introduce a variety of functionalities to the BODIPY core by both metal-catalyzed
cross-coupling (e.g., Suzuki, Stille, Heck, and Sonogashira)16-17 and nucleophilic substitution
reactions18-20.
Halogenated BODIPYs can be prepared from halogenated precursor including halogenated
pyrroles, dipyrromethanes and dipyrroketones, as shown in Scheme 5.4. Another alternative
strategy to synthesize halogenated BODIPYs is to employ direct electrophilic substitution
reactions at different positions of BODIPYs. As shown in Scheme 5.6. mono-, di-, tetra,
hexabromo-BODIPYs were synthesized via regioselective electrophilic bromination of pyrrolicunsubstituted BODIPYs using bromine.21 The step-wise bromination first took place at 2,6-, then
at 3,5-, and eventually at 1,7-positions, as confirmed by NMR and X-ray analysis. These
polybrominated BODIPYs showed regioselectivity towards the nucleophilic aromatic substitution
(SNAr) reaction and exhibited a decreasing reactivity order as followed: 3,5-bromo > 1,7-bromo >
2,6-bromo. On the other hand, tetrabromo BODIPY exhibited a high reactivity towards Suzuki
coupling reactions, while the regioselectivity of different bromo groups was not investigated.
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Scheme 5.6. Bromination of BODIPY.

To increase the regioselectivity of the post-functionalization of halogenated BODIPYs, a
pentachloro-BODIPY synthesized from meso-chloro-BODIPY (32) using TCCA/AcOH was
reported recently (Scheme 5.7A).14 The regioselective chlorination reaction produced di-, tri-,
tetra-, and pentachloro-BODIPYs in moderate to good yields. In this work, the pentachloroBODIPY 36 was shown to undergo regioselective Pd (0)-catalyzed Suzuki and Stille crosscoupling reactions, first at the 8-position, followed by the 3,5- and then the 2,6-positions. The
similar reactivity trend was also observed for the nuceophilic substitution reactions. To illustrate
the versatility of BODIPY 36, multifunctionalization was performed on this BODIPY. 4Methoxylphenyl group was selectively introduced at the 8-position via a Suzuki coupling reaction,
followed by a Stille coupling reaction to introduce the phenylethynyl groups at the 3,5-positions.
The second Stille coupling reaction catalyzed by Pd(PCy3)G2 introduced the thienyl group at the
2,6-positions to provide penta-coupled BODIPY 37 that absorbs and emits in the NIR region, as
shown in Scheme 5.7B.
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Scheme 5.7. Chlorination of meso-Cl-BODIPY (A) and multifunctionalization of penta-ClBODIPY (B)

Extending the above work, three-perhalogenated BODIPYs (40-1, 40-2, 40-3), bearing
chloro and bromo groups at all carbon positions of the BODIPYs were synthesized recently from
the corresponding chloro-BODIPYs (39-1, 39-2, 39-3) using bromine (Scheme 5.8). The
regioselectivity of the BODIPY 40-3 was investigated at all carbon positions by using Stille crosscoupling reactions and boron substitution reactions.15 The reactivity order of the halogens under
these conditions is: 8-Cl ≈ 1,7-Br > 3,5-Cl > 2,6-Cl > 4,4’-F. It was also the first time to report the
nona-functionalized BODIPYs.
Scheme 5.8. Synthesis of perhalogenated BODIPYs.
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5.1.3 Application of BODIPYs
BODIPYs, featuring strong UV-vis absorbance and sharp fluorescence with high quantum
yields, are relatively stable in the physiological environment, and also have high photostability.
Moreover, the functionalizability of the halogen-BODIPYs in section 5.1.2 render them high
tunability to approach various BODIPYs for different applications. Therefore, BODIPYs have
shown growing interest in various applications such as biological imaging, biological labeling,
drug delivery, and sensing.1,

22-24

For example, the 2,6-diiodo BODIPYs, were shown to be

efficient photodynamic (PDT) sensitizers due to the enhanced quantum yield of singlet oxygen
induced by the heavy atom effect.25

Also, a variety of fluorescent probes for Pd2+,26 and

Cu2+,27could be prepared by substitution reactions between dihalo-BODIPYs and nuleophiles (e.g.,
azacrown) in high yields.
5.2 Introduction to BNCT
5.2.1 Mechanisms of BNCT
BNCT is a promising binary anticancer therapy that selectively targets and destroys
malignant tumor cells, while spare the damage to healthy normal cells.28-32 BNCT involves the
irradiation of non-radioactive
neutrons, produces excited

11

10

B-containing tumors with low-energy thermal or epithermal

B nuclei which spontaneously fission to give cytotoxic high linear

energy transfer (high-LET) α and recoiling 7Li particles, along with γ radiation, and approximately
2.4 MeV of kinetic energy (Figure 5.2). Low-energy epithermal neutrons are able to penetrate 8
cm into tissues to reach deep-located tumors. The generated high-LET particles have short path
lengths of 5-9 µM in tissue (about the diameter of a single cell), restricting the damage to
containing tumor cells. The biologically abundant nuclei
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12

10

B-

C (0.0034 barn), 1H (0.33 barn), and

14

N (1.8 barn) show negligible interference with the 10B (n,)7Li neutron capture reaction due to

their much smaller nuclear cross sections in comparison with 10B.

Figure 5.2. The 10B(n, α)7Li neutron capture and fission reactions
BNCT has been used clinically for several decades in the treatment of various types of
tumors including head and neck cancers, primary and metastatic melanomas, and high-grade brain
tumors (e.g., glioblastoma multiforme, GBM).31, 33-34
5.2.2 General criteria for BNCT agents
Generally, an effective boron delivery drug for BNCT should display the following
characteristics:28-32 1) deliver therapeutic amounts of 10B to tumor, estimated to be at least 20 μg/g
tumor or approximately 109 atoms/cell), 2) high tumor-to-normal tissue and tumor-to-blood
concentration ratios (> 5), 3) low systemic toxicity, 4) rapid clearance from blood and normal
tissues while persisting in tumor during the irradiation treatment, and 5) easy quantification of
tissue-localized boron. In addition, for brain tumor treatment, the BNCT drugs should be able to
permeate across the blood-brain barrier (BBB), either by passive transmembrane diffusion or
through targeting of transporters and receptors that are expressed at the BBB.35 The passive
diffusion of compounds across cellular membranes and the BBB depends on various factors,
including the compound’s lipophilicity, molecular weight, electrical charge, degree of ionization,
hydrogen bonding ability, and intermolecular interactions.35-37 In general, low molecular weight
(< 500 Da) boron delivery agents with favorable lipophilicity (octanol−water partition coefficient,
log P <5) show enhanced passive diffusion across cellular membranes and the BBB.36-39 However,
a major challenge in drug development for BNCT has been the selective delivery of therapeutic
amounts of boron to tumor cells, with minimal toxicity to normal tissues. Another challenge in the
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treatment of brain tumors is the often inefficient BBB permeability of the BNCT drugs. Over the
last few decades, thousands of boron carriers for BNCT have been designed and synthesized, but
only a few have been tested in pre-clinical trials. Among these, many are able to deliver higher
amount of boron to tumors relative to the surrounding normal tissue, due to the so-called “enhanced
permeability and retention (EPR) effect”. However, the selectivity of boron accumulation is often
low, which can cause undesired toxic effects to healthy tissues. In order to improve the tumor
selectivity of BNCT agents, their encapsulation into delivery agents, such as liposomes, and/or
association with tumor-targeting moieties (e.g. peptides, folic acid, antibodies) has been explored.
In addition, several administration methodologies and combination therapies have also been
investigated. One very promising methodology that bypasses the BBB and enhances boron tumor
uptake is convection-enhanced delivery (CED), a method for local drug infusion directly into
brain. CED bypasses the BBB and is able to delivery high amounts of boron (>100 µg/g tumor) to
intracerebral tumors, with very high tumor-to-blood and tumor-to-normal brain ratios.32, 40 More
recently, another tumor treatment strategy designated magnetic drug targeting (MDT) has also
been introduced.41 MDT uses an external magnetic field to direct boron-containing magnetic
nanoparticles, administrated intraarterially, to tumor tissues. The MTD strategy is independent
from molecular and biological recognition or passive accumulation, and allows selective
accumulation of the drug.
5.2.3 Main categories of BNCT agents
The two clinically used boron-containing drugs are the sodium salt of sulfhydryl boron
hydride Na2B12H11SH (BSH) and the amino acid (L)-4-dihydroxyborylphenylalanine (BPA)
(Figure 5.3, 41-42).31, 33-34, 42-45 Although BSH and BPA show low toxicity and have recorded
efficacy in clinical BNCT trials, they have only low selectivity for tumors, and low retention
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times.32, 45-46 Other promising classes of boronated compounds, including boronated amino acids,
peptides, monoclonal antibodies (MAb), nucleosides, lipids, carbohydrates, liposomes, porphyrin
derivatives, BODIPYs, and nanoparticles, have been synthesized and investigated as potential
BNCT agents.30, 32, 40, 47 The preferred boron sources in these compounds are the neutral isomeric
carboranes ortho-, meta-, and para-C2B10H12, negatively charged closo-B12H122-, closo-CB11H12-,
the open cage nido-C2B9H12-, and metallo-bis(dicarbollides) such as [3,3’-Co(1,2- C2B9H11)2](Figure 5.3, 43-49) as a result of their remarkable properties that include: 1) high boron content,
2) amphiphilicity, 3) high photochemical, kinetic, and hydrolytic stabilities, and 4) ease of
functionalization and attachment to targeting molecules.40, 48 Several reviews have been published
on compound development for BNCT.29-30, 32, 40, 47-57 Among the different classes of boron delivery
agents, nucleosides, amino acids, porphyrin derivatives and tumor-targeted compounds that
recognize a tumor-associated epitope, are amongst the most promising BNCT agents due to their
generally lower toxicity and increased tumor specificity and uptake. Porphyrin derivatives and
boron dipyrromethenes (BODIPYs) have attracted considerable interest as potential BNCT drugs
due to their fluorescent characteristic which facilitate the quantification of tissue-localized boron.

Figure 5.3. Structures of BSH, BPA and common boron clusters currently used in BNCT drug
development.
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Taking advantage of the synthetic development of BODIPYs and the attractive properties
of BODIPYs including strong absorbance and fluorescence with high quantum yields, high
stability in physiological environment, and high photostability, as mentioned in section 5.1, a series
of carborane-containing BODIPYs were synthesized and their in vitro biological studies were
investigated. Detailed information was included in Chapter 6. In Chapter 7, a series of push-pull
BODIPYs were synthesized and their photophysical and electrochemical properties were
compared.
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CHAPTER 6 : SYNTHESIS AND IN VITRO STUDIES OF A SERIES OF
CARBORANE-CONTAINING BORON DIPYRROMETHENES (BODIPY)
6.1 Introduction
Boron neutron capture therapy (BNCT), which can selectively target and destroy malignant
cells in the presence of healthy normal cells, is a very promising binary anticancer methodology
especially for the treatment of brain tumors1-3 BNCT involves the irradiation of nonradioactive
10

B-containing tumors with low-energy thermal neutrons, causing the excitation of

10

B to

11

B,

which rapidly produces cytotoxic high linear energy transfer (high-LET) α and 7Li particles, γ
radiation, and about 2.4 MeV of kinetic energy through a nuclear fission reaction. The generated
high-LET particles have short path lengths about the diameter of a single cell (< 10 μm), therefore
restricting the damage to
the

10

10

B-containing tumor cells. In addition, there is little interference with

B (n,α)7Li capture reaction due to the very small nuclear cross sections of biologically

abundant nuclei including

12

C, 1H, and

14

N. Another advantage of BNCT is that thermal and

epithermal neutrons are able to penetrate deep into tissues to reach deep-seated tumors. However,
a relatively high boron tumor concentration of at least 20 μg

10

B/g tumor or approximately 109

atoms/cell is required for effective BNCT treatment, and this has driven recent research in the
areas of boron drug development and delivery methodologies for BNCT.
BNCT has been used clinically for several decades in the treatment of high-grade brain
tumors, such as glioblastoma multiforme (GBM), and other difficult-to-treat malignancies,
including primary and metastatic melanomas and recurrent head and neck cancers.3-5 One major
challenge in the BNCT modality for brain tumors is the existence of the blood−brain barrier (BBB)
* Chapter 6 previously appeared as Xuan, S.; Zhao, N.; Zhou, Z.; Fronczek, F. R.; Vicente, M. G.
H. Synthesis and in Vitro Studies of a Series of Carborane-Containing Boron Dipyrromethenes
(BODIPYs). J. Med. Chem. 2016, 59, 2109-2117. It is reprinted by permission of ACS Publisher
(see page 261).
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that prevents most drugs from penetrating into the brain and from reaching the targeted tumor
cells.6-11 In the brain tumor treatment, the prerequisite is that the boron drug should permeate across
the BBB, ether by passive transmembrane diffusion or through active transportation of targeting
transporters and receptors that are expressed at the BBB.12 The passive diffusion of boron drugs
across the BBB are strongly dependent on the physicochemical properties of the drugs, including
their lipophilic character, molecular weight (MW), size, polar surface area, charge, and extent of
ionization.13-15 Among these, the two main characteristics in a small molecule that favor its
crossing of cellular membrane and BBB by passive diffusion are (1) molecular weight under 500
Da and (2) high lipophilic character, usually measured by the octanol−water partition coefficient,
log P <5.6, 13-15 Although significant hydrophobicity is important for enhanced permeability across
the BBB, BNCT drugs also need to be soluble in aqueous media to enable their systemic
administration.2 Therefore, there is continued need to develop amphiphilic boron drugs with
appropriate hydrophilic and lipophilic balance (HLB) and low molecular weight of <500 Da for
efficient BBB permeability and tumor cell uptake.
The two boron drugs that have been extensively used in BNCT clinical trials are the sodium
salt of the sulfhydryl boron hydride Na2B12H11SH (BSH) and L-4- dihydroxyborylphenylalanine
(BPA).3-5 Although BSH and BPA have demonstrated efficacy in BNCT clinical trials, they have
low selectivity, low tumor retention time and limited BBB permeability,10, 16 which limit their use
in brain tumor treatment. Other boronated compounds have been investigated as potential BNCT
drugs, including amino acids, peptides, carbohydrates, nucleosides, liposomes, porphyrins,
monoclonal antibodies (mAbs), and nanoparticles.2-3, 7 the Among these, particularly promising
are mAbs due to their very high specificity for a tumor-associated epitope, and porphyrin
derivatives due to their ability to transport large amounts of boron within cells. However, these
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BNCT agents have limited BBB crossing ability, mainly due to their large size, high molecular
weight, and hydrophobicity.2, 16
Recently, we have reported the investigation on the BBB crossing ability of a series of
carboranylporphyrins conjugated to polyamines, glucose, arginine, and an opioid peptide,17 but
they all exhibited low permeabilities (Pe < 3.3 × 10−6 cm/s) across hCMEC/D3 cell monolayers as
the BBB model. In contrast, amphiphilic boron dipyrromethene (BODIPY), referred to as “semiporphyrins”, of low molecular weight displayed enhanced BBB permeability and promise as boron
delivery drugs for BNCT.18 BODIPY dyes have attracted special interest in recent years due to
their various applications in biological labeling, drug delivery, imaging, sensing, and
theranostics.19-22 As mentioned in Chapter 5, BODIPYs are strongly UV−vis absorbing and
generally emit sharp fluorescence with high quantum yields, which can facilitate detection and
quantification of tissue-localized boron in BNCT. BODIPYs have also shown negligible
sensitivity toward solvent polarity and solution pH, high permeability across cellular membranes,
and relatively high stability under physiological conditions.
BODIPYs functionalized with carborane clusters have been prepared using Suzuki18 and
Sonogashira23 cross-coupling reactions of the corresponding 2,6-diiodo-substituted BODIPYs.
Alternatively, carboranes can be introduced onto the BODIPY at the 3(5)- and/or 8-positions
through substitution reactions of the corresponding chlorinated derivatives.18, 24-25 Herein we report
the synthesis of a series of seven carboranyl-BODIPYs from the corresponding chloro-BODIPY
derivatives, with molecular weights in the range 366−527 Da and log P in the range 1.5−2.7. The
cytotoxicity and uptake of the BODIPYs in human glioma T98G cells, as well as their permeability
across the BBB using hCMEC/D3 cells, were investigated and compared.
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6.2 Experimental
6.2.1 General considerations
All the chemicals and reagents were purchased from Sigma-Aldrich and Fisher Scientific
and used as received. 1-Mercapto-1,2-carborane was purchased from Katchem. Reactions were
monitored by analytical thin-layer chromatography (TLC) performed on precoated plates
(polyester-back, 60 Å, 0.2 mm, Sorbent Technologies). Purifications were conducted by column
chromatography on silica gel (230−400 mesh, 60 Å, Sorbent Technologies) or preparative TLC
plates (f254, VWR). 1H and

13

C {1H} NMR spectra were obtained using a Bruker AV-400

NanoBay (400 MHz for 1H NMR and 100 MHz for 13C NMR) and a Bruker AV-500 spectrometer
(125 MHz for 13C NMR) at room temperature. 11B NMR was obtained on a Bruker AV-400 III
(128 MHz), using BF3·OEt2 as reference. Chemical shifts (δ) are given in parts per million (ppm)
in CDCl3 (7.27 ppm for 1H NMR, 77.0 ppm for 13C NMR); coupling constants (J) are given in Hz.
High resolution mass spectrometry (HRMS) spectra were obtained using a 6210 ESI-TOF mass
spectrometer (Agilent Technologies). 4-(1-Methyl-1,2-carborane)-methylphenylboronic acid26
and BODIPYs 1a,27 3a,24 3b,18 6a,25and 725 were synthesized as previously reported.
6.2.2 General procedure for synthesis of BODIPYs via nucleophilic substitution reaction
The starting chloro-BODIPY (0.05 mmol) was dissolved in 2 mL of THF. 1-Mercapto-1,2carborane (0.055 mmol) and K2CO3 (0.5 mmol) were added, and the final mixture was stirred at
room temperature. TLC was used to monitor the reaction until completion (2−5 h). The crude solid
product was filtered and purified by column chromatography or preparative TLC using
CH2Cl2/hexanes or ethyl acetate/hexanes for elution.
8-(1,2-Carboranyl-1-thio)-BODIPY 1b. 16.1 mg (88%), mp 213-215 °C. 1H NMR
(CDCl3, 400 MHz): δ 8.01 (2H, s), 7.36 (2H, s), 6.64 (2H, s), 3.77 (1H, s), 1.8−3.5 (10H, br). 13C
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NMR (CDCl3, 100 Hz): δ 148.6, 139.4, 133.3, 132.2, 120.4, 72.2, 65.0.

11

B NMR (CDCl3, 128

MHz): δ −0.08 (1B, t, 1J(B,F) = 27.8 Hz), −12.97 to - −1.57 (10B, m). HRMS (ESI-TOF) m/z
calcd for C11H17B11F1N2S [M − F]+ 347.2199; found 347.2200.
8-(1,2-Carboranyl-1-thio)-1,3-dimethyl-BODIPY 2b. 18.7 mg (95%). 1H NMR (CDCl3,
400 MHz): δ 7.71 (1H, s), 7.10 (1H, s), 6.49 (1H, s), 6.29 (1H, s) 3.79 (1H, s), 2.65 (1H, s), 2.55
(1H, s), 1.8-3.5 (10h, br); 13C NMR (CDCl3, 100 Hz): δ 166.9, 148.6, 141.4, 138.3, 137.2, 130.0,
127.0, 126.0, 117.4, 73.3, 65.1, 16.7, 15.7;

11

B NMR (CDCl3, 128 MHz): δ 0.14 (1B, t, 1J(B,F)=

29.8 Hz), -12.97-(-1.60) (10B, m); HRMS (ESI-TOF) m/z calcd for C13H22B11F2N2S [M+H]+
395.2576; found 395.2566.
BODIPY 5b. 20.9 mg (93%). 1H NMR (CDCl3, 400 MHz): δ 7.44 (1H, s), 3.70 (2H, s),
2.58 (3H, s), 2.44-2.45 (8H, overlap, m), 2.02 (3H, s), 1.8-3.5 (10h, br), 1.05-1.09 (3H, t, 3J(H,H)=
7.4 Hz); 13C NMR (CDCl3, 100 Hz): δ 162.7, 141.5, 141.1, 137.8, 137.2, 134.1, 130.1, 128.4, 74.9,
64.1, 17.3, 14.5, 14.2, 14.0, 13.4, 10.2; 11B NMR (CDCl3, 128 MHz): δ -0.06 (1B, t, 1J(B,F)= 30.0
Hz), -11.89-(-1.64) (10B, m); HRMS (ESI-TOF) m/z calcd for C17H30B11F2N2S [M+H]+ 451.3204;
found 451.3195.
BODIPY 6b. 17.9 mg (74%). 1H NMR (CDCl3, 400 MHz): δ 3.69 (1H, s), 2.60 (3H, s),
2.44 (8H, overlap, m), 2.00 (3H, s), 1.8-3.5 (10h, br), 1.06-1.10 (3H, t, 3J(H,H)= 7.6 Hz); 13C NMR
(CDCl3, 125 Hz): δ 163.1, 141.3, 141.2, 137.8, 137.7, 137.6, 132.7, 128.5, 126.4, 74.9, 64.1, 17.3,
14.8, 14.6, 14.1, 13.5, 9.1;

11

B NMR (CDCl3, 128 MHz): δ 0.08 (1B, t, 1J(B,F) = 30.0 Hz), -12.94-

(-1.45) (10B, m); HRMS (ESI-TOF) m/z calcd for C17H29B11ClF2N2S [M+H]+ 485.2818; found
485.2824.
BODIPY 4. BODIPY 1a (11.3 mg, o.o5 mmol) was dissolved in toluene (4 ml). 1M
Na2CO3 (aq) (1 ml), Pd(PPh3)4 (5% mol), and 4-(1-methyl-ortho-carborane)methylphenyl boronic
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acid (29.2 mg, 0.1 mmol) were added and the final mixture was refluxed overnight. The mixture
was poured into water (10 ml) and extracted with dichloromethane (10 ml  3). The organic layers
were collected, washed with H2O and brine, and dried over anhydrous Na2SO4. The solvents were
removed by rotary evaporation to give the crude products. The further purification was performed
by column chromatography (ethyl acetate/hexanes as the eluent) to provide the titled product (10.6
mg), in 45% yield. 1H NMR (CDCl3, 400 MHz): δ 8.0 (2H, s), 7.56-7.58 (2H, m), 7.37-7.39 (2H,
m), 6.92 (2H, s), 6.58 (2H, s), 3.57 (2H, s), 2.22 (3H, s), 1.8-3.5 (10h, br); 13C NMR (CDCl3, 100
Hz): δ 146.4, 144.5, 137.7, 134.9, 133.6, 131.5, 130.7, 130.4, 118.7, 75.0, 40.9, 23.8;

11

B NMR

(CDCl3, 128 MHz): δ 0.18 (1B, t, 1J(B,F)= 28.6 Hz), −10.74- −3.16) (10B, m); HRMS (ESI-TOF)
m/z calcd for C19H25B11FN2 [M-F]+ 419.3108; found 419.3111.
6.2.3 HPLC analysis of BODIPYs
Normal-phase HPLC was performed on a Dionex system including a P680 pump and UVD
340 detector connected to a Dynamax axial compression column packed with Rainin 60 Å irregular
silica gel. The flow rate of 1 mL/min was used. For compound 1b, a stepwise gradient of 50% B
(ethyl acetate) and 50% A (hexane) in the first 3 min to 80% B and 20% A during the next 18 min
to 50% B and 50% A for the next 6 min was used. For all other compounds, a stepwise gradient
of 10% B and 90% A in the first 5 min to 70% B and 30% A during the next 10 min to 10% B and
90% A for the next 10 min was used.
6.2.4 Spectroscopic studies
UV−visible and fluorescence spectra were collected on a PerkinElmer Lambda 35 UV/vis
spectrometer and PerkinElmer LS 55 luminescence spectrometer at room temperature. Quartz
cuvettes (10 mm path length) and spectroscopic grade solvents were used for both measurements.
Optical density (ε) was determined by using the solutions with absorbance at λmax (0.5−1).
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Quantum yields were determined by using the dilute solutions with absorbance (0.04−0.06) at the
particular excitation wavelength. Cresyl violet perchlorate (0.54 in methanol) and rhodamine 6G
in ethanol (0.95) were used as external standards for the carboranyl BODIPYs 5b, 6b, and 1b−3b,
4, 7, respectively. The relative fluorescence quantum yields (Φf) were determined by calculations
using the following equation,28
ΦX = ΦR × (FX/FR)×(AR/AX)×(nX/nR)2
where Φ stands for fluorescence quantum yields; n stands for refractive indexes; F stands
for the areas under the emission peaks; A stands for absorbance at the particular excitation
wavelength, subscripts X and R refer to the tested samples and standard sample, respectively.
6.2.5 Crystallography
X-ray data for 2b and 5b were collected at 90 K with Mo Kα radiation (λ = 0.71073 Å) on
a Bruker Kappa Apex-II DUO diffractometer. For BODIPY 2b, C13H21B11F2N2S, monoclinic
space group P21/c, a = 10.7729(5), b = 15.7487(7), c = 12.5738(6) Å, β = 104.222(2)°, V =
2067.88(17) Å3, Z = 4,22,855 measured data. Final R = 0.040, Rw = 0.106 for 264 refined
parameters and 7883 independent reflections having θmax = 33.2°. For BODIPY 5b,
C17H29B11F2N2S, monoclinic space group P21/c, a = 13.688(2), b = 12.1938(17), c = 15.488(2) Å,
β=113.231(6)0, V = 2375.3(6) Å3, Z = 4,47,866 measured data. Final R = 0.040, Rw = 0.110 for
303 refined parameters and 8658 independent reflections having θmax = 32.6°. The CIFs have been
deposited at the Cambridge Crystallographic Data Centre (CCDC 1426277-1426278).
6.2.6 Octanol-water partition coefficients
The partition coefficients (Log P) were measured by adapting a reported procedure.29 1Octanol and Milli-Q water were mutually saturated and the two phases were separated. A 64 µM
stock solution was prepared by dissolving the BODIPY into water-saturated 1-octanol. 2 mL of
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the stock solution was added to 6 mL Milli-Q water in a 15 mL volumetric tube and the mixture
was intensively vortexed for 10 min. After complete separation of the two phases, an aliquot from
the 1-octanol layer was diluted with water-saturated 1-octanol and its absorbance was recorded
with a Varian Cary 50 Bio UV-Vis spectrophotometer with a 10 mm path length quartz cuvette.
The Log P values were calculated as follows:

LogP  Log (

Aoct
V
 W)
A0  Aoct VO

where A0 and Aoct are the absorbance of the compound in the water-saturated octanol before
and after partitioning; Vw and Vo are the water and 1-octanol volumes, respectively.
6.2.7 Cell studies of BODIPYs
The T98G cell line used in this study was purchased from ATCC and cultured in ATCCformulated Eagle's Minimum Essential Medium containing 10% FBS and 1% antibiotic
(Penicillin-streptomycin). The hCMEC/D3 cells were obtained from Dr. Pierre-Olivier Couraud
from Institut COCHIN in Paris (France). All other reagents were purchased from Life
Technologies.
Dark Cytotoxicity. A 32 mM compound stock solution wasprepared by dissolving the
BODIPY in 100% DMSO. The stock solution was diluted into final working concentrations (0,
6.25, 12.5, 25, 50, and 100 μM). Human glioma T98G cells were plated at 15 000 cells per well in
a Costar 96-well plate (BD biosciences) and allowed to grow for 24 h. The cells were exposed to
the working solutions of compounds up to 100 μM and incubated overnight (37 °C, 95% humidity,
5% CO2). The working solution was removed, and the cells were washed with 1× PBS. The
medium containing 20% CellTiter Blue (Promega) was added and incubated for 4 h. The viability
of cells is measured by reading the fluorescence of the medium at 570/615 nm using a BMG
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FLUOstar Optima microplate reader. This fast, sensitive, and popular assay uses the indicator dye
resazurin which is reduced to fluorescent resorufin in viable cells, while nonviable cells are not
able to reduce resazuin or to generate a fluorescent signal. The fluorescence signal of the untreated
cells was normalized to 100%.
Phototoxicity. Human glioma T98G cells were prepared as described above. The cells
were incubated with compound concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 0 μM for 24
h. The loading medium was removed, and the cells were washed with 1×PBS buffer and then
refilled with fresh media. The cells were exposed to a 600 W halogen lamp light source filtered
with a water filter (transmits radiation 250−950 nm) and a beam turning mirror with 200 nm to 30
μm spectral range (Newport), for 20 min. The total light dose was approximately 1.5 J/cm2. After
light exposure, the cells were returned to the incubator for 24 h and assayed for cell viability as
described above.
Time-dependent cellular uptake. Human T98G cells were prepared as described above.
The cells were exposed to 10 μM of each compound solution for 0, 1, 2, 4, 8, and 24 h. The loading
medium was removed at the end of each incubation period, and the cells were washed with 1×
PBS and solubilized by adding 0.25% Triton X-100 in 1× PBS. Standard curves using 10, 5, 2.5,
1.25, 0.625, and 0.3125 μM concentrations were obtained by diluting 400 μM of each BODIPY
solution with 0.25% Triton X-100 (Sigma-Aldrich) in 1× PBS. A cell standard curve was prepared
using 104, 2 × 104, 4 × 104, 6 × 104, 8 ×104, and 105 cells per well. The cell number was quantified
using a CyQuant cell proliferation assay (Life Technologies). The compound concentration in cells
at each time period was determined using a BMG FLUOstar Optima microplate reader at 485/590
nm. Cellular uptake is expressed in terms of compound concentration (nM) per cell.
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Microscopy. Human HEp2 cells were incubated in a six-well plate (MatTek) and allowed
to grow overnight. The cells were exposed to 10 μMof each BODIPY and incubated for 6 h (37 °C,
95% humidity, 5% CO2), followed by the addition of organelle tracers obtained from Invitrogen.
The organelle tracers were used at the following concentrations: LysoSensor Green, 50 nM;
MitoTracker Green, 250 nM; ER Tracker Blue/White, 100 nM; and BODIPY FL C5 Ceramide,
50 nM. The cells were incubated with the BODIPY and tracers for 30 min and washed with PBS
three times before imaging. The images were acquired using a Leica DMRXA2 upright
microscope with a water immersion objective and DAPI, GFP, and Texas Red filter cubes (Chroma
Technologies).
hCMEC/D3 cell line (BBB model) (Figure 6.1).

Figure 6.1. The blood-brain mimic for experimental in vitro BBB study. The upper chamber
mimics the blood compartment, the lower chamber mimics the cerebral compartment, and the
hCMEC/D3 cell monolayer represents the BBB.
The BBB permeabilities were determined following a pulished procedure.30-31 Specifically,
the hCMEC/D3 cells were incubated in a six-well, 0.4 μm porosity PET Transwell plate (Corning)
for 48 h, allowing the formation of a model brain capillary endothelial monolayer (checked by
microscopy). EBM-2 medium containing 5% FBS, 1% penicillin/streptomycin, hydrocortisone,
ascorbic acid, chemically defined lipid concentrate (1/100), HEPES, and bFGF was used as the
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growth medium. The coated PET Transwell plates with and without endothelial cells were
transferred into six-well plates. The measurements were performed in triplicate for each compound,
using three PET Transwell plates with cells and three without cells. The time points of the
treatment were 0, 10, 25, and 45 min. At time 0, a 0.5 mL sample of each BODIPY or standard
Lucifer yellow (LY) at 50 μM concentration in transport buffer was added to the upper chamber
(mimicking the blood), and 1.5 mL of transport buffer was added to the lower chamber (mimicking
the BBB); see Figure S24 in the Supporting Information. The transport buffer was prepared by
adding 5 mL of HEPES (1 M) and 5 mL of sodium pyruvate (100 μM) to 400 mL of HBSS. The
plates were incubated at 37 °C, 95% humidity, and 5% CO2. At time 10 and 25 min, each upper
PET Transwell was transferred to the corresponding prepared six-well plate containing 1.5 mL of
transport buffer: the so-called “25 min” first and then the “45 min”. At each time point, solution
in the lower chamber was added into a 96-well plate with 100 μL for each well (five wells). The
fluorescence intensity of the solution was measured by using a BMG FLUOstar plate reader at
485/590 nm and 425/538 nm (excitation/emission) for BODIPYs and LY, respectively, and the
concentrations were determined from the corresponding standard curves. The calculations of
permeability coefficients (Pe, in cm/s) were performed following the clearance principle as
described in the equations below (eqs 1 and 2), where X is the amount of sample in the lower
chamber and Cd is the concentration of sample in the upper chamber at each time point. The total
cleared volume at each time point is calculated by summing the incremental cleared volumes up
to the given time point.
clearance (mL) = X/Cd (1)
The cleared volume is plotted vs time, and a linear fit is applied.
Pe (cm/s) = (

1
1

) /( A  60) (2)
PSt PSf
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where PSt is the slope of the clearance curve for the culture, PSf is the slope of the clearance
curve with the control Transwell plate without cells, and A is the surface area of the PET Transwell
plate.
6.3 Results and discussion
6.3.1 Synthesis and characterization
Synthesis of carboranyl BODIPYs. A series of seven carboranyl-BODIPYs 1b, 2b,
3b,184, 5b, 6b, and 7,25 were synthesized as shown in Scheme 6.1. The ortho-carborane cluster was
chosen as the boron source because of its high boron content, high hydrophobicity, high stability
under physiologic conditions, and low toxicity.7, 11 The key chloro-BODIPY starting materials
were synthesized from the corresponding dipyrroketones, as previously reported.24-25, 27 8-ChloroBODIPYs 1a−3a and 5a were converted into their corresponding 8-carboranylthio-BODIPYs by
reaction with 1.1 equiv of 1-mercapto-o-carborane in THF at room temperature, in yields ranging
from 88% to 95%. We have previously reported that 3,8-dichloro-BODIPY 6a undergoes highly
regioselective substitutions at the 8-position in the presence of N- and O-centered nucleophiles.25
Using more reactive S-nucleophiles, the 8- vs 3-substitution regioselectivity tends to decrease.
However, due to the electron-withdrawing nature of the carborane cluster, BODIPY 6a reacted
smoothly with 1.1 equiv of 1-mercapto-o-carborane, affording 6b with high regioselectvity in 74%
yield. On the other hand, BODIPY 7 was prepared from 6a via two successive regioselective
reactions, a Stille cross-coupling at the 8-position using 1 equiv of tributylphenylstannane and
Pd(PPh3)4, followed by substitution using an excess of 1-mercapto-o-carborane, as we have
previously reported.25 The Suzuki cross-coupling reaction of BODIPY 1a with 1.5 equiv of 4-(1methyl-o-carborane)-methylphenylboronic acid in toluene and in the presence of Pd(PPh3)4 and 1
M Na2CO3(aq) produced BODIPY 4 in 45% isolated yield.
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Scheme 6.1. Synthesis of carborane-containing BODIPYs.

HPLC, NMR and X-ray analysis. All compounds were of ≥95% purity, as determined by
HPLC (Figures 6.2-6.8). The commercially available LY standard is of 97% purity, as provided
by Life Technologies. The structures of the new BODIPYs 1b, 2b, 5b, 6b and 4 were confirmed
by 1H-, 13C- (Figures 6.9-6.18) and 11B-NMR (Figures 6.19-6.24), HRMS, and in the case of 2b
and 5b by X-ray crystallography (Figure 6.25). The X-ray structures of 3b20 and 7.27 have been
previously reported. Crystals of BODIPYs 2b and 5b suitable for X-ray analysis were obtained by
slow diffusion of hexanes into chloroform. In 2b, the B atom of the central C3N2B ring lies slightly
(0.214 Å) out of the plane of the other five atoms, which are fairly coplanar, having a mean
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deviation of 0.013 Å. The carborane lies on the bisector of this plane, with C-C-S-C torsion angle
93.9°. In 5b, the central ring is slightly more planar, with the meso C atom lying 0.098 Å out of
the C2N2B plane. The S atom lies 0.319 Å out of this plane, and as in 2b, the carborane lies on the
bisector, with C-S-C-C torsion angle 94.1°. The ethyl group is also approximately perpendicular
to the ring system, with C-C-CH2-CH3 torsion angle 83.7°.

Figure 6.2. HPLC trace for BODIPY 1b.
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Figure 6.3. HPLC trace for BODIPY 2b.

Figure 6.4. HPLC trace for BODIPY 3b.
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Figure 6.5. HPLC trace for BODIPY 4.

Figure 6.6. HPLC trace for BODIPY 5b.
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Figure 6.7. HPLC trace for BODIPY 6b.

Figure 6.8. HPLC trace for BODIPY 7.
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Figure 6.9. 1H NMR spectrum of BODIPY1b.

Figure 6.10. 13C {1H} NMR spectrum of BODIPY1b.
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Figure 6.11. 1H NMR spectrum of BODIPY2b.

Figure 6.12. 13C {1H} NMR spectrum of BODIPY2b.
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Figure 6.13.1H NMR spectrum of BODIPY 5b.

Figure 6.14. 13C {1H} NMR spectrum of BODIPY5b.
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Figure 6.15. 1H NMR spectrum of BODIPY6b.

Figure 6.16. 13C {1H} NMR spectrum of BODIPY6b.
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Figure 6.17. 1H NMR spectrum of BODIPY4.

Figure 6.18. 13C {1H} NMR spectrum of BODIPY4.
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Figure 6.19. 11B NMR spectrum of BODIPY 1b.

Figure 6.20. 11B NMR spectrum of BODIPY 2b.
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Figure 6.21. 11B NMR spectrum of BODIPY3b.

Figure 6.22. 11B NMR spectrum of BODIPY 4.
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Figure 6.23. 11B NMR spectrum of BODIPY 5b.

Figure 6.24. 11B NMR spectrum of BODIPY 6b.
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Figure 6.25. X-ray crystal structure of 2b (left) and 5b (right).
Spectroscopic analysis. The spectroscopic properties of all BODIPYs in dichloromethane
solution were investigated and the results are summarized in Table 1 (see also Figures 6.26-6.27).
The absorption spectra of all BODIPYs followed the Lambert-Beer law, indicating there is no
appreciable aggregation in this solvent at the concentrations investigated. The introduction of an
ortho-carboranylthio group at the 8-position in BODIPYs 1b-3b, 5b and 6b, caused large redshifts on the maximum absorption (up to 57 nm) and emission (up to 73 nm) bands (Figure 6.26).
This is probably due to the stabilization of the LUMO by this group, which decreases the HOMOLUMO gap.34 On the other hand, introduction of the same group at the 3-position, as in BODIPY
7, induced a slight blue-shift (ca. 5 nm) relative to the starting BODIPY 6a.27 Arylation at the 8position, as in BODIPY 4, also produced a slight blue-shift compared with the starting 8-chloroBODIPY 1a probably due to a large dihedral angle between the aryl group and the BODIPY core.
The fluorescence quantum yields were higher for BODIPY 1b, suggesting low rotational freedom
for the 8-carboranylthio group, and it decreased with increasing alkyl substitution for 2b, 3b and
5b. This is attributed to increased energy lost to non-radiative deactivation processes.27,34 On the

198

other hand, BODIPY 4 shows much lower quantum yield than 7, probably due to the higher
rotation of the 8-aryl group in the absence of 1,7-methyl groups.
Table 6.1. Spectroscopic properties of BODIPYs in dichloromethane at room temperature.
BODIPY
1b
2b
3b
4
5b
6b
7

Absorption
λmax (nm)
544
537
554
502
577
582
521

log ε (M1
cm-1)
4.42
4.54
4.45
4.50
4.29
4.16
4.18

Emission,
λmax (nm)
556
553
576
517
608
609
540

Φfa
0.52
0.29
0.065
0.034
0.060
0.090
0.58

Stokes shift
(nm)
12
16
22
15
31
27
19

a

Rhodamine 6G in ethanol (0.95) was used as standard for all compounds except for 5b and 6b,
which used crystal violet perchlorate in methanol (0.54) as the standard.

Figure 6.26. (A, B) Normalized UV/Vis spectra of BODIPYs 1b, 2b, 4, 3b, 5b and 6b; (C, D)
Normalized fluorescence spectra of BODIPYs 1b, 2b, 4, 3b, 5b and 6b in dichloromethane at
room temperature.
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Figure 6.27. (A-C) Absorption spectra of BODIPY 1b, 2b and 3b at different concentrations in
dichloromethane; (E-F) Plot of absorbance intensity of BODIPY 1b, 2b and 3b vs. concentration
in dichloromethane.
6.2.2 Cytotoxicity and uptake in T98G Cells
This is the first report on the cytotoxicity and cellular uptake of carborane-containing
BODIPYs. The cytotoxicity (dark and light, using 1.5 J/cm2 light dose) and time-dependent uptake
of all carboranyl-BODIPYs were investigated in human glioma T98G cells and the results are
summarized in Table 6.2 and Figures 6.28-6.29. The IC50 values were calculated from
dose−response curves.
None of the BODIPYs, with the exception of 5b, showed any toxicity in the dark at
concentrations up to 100 μM investigated, as shown in Figure 6.28A. Upon irradiation with light,
all the BODIPYs, with exception of 3b (IC50 = 80 μM) and 5b (IC50 = 40 μM), exhibited minimal
photocytotoxicity (IC50 > 98 μM) (Figure 6.28B). The higher phototoxicity observed for 5b (IC50
= 40 μM ) might be a result of its higher uptake by T98G cells, which was evidenced by the cellular
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uptake study showing 5b accumulated the most within cells at all the time points investigated.
BODIPY 7 accumulated the least, among this series of BODIPYs, which was probably due to its
poor aqueous solubility. The lipophilic character of this series of BODIPYs was evaluated by
determining their distribution between 1-octanol and water, and the values obtained for the
partition coefficients (log P) are given in Table 6.2. The extent of cellular uptake did not correlate
with the hydrophobic character of the BODIPYs, which increased in the order 1b < 2b < 3b < 5b
∼ 6b < 4 ≪ 7.
Table 6.2. Dark, photocytotoxicity (1.5 J/cm2) and uptake plateau concentration of BODIPYs in
human glioma T98G cells. Permeabilty coefficients (Pe) of BODIPYs and lucifer yellow (LY) in
human endothelial hCMEC/D3 cells. Octanol-water partition coefficients (log P) of BODIPYs.
Major sites
Pe10-5
of
(cm/s)
localization
LY
457.24
2.2±0.8
366.25
1.50
Lyso, Mito, 16.4±3.3
1b
Golgi, ER
394.31
1.69
>100
>98
0.36±0.03
Lyso, Mito, 6.0±1.0
2b
Golgi, ER
422.36
1.73
>100
>80
0.11±0.02
Lyso, Mito, 4.4±0.5
3b
Golgi, ER
a
438.33
2.11
>100
>100
0.41±0.03
Lyso, Mito,
4
Golgi, ER
450.41
1.95
>100
>40
1.5±0.05
Lyso, Mito, 2.6±0.9
5b
Golgi, ER
484.85
1.93
>100
>100
0.46±0.06
Lyso, Mito, 5.4±0.6
6b
Golgi, ER
a
526.50
2.70
>100
>100
0.0034±0.000 Lyso, Mito,
7
4
Golgi, ER
a
The Pe values were not determined for these compounds due to their limited solubility in
Comp.

MW
(g/mol)

log P

Darktoxi
city IC50
(µM)
>100

Phototoxici
ty IC50
(µM)
>100

buffer.
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Cellular
uptake at 24 h
(nM/cell)
0.23±0.05

\\
Figure 6.28. Dark cytotoxicity (A) and Phototoxicity (B) of 1b-7 using human glioma T98G
cells.

Figure 6.29. Time-dependent uptake of BODIPYs 1b (green), 2b (black), 3b (red), 4 (blue), 5b
(purple), 6b (dark red) and 7 (orange) at 10 µM in human glioma T98G cells.
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All compounds, with the exception of 7, were taken up rapidly in the first 2 h after which
slower uptake was observed for all compounds except for 1b where a plateau was reached. After
24h, the amount of compound accumulated within cells varied considerably (Table 6.2);
compound 5b showed the highest uptake, about 436-fold higher than 7, followed by 6b (135-fold
higher than 7), 4 (118-fold higher than 7), 2b (106-fold higher than 7), 1b (67-fold higher than 7),
and 3b (33-fold higher than 7). These results indicate that among this series of compounds,
BODIPY 5b could deliver the largest and therapeutic amount of boron within glioma cells, with
very low dark toxicity.
To investigate the sites of subcellular localization of the carboranyl-BODIPYs, HEp2
rather than T98G cells were used for fluorescence microscopy, as the HEp2 cells facilitate imaging
by nicely spreading on the surface of the six-well plate. This work was done in collaboration with
Ms. Zehua Zhou. The organelle-specific probes BODIPYCeramide (Golgi), LysoSensor Green
(lysosomes), MitoTracker Green (mitochondria), and ER Tracker Blue/White (endoplasmic
reticulum) were used in the overlay experiments. The results are shown in Figures 6.30-6.33 for
BODIPYs 1b-7. All carboranyl-BODIPYs localized preferentially in the cell ER, as shown in
Figures 6.30-6.33. In addition, the BODIPYs were also observed, but to a smaller extent, in the
lysosomes, mitochondria, and Golgi apparatus. These results are in agreement with previous
studies showing preferential ER-localization for BODIPY molecules.
6.2.3 BBB permeability
The in vitro BBB model, as shown in Figure1, was used for the evaluation of BBB
permeability of the carboranyl BODIPYs. The hCMEC/D3 cell line is a useful model for studies
of BBB permeability because it retains many of the morphological and functional characteristics
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Figure 6.30.Subcellular localization of 1b (left) and 5b (right) in HEp2 cells at 10 μM for 6 h: (a)
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green,
(j) overlay of BODIPY and LysoSensor. Scale bar: 10 μm.
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Figure 6.31. Subcellular localization of 2b (left) and 3b (right) in HEp2 cells at 10 μM for 6 h: (a)
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green,
(j) overlay of BODIPY and LysoSensor. Scale bar: 10 μm.
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Figure 6.32. Subcellular localization of 4 (left) and 6b (right) in HEp2 cells at 10 μM for 6 h: (a)
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green,
(j) overlay of BODIPY and LysoSensor. Scale bar: 10 μm.
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Figure 6.33. Subcellular localization of 7 in HEp2 cells at 10 μM for 6 h: (a) phase contrast, (b)
overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay of BODIPY and
ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY ceramide, (g)
MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green, (j) overlay
of BODIPY and LysoSensor. Scale bar: 10 μm.
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of human brain endothelial cells.31-33 Recently, the BBB permeability of a series of carboranyl
porphyrins17 and BODIPYs18 have been investigated using this model. All the carboranyl
porphyrins and BODIPYs tested showed low permeability values (Pe < 3 × 10−6 cm/s) with the
exception of BODIPY 3b which showed higher permeability (Pe = 4 × 10−5 cm/s) than LY. This
was attributed to its smaller MW and lower hydrophobic character among the compounds tested.
To investigate the effect of MW and lipophilicity of compounds on their ability to cross the BBB,
a new series of derivatives of 3b (MW = 422, log P = 1.7), with MW and hydrophobic character
(log P) in the ranges 366−527 Da and 1.5−2.7, respectively, were evaluated. For comparison
purposes and for evaluation of the cell monolayer integrity, the BBB permeability of LY, a polar
fluorescent molecule with MW in the same range (457.24 Da) as the BODIPYs, was also
determined. The results obtained are shown in Table 6.2. The Pe values could not be determined
for 4 and 7, due to the precipitation of these compounds in buffer associated with their high
lipophilicity and poor water solubility. All carboranyl-BODIPYs tested showed higher BBB
permeability compared with LY, a marker for low BBB permeability. Among this series of
compounds, 1b showed the highest Pe value (7-fold higher than LY), probably due to its lower
MW (366 Da) and favorable hydrophobic character (log P = 1.50), conferring it the highest
solubility in buffer as well as lipophilicity. Compound 2b, of similar MW (394 Da) and
hydrophobicity (log P = 1.69) to 1b, showed the second highest Pe value. The other BODIPYs,
including 3b, with increased alkyl and/or aryl substitution, MW > 400 Da, and log P > 1.7, showed
lower Pe values although still higher than that determined for LY. Compound 5b showed the lowest
Pe value among this series of BODIPYs, slightly higher than LY, and therefore is considered to
have low BBB permeability, although it was the most efficiently taken up by the T98 glioma cells
(Figure 6.29). All other BODIPYs displayed BBB permeabilities higher than that reported for
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phenytoin, which has been used as a marker for medium BBB permeability.31, 34 Among the new
BODIPYs, 1b, 2b, and 6b showed higher permeability than 3b, which displays a slightly higher
Pe value than phenytoin. These results show that both the MW and amphiphilicity of the BODIPYs
influence their permeability across the BBB and that small amphiphilic carboranyl-BODIPYs of
MW < 400 Da and log P < 1.7, such as 1b and 2b, are the most efficient at diffusing across the
BBB by passive diffusion.
6.4 Conclusions
A series of seven amphiphilic carboranyl-BODIPYs with MW within the range 366−527
Da, including a previously reported BODIPY known to permeate across a BBB model, were
synthesized in good yields from the corresponding chloro-BODIPYs by nucleophilic substitution.
The structures of the BODIPYs were confirmed by NMR, HRMS and, in the cases of 2b and 5b,
by X-ray crystallography. The carboranyl-BODIPYs display strong absorption and emission bands
in the visible region of the spectrum and quantum yields in dichloromethane in the range 0.6−0.03.
All BODIPYs showed low dark toxicity (IC50 > 100 μM) in human glioma T98G cells, an
important property of potential boron delivery agents because of the high boron concentration
requirement in BNCT (>20 μg/g tumor). The BODIPYs also showed low phototoxicity (IC 50 >80
μM) with the exception of 5b (IC50 =40 μM), probably as a result of its remarkably high uptake
into T98G glioma cells. On the other hand, BODIPY 1b showed the largest permeability across
the BBB model consisting of hCMEC/D3 cells. Our results showed that the BODIPYs with MW
< 400 Da and log P < 1.7 are the most efficient at crossing the BBB model. The most hydrophobic
compound 7 (log P = 2.7) was poorly soluble in aqueous solutions, showed very low uptake into
T98G cells, and its precipitation in buffer precluded determination of its BBB permeability. All
BODIPYs tested showed higher BBB permeability compared with LY, as well as low dark
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cytotoxicity and therefore could potentially be efficient boron delivery agents for BNCT of brain
tumors. Among this series, 1b and 2b showed the highest BBB permeability while 5b and 6b
accumulated the most within tumor cells; therefore, these are the most promising BNCT agents.
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CHAPTER 7 : SYNTHESIS AND OPTOPPHYSICAL INVESTIGATION OF
A SERIES OF PUSH-PULL BORON DIPYRROMETHENES (BODIPYS)
7.1 Introduction
Push-pull chromophores with electron donors (D) and electron acceptors (A) attached to a
π spacer (D- π -A) have been a subject of interest due to their wide applications in organic lightemitting devices,1 two photon dyes,2-3 and dye-sensitized solar cells4-6. Porphyrins and
phthalocyanines, bearing both electron donors and electron acceptors (D- π -A), have attracted
considerable interest in the recent decades to be potentially used as dye-sensitized solar cells.5, 7-13
Recently, boron dipyrromethanes (BODIPYs), an analogue of porphyrins, featuring excellent
optical and electrochemical properties, have emerged as the π spacer of growing interest owing to
their potential applications in biological imaging, biological labeling, drug delivery, sensing and
in theranostics as well as in photovoltaic field.14-19 BODIPYs are usually strongly UV-vis
absorbing and emit sharp fluorescence peaks with high quantum yields. BODIPYs are also
relatively stable in physiological environment and have high photostability. Besides, BODIPYs
have high structural tunability which render them easy access to manipulate their properties (e.g.,
photophysical properties, water solubility, redox potential).
The BODIPY core itself is electron deficient and the installation of electron donating group
to the BODIPY endow them the push and pull effect within the molecule.20-22 In the recent years,
to increase the push-pull effect of the BODIPY, electron withdrawing group is also introduced to
the BODIPY core to further enhance the pull effect; however, the study of design, characterization
and investigation of BODIPYs with both push and pull substituents is limited so far. Currently,
the push-pull effect has been studied mainly on three BODIPY platforms with both electron
donating (push) and withdrawing (pull) substituents23-31 (Figure 7.1: I, II and III). The push-pull
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investigation on extended dimeric aza-BODIPY dyes was also reported.32 The attachment of push
and pull moieties to the BODIPY skeleton can cause dramatic change in their spectroscopic and
electrochemical properties.24-26,

33

For example, the strong electron donating group (e.g.,

diphenylaminophenyl) and electron withdrawing group (e.g., 4-carboxylic phenyl) on the
BODIPY could lead to enhancement of charge transfer within the molecule for them to be
potentially used as dye-sensitized solar cells27-30 or two photon excitation dyes2, 31. The push-pull
effects can also red-shift the BODIPYs to the near-infrared (NIR) absorbing region and render
them potential use in biological sciences (e.g., biological imaging and sensing).34 For example, a
66 nm bathochromic shift was caused by introducing electron withdrawing cyano group (-CN) and
electron donating methoxy group (-OMe) to the para positions of 1,7-phenyl and 3,5-phenyl
substituents of the tetra-phenyl aza BODIPY, respectively.34

Figure 7.1. Platforms of push-pull BODIPYs.
The reported DFT calculated electronic structure of an unsubstituted model BODIPY
showed large electron density of HOMO at 3,5-positions and large electron density of LUMO at
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8-position.16 Therefore, introducing the electron donating group to the 3,5-positions and electron
withdrawing group to the 8-positon of the BODIPYs should have effect on their spectroscopic and
electrochemical properties by changing the characteristics of HOMO and LUMO (e.g., lower the
energy gap between HOMO and LUMO).
Herein, we design and synthesize three new push-pull BODIPY platforms (Figure 7.1: IV,
V, VI) with multiple sets of push-pull moieties from the penta-Cl BODIPY using Pd (0)-catalyzed
Stille and Suzuki cross-coupling reactions with easily obtained boronic acids and stannane
reagents. For all the platforms, electron donating group (-OMe) and electron withdrawing group
(-COOBn, -CN) were introduced to para positions of 3,5- and 8- phenyl substituents on the
BODIPYs, respectively. As the electron-rich thiophene, especially at the 2 and 6 positions, was
shown to cause large bathochromic shift and Stokes shift of BODIPYs,35-37 two thiophene groups
(donor) were additionally installed at 2 and 6 positions to have platform V (Figure 7.1). To
investigate how push-pull effect on 2,6 positions affect the spectroscopic and electrochemical
properties of BODIPYs, an additional set of push-pull moiety was introduced to 2,6 position to
have platform VI (Figure 7.1). Cyclic voltammetry and DFT calculations were conducted on all
the BODIPYs and a systematic comparison of these BODIPYs was made to investigate the
influence of push-pull effect on their spectroscopic and electrochemical properties. The systematic
structure-property investigation exhibit tunability of BODIPY’s spectroscopic and electrochemical
properties and may provide guidance for the future design of new BODIPYs in different
applications.
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7.2 Experimental
7.2.1 Synthesis of BODIPYs
All reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific and
used as received. Reactions were monitored by analytical TLC (precoated, polyester backed, 60
Å, 0.2 mm, Sorbent Technologies). Purifications were completed by column chromatography that
was performed on silica gel (230-400 mesh, 60 Å, Sorbent Technologies) or preparative TLC
plates (f 254 VWR). 1H and

13

C {1H} NMR spectra were obtained using a Bruker AV-400

Nanobay spectrometer (400 MHz for 1H NMR and 100 MHz for 13C {1H} NMR) and a Bruker
AV-500 spectrometer (500 MHz for 1H NMR and 125 MHz for

13

C {1H} NMR) at 298 K.

11

B

NMR spectra were obtained on a Bruker AV-400 III (128 MHz), using BF3•OEt2 as reference.
Chemical shifts (δ) are given in parts per million (ppm) in CDCl3 (7.27 ppm for 1H NMR, 77.0
ppm for

13

C {1H} NMR) and coupling constants (J) are given in Hz. All High resolution mass

spectra (HRMS) were obtained using a 6210 ESI-TOF mass spectrometer (Agilent Technologies).
Melting points were measured using a MEL-TEMP® capillary melting point apparatus equipped
with a FLUKE 51 II thermometer. Crystal structures were determined using data collected at low
temperature (90K) on a Bruker Kappa Apex-II DUO diffractometer equipped with a Triumph
focusing monochromator for the Mo X-ray beam, a Cu microfocus X-ray source, and an Oxford
Cryosystems Cryostream chiller.
General Procedure for Suzuki Cross-Couplings of BODIPYs. The starting BODIPY
was added to a 15 mL round-bottomed flask followed by the addition of either 3 mol % of
Pd(PPh3)4 (for 5a, 5b) or Pd(PCy3)G2 (for 6a, 6b and 8). The flask was evacuated and refilled
with nitrogen three times and toluene (4 mL) and 1M Na2CO3 (aq) (1 mL) were added under
nitrogen. Boronic acid was added portionwise, and the reaction mixture was stirred and heated
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under nitrogen at 90-100oC. The reaction was monitored by analytical TLC every 30-60 min. After
completion, the reaction mixture was added water (20 mL) and extracted with dichloromethane
(10 mL × 3). The organic layers were combined, washed with aqueous saturated brine and water,
and dried over anhydrous Na2SO4. The solvent was removed by rotary evaporator and the obtained
reaction residue was purified by column chromatography with dichloromethane/hexanes or ethyl
acetate /hexanes as the elution solvents.
8-(4-benzyloxycarbonylphenyl)-2,3,5,6-tetrachloro-BODIPY 5a. The BODIPY 5a was
prepared from BODIPY 1 (20.00 mg, 0.0549mmol) synthesized as previously reported35 and 2.5
eq of 4-benzyloxycarbonylphenyl boronic acid (70.3 mg, 0.275 mmol), yielding 20.8 mg, 70.0 %
of BODIPY 5a as red solid: mp (185.9-187.5 oC); 1H NMR (CDCl3, 400 MHz) δ (ppm) = 8.268.28 (m, 2H), 7,57-7.59 (m, 2H), 7.42-7.51 (m, 5H), 6.79 (s, 2H), 5.45 (s, 2H); 13C NMR (CDCl3,
125 MHz) δ (ppm) = 166.2, 143.9, 142.2, 135.8, 235.5, 132.9, 131.2, 130.3, 130.1, 128.7, 128.6,
128.3, 127.9, 122.3, 67.4; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = -0.24-0.18 (1B, t, 1J(B,F) = 26.4
Hz); HRMS (ESI-TOF): m/z calculated for C23H13BCl4F2N2O2: 536.9834; found: 536.9809 [M-].
8-(4-cyanophenyl)-2,3,5,6-tetrachloro-BODIPY 5b. The BODIPY 5b was prepared
from BODIPY 1 (11.4 mg, 0.0310mmol) and10 eq of 4-cyanophenyl boronic acid (46.0 mg, 0.320
mmol), yielding 6.68 mg, 50.2 % of BODIPY 5b as red solid: mp (280.1-282.2 oC); 1H NMR
(CDCl3, 400 MHz) δ (ppm) = 7.89-7.90 (m, 2H), 7.62-7.64 (m, 2H), 6.76 (s, 2H); 13C {1H} NMR
(CDCl3, 125 MHz) δ (ppm) = 144.6, 140.6, 135.9, 132.6, 131.0, 130.8, 127.6, 122.7, 117.4, 115.3;
11

B NMR (CDCl3, 128 MHz ) δ (ppm) = -0.26-0.15 (1B, t, 1J(B,F) = 26.7 Hz); HRMS (ESI-TOF):

m/z calcd for C16H6BCl4F2N3: 427.9419; found: 427.9412 [M-].
8-(4-benzyloxycarbonylphenyl)-3,5-di (4-methoxyphenyl)-2,6-dichloro-BODIPY 6a.
The BODIPY 6a was prepared from BODIPY 5a (12.9 mg, 0.0239 mmol) and 3 eq of 4-
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methoxyphenyl boronic acid (36.3 mg, 0.238 mmol), yielding 9.83 mg, 60.2 % of BODIPY 6a as
dark blue solid: mp (233-235 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 8.28-8.29 (m, 2H), 7.667.69 (m, 6H), 7.51-7.53 (m, 2H), 7.41-7.47 (m, 3H), 6.98-6.99 (m, 4H), 6.82 (s, 2H), 3.87 (s, 6H);
C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 165.5, 161.0, 155.2, 137.9, 135.7, 132.6, 132.1,

13

132.0, 130.4, 129.9, 128.7, 128.5, 128.3, 127.8, 123.2, 121.4, 113.6, 67.2, 55.3; 11B NMR (CDCl3,
128 MHz ) δ (ppm) = 0.35-0.82 (1B, t, 1J(B,F) =30.7 Hz); HRMS (ESI-TOF): m/z calcd for
C37H27BCl2F2N2O4: 681.1451; found: 681.1450 [M-].
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2,6-dichloro-BODIPY 6b. The BODIPY
6b was prepared from BODIPY 5b (8.50 mg, 0.0197 mmol) and 3 eq of 4-methoxyphenyl boronic
acid (30.0 mg, 0.197 mmol), yielding 7.47 mg, 66.0 % of BODIPY 6b as dark blue solid: mp (288290 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 7.87-7.89 (d, J = 7.7 Hz, 2H), 7.66-7.71 (m, 6H),
6.97-6.98 (d, J = 8.2 Hz, 4H), 6.76 (s, 2H), 3.86 (s, 6H);

13

C {1H} NMR (CDCl3, 125 MHz) δ

(ppm) = 161.1, 155.7, 139.6, 138.0, 132.3, 132.0, 131.0, 128.0, 127.5, 123.6, 121.2, 117.8, 114.5,
113.6, 55.3; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.35-0.82 (1B, t, 1J(B,F) =30.6 Hz); HRMS
(ESI-TOF): m/z calcd for C30H20BCl2F2N3O2: 572.1035; found: 572.1026 [M-].
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2-(4-methoxyphenyl)-6-(4cyanophenyl)-BODIPY 8. The BODIPY 8 was prepared from BODIPY 6b (8.12 mg, 0.0141), 5
eq of 4-methoxyphenyl boronic acid (10.7 mg, 0.0707 mmol), and 5 eq of 4-cyanophenyl boronic
acid (10.4 mg, 0.0707 mmol), yielding 5.43 mg, 54.0 % of BODIPY 8 as dark blue solid: mp (273275 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 7.90-7.88 (m, 2H), 7.78-7.80 (m, 2H), 7.44-7.47
(m, 4H), 7.38-7.40 (m, 2H), 7.12-7.10 (M, 2H), 6.93-6.95 (M, 2H), 6.83-6.89 (m, 6H), 6.73-6.75
(m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) =
160.8, 160.5, 160.0, 159.1, 155.2, 139.4, 138.9, 138.8, 136.5, 134.9, 133.7, 132.3, 132.1, 132.0,
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131.9, 131.1, 129.6, 128.7, 128.1, 126.6, 125.7, 123.4, 123.3, 118.9, 118.0, 114.2, 113.8, 113.8,
113.6, 110.2, 55.3, 55.2; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.68-1.15 (1B, t, 1J(B,F) =30.5
Hz); HRMS (ESI-TOF): m/z calcd for C44H31BF2N4O3: 711.2499; found: 711.2482 [M-].
General Procedure for Stille Cross-Couplings of BODIPYs. The starting BODIPY 1
was added to a 15 mL round-bottomed flask followed by the addition of organotin reagent, 3%
mol of Pd(PPh3)4 (for 2) or Pd(PCy3)G2 (for 3, 4, 7). The flask was evacuated and refilled with
nitrogen three times. Toluene (5 mL) was added, and the reaction mixture was stirred and heated
at 90-100oC under nitrogen. Analytical TLC was used to monitor the reaction every 30-60 min.
After completion, toluene was removed by rotary evaporator, and the resulting residue was purified
by column chromatography with dichloromethane/or ethyl acetate /hexanes as the elution solvents.
The BODIPY 2 was prepared from BODIPY 1 (10.5 mg, 0.0288 mmol) and 10 eq of
tributylphenylstannane (106 mg, 0.288 mmol), yielding 8.55 mg, 60.7 % of BODIPY 2 as purple
solid: mp (215-217 oC); 1H NMR (CDCl3, 400 MHz) δ (ppm) = 7.58 – 7.68 (m, 9H), 7.44-7.45
(m, 6H), 6.91 (s, 2H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 155.0, 144.6, 133.4, 133.0,
130.9, 130.4, 130.2,130.2, 130.0, 129.2, 128.7, 128.4, 127.9, 123.0, 122.9; 11B NMR (CDCl3, 128
MHz ) δ (ppm) = 0.27-0.74 (1B, t, 1J(B,F) = 29.9 Hz); HRMS (ESI-TOF): m/z calcd for
C27H17BCl2F2N2: 487.0872; found: 487.0868 [M-].
3,5,8-triphenyl-2,6-dithiophen-BODIPY 3. The BODIPY 3 was prepared from BODIPY
2 (6.21 mg, 0.0127 mmol) and 10 eq of 2-(tributylstannyl) thiophene (47.4 mg, 0.127 mmol),
yielding 4.60 mg, 62.0 % of BODIPY 3 as dark blue solid: mp (178-180 oC); 1H NMR (CDCl3,
500 MHz) δ (ppm) = 7.72 – 7.70 (m, 2H), 7.68 – 7.62 (m, 3H), 7.54-7.53 (m, 4H), 7.46-7.39 (m,
6H), 7.10-7.09 (dd, J = 5.1, 1.1 Hz, 2H), 7.01 (s, 2H), 6.84-6.82 (dd, J = 5.1, 3.6 Hz, 2H), 6.566.55 (dd, J = 3.7, 1.1 Hz, 2H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 156.2, 144.27, 135.8,
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134.5, 134.1, 131.4, 130.6, 130.5, 130.2, 129.5, 128.6, 128.1, 128.0, 127.2, 126.8, 125.1, 124.7;
11

B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.44-0.90 (1B, t, 1J(B,F) = 29.7 Hz); HRMS (ESI-TOF)

m/z calcd for C35H23BFN2S2: 564.1411; found: 564.142 [M-F]+.
2,3,5,6,8-pentaphenyl-BODIPY 4. The BODIPY 4 was prepared from BODIPY 2 (6.51
mg, 0.0133 mmol) and 10 eq of tributylphenylstannane (48.8 mg, 0.133 mmol) with , yielding 3.12
mg, 41.0 % of BODIPY 4 as dark blue solid: mp (273-275 oC). 1H NMR (CDCl3, 400 MHz) δ
(ppm) = 7.71-7.73 (m, 2H), 7.58-7.66 (m, 3H), 7.50-7.52 (m, 4H), 7.32-7.39 (m, 6H), 7.17-7.19
(m, 6H), 7.03 (s, 6H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 156.5, 143.9, 134.7, 134.4,
133.9, 131.8, 130.7, 130.4, 130.3, 129.1, 128.6, 128.4, 128.3, 128.2, 127.9, 126.9;

11

B NMR

(CDCl3, 128 MHz ) δ (ppm) = 0.69-1.16 (1B, t, 1J(B,F) = 30.4 Hz); HRMS (ESI-TOF): m/z calcd
for C39H27BF2N2Na: 594.2164; found: 594.2147 [M+Na]+.
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2,6-dithiophen-BODIPY 7. The BODIPY
7 was prepared from BODIPY 6b (4.81 mg, 0.00838 mmol) and 10 eq of 2-(tributylstannyl)
thiophene (31.3 mg, 0.0838 mmol), yielding 3.11 mg, 55.4 % of BODIPY 7 as dark blue solid: mp
(268-270 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) =7.93 (m, 2H), 7.81 (m, 2H), 7.49 – 7.48 (m,
4H), 7.14 (dd, J = 5.1, 1.1 Hz, 2H), 6.94 (m, 4H), 6.87 (dd, J = 5.1, 3.6 Hz, 2H), 6.84 (s, 2H), 6.62
(dd, J = 3.7, 1.2 Hz, 2H), 3.86 (s, 6H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 160.7, 157.2,
139.8, 138.7, 135.5, 134.0, 132.3, 131.8, 131.1, 128.7, 127.3, 125.9, 125.4, 125.0, 123.2, 118.1,
114.2, 113.6, 55.2; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.47-0.94 (1B, t, 1J(B,F) = 29.8 Hz);
HRMS (ESI-TOF): m/z calcd for C38H26BFN3O2S2: 649.1574; found: 649.1546 [M-F]+.
7.2.2 Crystallography
Crystal structures were determined using data collected at T=90K on a Bruker Kappa
Apex-II DUO diffractometer. MoKα radiation was used for 2, 4, 5a, 6a, and 6b, while CuKα was
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used for 7 and 8. Compound 5a exhibited a small amount (ca. 10%) of rotational disorder which
was evident from partially-populated secondary sites for all the Cl atoms. Compound 6a was a
twin and has two molecules in the asymmetric unit. Compound 7 had both thiophenes disordered
into two orientations, with relative occupations 70:30 and 80:20. It also had disordered solvent,
which was removed using the SQUEEZE procedure. Compound 8 had one methoxy group
disordered into 54:46 orientations and also had disordered solvent removed by SQUEEZE. Crystal
Data: 2, C27H17BCl2F2N2, monoclinic, a = 15.5375(10), b = 6.0426(4), c = 23.7983(16) Å,  =
93.080(3)°, space group P21/c, Z = 4, 48,015 reflections measured, max = 36.5°, 10,891 unique
(Rint = 0.052), final R = 0.041 (8237 I>2(I) data), wR(F2) = 0.109 (all data), CCDC 1509815; 4,
C39H27BF2N2, monoclinic, a = 27.801(3), b = 8.5828(11), c = 25.471(4) Å,  = 105.021(10)°, space
group C2/c, Z = 8, 16,414 reflections measured, max = 23.3°, 4177 unique (Rint = 0.115), final R
= 0.077 (2159 I>2(I) data), wR(F2) = 0.218 (all data) , CCDC 1509816; 5a, C23H13BCl4F2N2O2,
monoclinic, a = 13.7912(4), b = 10.6546(4), c = 15.2354(6) Å,  = 99.863(2)°, space group P21/n,
Z = 4, 24,073 reflections measured, max = 31.0°, 7034 unique (Rint = 0.035), final R = 0.045 (5519
I>2(I) data), wR(F2) = 0.130 (all data) , CCDC 1509817; 6a, C37H27BCl2F2N2O4, triclinic, a =
13.0943(15), b = 13.8006(16), c = 17.659(2) Å, α = 83.546(7),  = 83.396(7), γ = 80.198(7)°,
space group P-1, Z = 4, 27,197 reflections measured, max = 24.0°, 16,564 unique (Rint = 0.119),
final R = 0.093 (8684 I>2(I) data), wR(F2) = 0.264 (all data), CCDC 1509818; 6b,
C30H20BCl2F2N3O2, triclinic, a = 6.4378(3), b = 13.1056(7), c = 15.3828(8) Å, α = 84.902(2),  =
79.560(2), γ = 84.620(2)°, space group P-1, Z = 2, 14,444 reflections measured, max = 28.3°, 5922
unique (Rint = 0.030), final R = 0.038 (4794 I>2(I) data), wR(F2) = 0.092 (all data), CCDC
1509819; 7, C38H26BF2N3O2S2, triclinic, a = 9.8322(8), b = 13.3203(11), c = 15.0587(12) Å, α =

221

72.208(6),  = 74.473(6), γ = 81.456(6)°, space group P-1, Z = 2, 19,146 reflections measured,
max = 62.8°, 5632 unique (Rint = 0.074), final R = 0.062 (3310 I>2(I) data), wR(F2) = 0.170 (all
data), CCDC 1509820; 8, C44H31BF2N4O3 . CHCl3, triclinic, a = 10.3829(9), b = 14.3659(14), c =
15.0975(14) Å, α = 75.674(7),  = 89.346(7), γ = 78.359(7)°, space group P-1, Z = 2, 19,963
reflections measured, max = 68.4°, 7279 unique (Rint = 0.061), final R = 0.105 (5062 I>2(I) data),
wR(F2) = 0.341 (all data), CCDC 1509821.
7.2.3 Spectroscopic Studies
All UV-Visible and fluorescence spectra were collected on a Varian Cary 50 spectrometer
and Perkin Elmer LS 55 luminescence spectrometer at 298 K, respectively. A 10 mm path length
quartz cuvette and spectroscopic solvents were used for all the measurements. Molar absorption
coefficient (ε) was determined from the slope of absorbance vs concentration of five dilute
solutions with absorbance in the range of 0.2-1.0. Quantum yields (Φf) were determined by using
a series of dilute solutions with absorbance in the range of 0.02-0.06 at particular excitation
wavelength. Cresyl violet perchlorate (0.55 in methanol) and methylene blue (0.03 in methanol)
were used as external standards for BODIPYs 2, 6a, 6b, 4 and 3, 7, 8, respectively. The relative
fluorescence quantum yields (Φf) were determined by the following equation38,
 GradX   X2 
 2 
 GradR    R 

 x  R 

where Φ stands for fluorescence quantum yields; ƞ stands for refractive indexes of solvents;
Grad stands for the gradient from the plot of integrated fluorescence intensity vs absorbance at λex;
subscripts X and R stands for the tested sample and standard sample, respectively.
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7.2.4 DFT calculations
The DFT calculations were carried out using the Gaussian 09 software package.39 The
ground state geometries of the BODIPYs were optimized by the DFT method with the B3LYP
functional and 6-31G (d) basis sets.
7.2.6 Cell studies
The cell studies were conducted by adapting reported procedures.40 All cell culture media
and reagents used in this study were purchased from Invitrogen. The Human HEp2 cells were
purchased from ATCC and maintained in a 50 : 50 mixture of DMEM : AMEM supplemented
with 5% FBS and 1% penicillin/streptomycin antibiotic. The cells were sub-cultured twice weekly
to maintain sub-confluent stocks.
Dark Cytotoxicity: The HEp2 cells were plated at 7500 cells per well in a Costar 96-well
plate (BD biosciences) and allowed to grow for 48 h. The stock solution of BODIPY compound
(32 mM) was prepared in 100% DMSO and diluted into final working concentrations (0, 6.25,
12.5, 25, 50, and 100 μM). The cells were exposed to the working solutions of compounds up to
200 μM and incubated overnight (37oC, 95% humidity, 5% CO2). The working solution was
removed, and the cells were washed with 1X PBS. The medium containing 20% CellTiter Blue
(Promega) was added and incubated for 4 h. The viability of cells is measured by reading the
fluorescence of the medium at 570/615 nm using a BMG FLUOstar Optima micro-plate reader. In
this assay, the indicator dye resazurin is reduced to fluorescent resorufin in viable cells, while nonviable cells are not able to reduce resazurin nor to generate a fluorescent signal. The fluorescence
signal of viable (untreated) cells was normalized to 100% and non-viable (treated with 0.2%
saponin from sigma) cells was normalized to 0%.
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Phototoxicity: The human HEp2 cells were prepared as described above and incubated
with compound concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 0 μM for 24 h. The loading
solution was removed and the cells were washed with 1 X PBS, and then refilled with fresh
medium. The cells were exposed to a 600 W halogen lamp light source filtered with a water filter
(transmits radiation 250 - 950 nm) and a beam turning mirror with 200 nm to 30 μm spectral range
(Newport), for 20 min. The total light dose provided was approximately 1.5 J/cm2. After light
exposure, the cells were stored in the incubator for 24 h and assayed for cell viability as described
above.
Time-Dependent Cellular Uptake: Human HEp2 cells were prepared as described above.
The cells were exposed to 10 μM of each compound solution for 0, 1, 2, 4, 8, and 24 h. The loading
medium was removed at the end of each incubation period and the cells were washed with 1X
PBS, and solubilized by adding 0.25% Triton X-100 in 1X PBS. Each compound solution was
diluted to 10, 5, 2.5, 1.25, 0.625 and 0.3125 μM concentrations using 0.25% Triton X-100 (SigmaAldrich) in 1X PBS for standard curve. A cell standard curve was prepared using 104, 2  104, 4
104, 6  104, 8  104, and 105 cells per well. The cell number was quantified using a CyQuant Cell
Proliferation Assay (Life Technologies). The compound concentration in cells at each time period
was determined using a BNM FLUOstar Optima micro-plate reader at 485/590 nm. Cellular uptake
is expressed in terms of compound concentration (nM) per cell.
7.3 Results and discussion
7.3.1 Synthesis and structural characterization
A series of BODIPYs 2, 3, 4, 6a, 6b, 7, and 8 were synthesized as shown in Schemes 7.1
and 7.2. The starting penta-chloro-BODIPY (1) was synthesized from 8-chloro-BODIPY, as
previously reported.35 Based on the regioselectivity of the penta-chloro-BODIPY (reactivity 8-Cl
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> 3,5-Cl > 2,6-Cl) as previously reported,35 different functional groups can be introduced for the
design of versatile push-pull BODIPYs through facile Pd (0) catalyzed cross-coupling reactions.
In this initial study, 4-methoxyphenyl boronic acid was chosen as the electron-donating source and
4-Benzyloxycarbonylphenyl and 4-Cyanophenyl boronic acid were chosen as the electronwithdrawing

source

to

endow

the

BODIPYs

push-pull

characteristics.

4-

Benzyloxycarbonylphenyl boronic acid was synthesized by adapting a reported procedure. 41 The
4-Benzyloxycarbonyl group can be further de-benzylated to carboxylic acid and used for
conjugation with peptides. All the compounds were synthesized by ether Suzuki or Stille crosscoupling reactions in fair to good yields. Penta-chloro-BODIPY was treated with 2.5 eq of 4Benzyloxycarbonylphenyl or 10 eq of 4-Cyanophenyl boronic acid with 3 mol % of Pd(PPh3)4 and
1M Na2CO3 (aq) in refluxing toluene to regioselectively produce BODIPY 5a and 5b in 70.0 %
and 50.2 % yield, respectively. Subsequently, BODIPY 5a and 5b were treated with 3 eq 4methoxyphenyl boronic acid with 3 mol% of Pd(PCy3)G2 and 1M Na2CO3 (aq) in refluxing
toluene to regioselectively produce 6a and 6b in 60.2 % and 66.0 % yield, respectively.
BODIPY 8 was synthesized by two-step Suzuki-cross coupling reactions using 5 eq of 4methoxyphenyl boronic acid and 4-cyanophenyl boronic acid, respectively, in overall 54.0 %
yield. Compared to catalyst Pd(PPh3)4, Pd(PCy3)G2 greatly increase the yield of 6a, 6b and 8
from around 10 % to nearly 70 %. The increased yields are due to the more reactive complex
formed by the more bulky ligands of Pd(PCy3)G2 catalyst.35, 42 For comparison purpose, BODIPY2
and 4 with no electron donor and acceptor on the phenyl substituents were synthesized with
tributylphenylstannane and 3 mol % of Pd(PPh3)4 in refluxing toluene, yielding 60.7 % and 41.0
%, respectively. BODIPY 7 was prepared by treating BODIPY 6b with 2-(tributylstannyl)
thiophene and Pd(PCy3)G2 in refluxing toluene in 55.4 % yield.
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Scheme 7.1. Synthetic routes of BODIPY 2-4, 5a, 5b, 6a and 6b.

Scheme 7.2. Synthetic routes of BODIPY 7-8.
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For comparison purpose, BODIPY 3 with no substituents on the phenyl ring were also
prepared using the 2-(tributylstannyl) thiophene and Pd(PCy3)G2, yielding 62.0 %. All the
compounds were characterized by 1H NMR, 13C NMR, and 11B NMR spectroscopy (Figures 7.27.28) as well as HRMS. The structures of BODIPYs 2, 4, 5b, 6b, 7 and 8 were further confirmed
by X-ray crystallography (Figure 7.29).

Figure 7.2. 1H NMR spectrum of BODIPY 5a.

Figure 7.3.13C {1H} NMR spectrum of BODIPY 5a.
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Figure 7.4. 1H NMR spectrum of BODIPY 5b.

Figure 7.5. 13C {1H} NMR spectrum of BODIPY 5b.
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Figure 7.6. 1H NMR spectrum of BODIPY 2.

Figure 7.7. 13C {1H} NMR spectrum of BODIPY 2.
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Figure 7.8. 1H NMR spectrum of BODIPY 6a.

Figure 7.9. 13C {1H} NMR spectrum of BODIPY 6a.
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Figure 7.10. 1H NMR spectrum of BODIPY 6b.

Figure 7.11. 13C {1H} NMR spectrum of BODIPY 6b.
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Figure 7.12. 1H NMR spectrum of BODIPY 3.

Figure 7.13. 13C {1H} NMR spectrum of BODIPY 3.
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Figure 7.14. 1H NMR spectrum of BODIPY 7.

Figure 7.15. 13C {1H} NMR spectrum of BODIPY 7.
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Figure 7.16. 1H NMR spectrum of BODIPY 4.

Figure 7.17. 13C {1H} NMR spectrum of BODIPY 4.

234

Figure 7.18. 1H NMR spectrum of BODIPY 8.

Figure 7.19. 13C {1H} NMR spectrum of BODIPY 8.
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Figure 7.20. 11B NMR spectrum of BODIPY 5a.

Figure 7.21. 11B NMR spectrum of BODIPY 5b.
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Figure 7.22. 11B NMR spectrum of BODIPY 2.

Figure 7.23. 11B NMR spectrum of BODIPY 6a.
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Figure 7.24. 11B NMR spectrum of BODIPY 6b.

Figure 7.25. 11B NMR spectrum of BODIPY 3.
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Figure 7.26. 11B NMR spectrum of BODIPY 4.

Figure 7.27. 11B NMR spectrum of BODIPY 7.
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Figure 7.28. 11B NMR spectrum of BODIPY 8.

Figure 7.29. Crystal structures of BODIPY 2, 6a, 6b, 4, 7 and 8.
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7.3.2 X-ray crystallography
According to the crystal structures, the dihedral angles of meso substituents with the 12atom BODIPY core for 2, 4, 6a, 6b, 7 and 8 were 62.0, 59.4, 56.6, 63.7, 54.1, and 60.7o,
respectively. With substituents (e.g., phenyl, thiophene) on 1,7 positions, the meso plane is almost
perpendicular (~90o) with the BODIPY core.37, 43 The dihedral angle of these BODIPYs without
1,7 substituents was much smaller (about 30o decrease) due to less steric interaction around the
meso positions. The decrease of the dihedral angle could lead to better conjugation of meso
substituents to the BODIPY core, and therefore enhance the transfer of pull effect. The dihedral
angle of the 3,5 substituents with the 12-atom BODIPY core is in the range of 45-65o for all the
compounds, except for BODIPY 7 which has a dihedral angle of 70.3 and 86.1, respectively. The
dihedral angle of 2,6 substituents, especially for BODIPY 7 with thiophene on 2,6 positions, is
smaller than the dihedral angle of 8, 3, and 5 substituents with the 12-atom BODIPY core. This
suggests that the push-pull moieties on the 2,6 positions have better electronic coupling with the
BODIPY core.
7.3.3 Spectroscopic properties
The spectroscopic properties of the push-pull BODIPYs were evaluated in solvents with
different polarities and the results are summarized in Table 7.1 and Figure 7.30-7.39. All the
compounds show a strong S0-S1 transition with an absorption coefficients in 25000-72000 M-1 cm1

range. A weak broad absorption band centered at around 400 nm was observed at higher energy,

which can be attributed to the S0-Sn (n ≥ 2) transition of the BODIPY moiety.16, 22, 24 The π-π*
transitions at 230-320 nm were also observed for all the compounds.24 In comparison with
BODIPY 2, BODIPY 6a and 6b with electron donor (MeO) on para positions of 3,5 phenyls and
electron acceptor (-CN, -BOOCN) on para position of 8 phenyl exhibit 25-37 nm and 40-48 nm
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bathochromic shifts for absorption and emission in different solvents, respectively. BODIPY 6b
displayed a larger red-shift for both absorbance and emission compared to 6a as the -CN group
(Hammett parameter σp = 0.66)44 is more electron withdrawing than -COOBn group (Hammett
parameter σp = 0.56)44 and results in enhanced pull effect associated with smaller HOMO-LUMO
gap, as evidenced by DFT calculation and cyclic voltammetry analysis (Table 7.2, Figure 7.40 and
7.42). Similarly, compared with BODIPY 3, BODIPY 4 showed a bathochromic shift of 22-25 nm
for absorption and 23-27 nm for emission in different solvents investigated. With three sets of
push-pull moieties installed on BODIPY 5, BODIPY 6 exhibited a bathochromic shift of 30-34
nm and 55-60 nm for absorption and emission in different solvents investigated, respectively.
These results indicated that the substituents of different push and pull ability on BODIPYs can
cause bathochromic shift to different extent. In solvents with different polarities, BODIPY 4
having two thiophene groups at 2 and 6 positions showed the longest λmax for absorption (635-653
nm) and emission (706-707 nm) and the largest Stokes shift (54-71 nm), which is consistent with
the reported studies showing that thiophene group, especially at 2,6 positions, can cause large
bathochromic shift and Stokes shift on BODIPYs.35, 37, 43 The larger Stokes shift was presumably
due to the geometry difference between S0 and S1 states upon excitation, resulting in increased
geometry relaxation.43, 45-46 As the polarity of solvents increased from toluene (solvent polarity
ETN=0.099) to acetonitrile (solvent polarity ETN=0.460)47, hypsochromic shift was observed to
different extent for both absorption (6-22 nm) and emission (0-15 nm) associated with a gradual
decrease of quantum yield. The slight hyperchromic shift of both emission and absorbance is
probably due to the decrease of dipole moment (µ) of BODIPY upon excitation associated with
the intromolecular charge transfer (ICT) between donor and acceptor (µg > µe, where µg and µe are
the ground- and excited-state dipole moments) and thus the ground state is better stabilized in polar
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Table 7.1. Spectroscopic properties of BODIPYs in toluene, tetrahydrofuran and acetonitrile at
298 K.
Cpds
2

6a

6b

3

7

4

8

a

Solvent λab(nm)

Tol
THF
CH3CN
Tol
THF
CH3CN
Tol
THF
CH3CN
Toluene
THF
CH3CN
Toluene
THF
CH3CN
Toluene
THF
CH3CN
Toluene
THF
CH3CN

572
566
558
604
594
583
609
597
587
628
620
613
653
645
635
592
586
576
626
618
606

λem(nm)

Stokes Shift (nm)

603
597
588
643
637
632
650
643
636
680
680
683
707
706
706
622
620
616
677
676
676

31
31
30
39
43
49
41
46
49
52
60
70
54
61
71
30
34
40
51
58
70

ε
(L·mol-1·cm-1)
71258
67346
51609
54004
31809
40192
50350
39753
44983
32361
26262
25952
38630
32363
33438
67517
54568
57143
29550
25219
23216

Φb
0.30
0.13
0.12
0.13
0.077
0.061
0.085
0.048
0.038
0.079
0.042
0.013
0.027
0.015
0.0055
0.64
0.33
0.34
0.055
0.025
0.0072

aSolvent

polarity (ETN): toluene=0.099; THF=0.207; CH3CN=0.460.47 bCresyl violet perchlorate
(0.55 in methanol) and methylene blue (0.03 in methanol) were used as external standards for
BODIPY 2, 6a, 6b, 4 and 3, 7, 8, respectively.
solvent.47-48 The decreased quantum yield with the increase of solvent polarity was consistent with
many reported results and was attributed to the increase of nonradiative decay in more polar
solvents.24, 26, 33-34, 49 A 2-4 fold decrease of quantum yield was observed from BODIPY 2 to 6a
and 6b, 3 to 7, and 4 to 8, which could be attributed to the ICT between donor and acceptor25, 29
and the internal conversion between narrower band gaps50-51. ICT is known to affect the rate of
nonradiative relaxation of fluorophores and results in decreased quantum yields.52 Another reason
associated with the low quantum yield of BODIPYs 3 and 7 is the greater freedom of rotation of
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the smaller thiophene groups in comparison with phenyl, increasing the energy lost to nonradiative
decay.43 Interestingly, the quantum yield of BODIPY 8 was decreased 11-48 fold in different
solvents compared to BODIPY 4, which could be due to the enhanced ICT resulting from the
multiple sets of push-pull moieties in the compound. The Stokes shift was increased as the polarity
of solvent increased for all the compounds. Among them, the Stokes shift of BODIPY 8 increased
the most (19 nm) from toluene to acetonitrile and indicated a large difference in dipole moment
between ground and excited state.24, 49

Figure 7.30. Absorbance (A) and fluorescence (B) of BODIPY 2, 6a and 6b in toluene.

Figure 7.31 Absorbance (A) and fluorescence (B) of BODIPY 3 and 7 in toluene.
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Figure 7.32. Absorbance (A) and fluorescence (B) of BODIPY 4 and 8 in toluene.

Figure 7.33. Absorbance (A) and fluorescence (B) spectra of BODIPY 2 in toluene,
tetrahydrofuran and acetonitrile.
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Figure 7.34. Absorbance (A) and fluorescence (B) spectra of BODIPY 6a in toluene,
tetrahydrofuran and acetonitrile.

Figure 7.35. Absorbance (A) and fluorescence (B) spectra of BODIPY 6b in toluene,
tetrahydrofuran and acetonitrile.
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Figure 7.36. Absorbance (A) and fluorescence (B) spectra of BODIPY 3 in toluene,
tetrahydrofuran and acetonitrile.

Figure 7.37. Absorbance (A) and fluorescence (B) spectra of BODIPY 7 in toluene,
tetrahydrofuran and acetonitrile.
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Figure 7.38. Absorbance (A) and fluorescence (B) spectra of BODIPY 4 in toluene,
tetrahydrofuran and acetonitrile.

Figure 7.39. Absorbance (A) and fluorescence (B) spectra of BODIPY 8 in toluene,
tetrahydrofuran and acetonitrile.
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7.3.4 Cyclic voltammetry

Figure 7.40. Cyclic voltammograms of BODIPY 2, 3, 4, 6a, 6b, 7 and 8.
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Table 7.2. Oxidation and reduction potentials from cyclic voltammetry.
Oxidation
Cpds

rd

3

nd

2

Reduction
st

st

1

1

nd

H-L (V)b

2

1

2.00a

1.58

-0.58

-1.62a

2.16

6a

1.69

1.38

-0.57

-1.31

1.95

6b

1.68

1.38

-0.53

-1.27

1.91

1.66a

1.22

-0.72

-1.76a

1.94

7

1.62a

1.15

-0.64

-1.38a

1.79

4

1.86a

1.34

-0.77

-1.81a

2.11

8

1.49

1.22

-0.68

-1.42a

1.90

3

1.78a

a. peak potential
b. Half-wave potential difference between 1st oxidation and 1st reduction
7.3.5 DFT calculations
To provide insights into the photophysical and electrochemical properties of the BODIPYs,
DFT calculations are conducted on all the compounds and the results are summarized in Table 7.3,
Figure 7.41 and 7.42, The installation of electron donating group (-MeO) and electron withdrawing
group (-CN and –COOBn) to the BODIPYs caused the electron density on the HOMO and
HOMO-1 shifted to the substituents bearing the electron donating groups, whereas the electron
density on the LUMO and LUMO+1 shifted to the meso substituent bearing the electron
withdrawing group. As a result, the overall HOMO-LUMO gap was decreased after introducing
the push-pull moieties from 2 to 6a and 6b, 3 to 7, and 4 to 8 (Table 7.3, Figure 7.42), which was
in agreement with the spectroscopic result that the maximum λab and λem was red-shifted after
installation of push-pull moieties to the BODIPYs. The trend of the HOMO-LUMO gap (2> 6a
and 6b, 3 > 7, 4 > 8) was consistent with the result from cyclic voltammetry (Figure 7.42).
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Figure 7.41. DFT calculated frontier orbitals for all the BODIPY 2, 3, 4, 6a, 6b, 7 and 8 (B3LYP/631G(d)).
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Table 7.3. DFT calculated molecular orbital energy levels for the BODIPYs.
Cpds
EHOMO (ev)
-5.83
2
-5.32
6a
-5.45
6b
-5.18
3
-5.13
7
-5.26
4
-5.29
8
a
ΔE = ELUMO - EHOMO

ELUMO (ev)
-3.25
-2.94
-3.13
-2.78
-2.92
-2.71
-2.71

a

ΔE (ev)
2.58
2.37
2.32
2.40
2.21
2.55
2.27

Figure 7.42. Molecular orbital energies of BODIPYs in DFT calculations. The HOMO-LUMO
gaps are plotted against a secondary axis and are denoted by red triangles.
7.3.6 Cytotoxicity and uptake in human HEp2 cells
The concentration-dependent dark and phototoxicity (1.5 J/cm2 light dose) and the timedependent cellular uptake of all the BODIPYs were evaluated in HEp2 cells, and the results were
summarized in Table 7.4, Figure 7.43 and 7.44. These results were obtained in collaboration with
Ms. Zehua Zhou. All of the BODIPYs showed minimum both dark toxicity (IC50 > 200 μM) and
phototoxicity (IC50 > 100 μM). All the BODIPYs, with the exception of 2 and 8, were taken up
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nearly linearly with time. BODIPY 2 and 8 were taken up rapidly in the first 2 h after which slower
uptake was observed and in the case of 8 a plateau was reached after 8 h. BODIPY 3, 5, 6a, and 7
exhibited very low uptake in HEp2 cells, which could be due to their poor water solubility. The
higher cellular uptake of 6b and 8 compared to other compounds probably was due to the
introduction of –MeO and –CN groups which enhance their water solubility. It’s interesting that
BODIPY 2 accumulated the most within cells at 24 hours, probably as a result of its lower MW
and favorable lipophilicity.
Table 7.4. Dark and phototoxicity and cellular uptake of BODIPYs using human HEp2 cells.
Cpds Dark toxicity IC50 (μM) Phototoxicity IC50 (μM) Cellular uptake at 24 h (nM/cell)
>200
>100
1.2±0.10
2
>200
>100
0.14±0.01
6a
>200
>100
0.51±0.01
6b
>200
>100
0.14±0.01
3
>200
>100
0.12±0.01
7
>200
>100
0.058±0.028
5
>200
>100
0.79±0.13
8

Figure 7.43. Concentration dependent dark toxicity (A) and phototoxicity (1.5 J/cm2 light dose)
(B) of BODIPYs in human HEp 2 cells.
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Figure 7.44. Time-dependent uptake of BODIPYs 2 (black), 6a (red), 6b (yellow), 3 (green), 5
(pink), 7 (navy) and 8 (brown) in human HEp2 cells.
7.4 Conclusion
A series of push-pull BODIPYs were synthesized in good yields by facile Suzuki and
Stille-cross coupling reactions from 2,3,5,6,8-penta-chloro-BODIPY. The structures of all the
compounds were characterized by HRMS, NMR, and X-ray crystallography (except for BODIPY
3). A systematic comparison was made before and after installation of electron-withdrawing and
electron-donating group to the BODIPYs to investigate the influence of push-pull effect on their
spectroscopic and electrochemical properties. Bathochromic shift was observed for both
absorbance (up to 37 nm) and emission (up to 60 nm) in different solvents after the installation of
electron donor (-MeO) and acceptor (-CN and –COOBn). This result was in agreement with the
DFT calculation that the HOMO-LUMO energy was decreased with the installation of push-pull
moieties. The trend of the HOMO-LUMO energy (2 > 6a and 6b, 3 > 7, 4 > 8) was consistent with
the HOMO-LUMO trends obtained from cyclic voltammetry. BODIPY 4 bearing thiophene
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groups at 2 and 6 positions exhibited the longest λmax for absorption (635-653 nm) and emission
(706-707 nm) and the largest Stokes shift (54-71 nm). The quantum yield was decreased up to 48
fold after introducing the push-pull moieties and was probably due to ICT between donor and
acceptor and the internal conversion. All BODIPYs tested showed minimum dark (IC50 > 200 µM)
and phototoxicity (IC50 > 100 µM) in human HEp2 cells. BODIPY 3, 5, 6a and 7 displayed very
low cellular uptake and was probably due to their poor water solubility. BODIPY 6b and 8 showed
higher cellular uptake, which could be attributed to the enhanced water solubility with the –MeO
and –CN groups. It’s interesting that BODIPY 2 accumulated the most within cells at 24 hours,
probably as a result of its lower MW. The systematic investigation of these push-pull BODIPYs
on their spectroscopic and electrochemical properties may provide guidance for the future design
of new BODIPYs for different uses.
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